Nasal drug delivery is emerging as 1 of the most promising frontiers in medicine. From needle-free vaccines ▶️emergency medicines & future CNS therapies, the potential is huge. Nice feature in @NLifeScience Magazine with Orexo CEO Nikolaj Sørensen & Maria Alriksson CEO at Abera.
Orexo
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. More on Wikipedia
-
Orexo
@OrexoABpubl
-
Orexo
@OrexoABpubl
On July 16 at 7 am Orexo will publish the Q2 Interim Report, incl the latest operational & financial developments & key priorities going forward. Later that day, our CEO & CFO will host a conference call to present the report & answer Qs. FMI view orexo.com
-
Orexo
@OrexoABpubl
Orexo är på plats i San Diego för att delta i Bio International. Fokus är sätta mer ljus på utvecklingsprogrammen & AmorphOX-teknologin. Ta del av kommentarer från bl a VD Nikolaj Sorensen i en färsk artikel i @LifeSciSwe : ”Amerikanska investerare har blivit mer optimistiska”
-
Orexo
@OrexoABpubl
New real-world data from ALK Abello highlight significant gaps in anaphylaxis preparedness:
▶️54% have been without adrenaline when needed
▶️40% don’t carry it regularly
Reinforces the importance of patient-friendly solutions - relevant for #ox640 #orexo
uk.finance.yahoo.com/news/anaphylaxis-management-falling-… -
Orexo
@OrexoABpubl
Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening our focus on partnerships. With ~20 yrs of global pharma & biotech experience, Raheleh brings a unique combination of scientific expertise, strategic insight, & strong track record in building partnerships
-
Orexo
@OrexoABpubl
Ta del av VD Nikolaj Sørensens presentation på @aktiespararna Aktiedagen imorgon kl 11.20. För dem som inte deltar på plats går det att se sen live här▶️ www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm…
#amorphox #biologics #ox640 -
Orexo
@OrexoABpubl
Thank you to Robert “Bob” DeLuca, President of Orexo US Inc., retiring after more than a decade of leadership. He built our US business and successfully commercialized Zubsolv®, leaving a lasting legacy. #orexo
-
Orexo
@OrexoABpubl
The substance atipamezole is gaining increasing attention in the scientific community as a potential component in treating complex opioid overdoses. [newswise.com]
Encouraging to see this momentum, as we advance OX390 including atipamezole, together with @BARDA. #orexo -
Orexo
@OrexoABpubl
Imorgon håller CFO Fredrik Järrsten en presentation på @ABGSC Investor Days. Tidsslott 14.15-14.40.
På agendan
- Strategiskt fokus efter avyttringen av Zubsolv US
- AmorphOX teknologin & prioriterade utv program
- Finansiell utv, kassa & finansiering
- Värdedrivare
#orexo -
Orexo
@OrexoABpubl
Positive in-vivo data for OX390: rapid nasal absorption of atipamezole using AmorphOX®. An important milestone toward a rescue treatment for overdoses involving #xylazine (“Tranq”) & #medetomidine (“Rhino Tranq”). OX390 is supported by @BARDA. #orexo orexo.com/media/detail?slug=orexo-announces-positive-outc…
-
Orexo
@OrexoABpubl
We apologize for the technical issues affecting yesterday’s Q1 call. A revised version of the presentation has been uploaded and is available on our website or via the link below: investorcaller.com/events/orexo/orexo-q1-report-2026
Thanks #orexo -
Orexo
@OrexoABpubl
Igår kom vi ut med Delårsrapporten för Kv 1. I den här intervjun sammanfattar VD Nikolaj Sørensen den senaste utvecklingen och fokus framåt. #orexo #amorphox #ox640 #biologics youtu.be/ar_Hv6PMaKc via @YouTube
-
Orexo
@OrexoABpubl
Needles not needed: 9 in 10 patients prefer nasal epinephrine over autoinjectors for treatment of anaphylaxis. OX640, Orexo’s intranasal powder-based epinephrine product, has already tested successfully in clinical trials. snacksafely.com/2026/03/90-of-patients-favor-epinephrine-… #amorphox
-
Orexo
@OrexoABpubl
On April 28 @ 7 am CEST we will publish the Q1 Interim Report, including the latest financial and operational developments. At 2 pm you are welcome to join a presentation also incl. a Q&A session. FMI orexo.com/media/detail?slug=invitation-to-presentation-of… Stay tuned #orexo
-
Orexo
@OrexoABpubl
För dem som missade presentationen på
@Redeye Healthcare Day igår - IRL eller live streaming - nu går den att se här ▶️ player.vimeo.com/video/1183359200. #orexo #amorphox #ox640 #biologics -
Orexo
@OrexoABpubl
Tomorrow on April 14 Orexo´s CEO, Nikolaj Sørensen, will present at @Redeye_ Healthcare Day. Presentation slot 3.10 pm - 3.30 pm. For more information redeye.se/events
#drugdelivery #innovation #rescuemedications #biologics -
Orexo
@OrexoABpubl
Great start to the day at Uppsala Business Park, where Robert Rönn, SVP & Head of R&D @Orexo, spoke at a breakfast seminar hosted by Corem.
Focus: building global leadership in amorphous drug delivery & the path forward post the Zubsolv US divestment - with AmorphOX at the core. -
Orexo
@OrexoABpubl
Orexo’s Annual Report 2025 is now available. Following a year of important strategic decisions, the report outlines our clearer direction, strengthened financial flexibility and continued advancement of the AmorphOX® platform.
#drugdelivery #biologics -
Orexo
@OrexoABpubl
We’re pleased to welcome Dr. Mark Smith to Orexo’s R&D Day on March 24. His recorded session will address emerging #opioid threats from #fentanyl combinations with #xylazine & #medetomidine - closely linked to our OX390 program developed with @BARDA . FMI orexo.com/investors/calendar/2026-03-24-orexo-rd-day-2026/
-
Orexo
@OrexoABpubl
We’re pleased to welcome Lisa Moore to Orexo’s management team as SVP, Product & Portfolio Strategy. With 25+ years of biopharma leadership, Lisa will help shape our focused development strategy & unlock the full potential of AmorphOX®
#drugdelivery #rescuemedications #biologics -
Orexo
@OrexoABpubl
Tomorrow we look forward to attend DNB Carnegie´s Annual Healthcare conference. #orexo #amorphox #ox640 #biologics FMI ir@orexo.com
-
Orexo
@OrexoABpubl
To investors, analysts & media: Join our R&D Day on March 24 (Sthlm) to discover how Orexo is shaping its next growth phase from AmorphOX® innovation to a focused pipeline & strategic partnerships.
FMI: Presenters, Agenda & Registration: orexo.com/investors/calendar/2026-03-24-orexo-rd-day-2026/
#drugdelivery -
Orexo
@OrexoABpubl
Nasal drug delivery is emerging as a powerful frontier in pharma - from emergency care to vaccines & CNS treatments.
In @NLifeScience Magazine, Orexo´s CEO shares how the AmorphOX® technology is unlocking speed & stability in drug development.
▶️ nordiclifescience.org/in-focus-nasal-drug-delivery-for-qu… -
Orexo
@OrexoABpubl
Today we would like to highlight our colleague Sören Andersson who is retiring after 15 years at Orexo. A key analytical chemist & LC‑MS expert across small molecules, peptides & proteins, and part of our AmorphOX journey. Proof that expertise has no age limit. Thank you, Sören.
-
Orexo
@OrexoABpubl
Färsk intervju med VD Nikolaj Sørensen. Fokus ligger på utvecklingen i Q4 men också på prioriteringarna framåt i ljuset av att Orexo -med avyttringen av Zubsolv® - går in i en ny era som renodlat forskningsbolag #amorphox #ox640 #biomolecules youtu.be/CpZmCzg1whs via @YouTube
-
Orexo
@OrexoABpubl
NEWS: Our improved cash position - SEK 912 m (123) -provides the financial flexibility to accelerate R&D and continue building the foundation for AmorphOX® to realize its full potential. #orexo #biomolecues #rescuemedications orexo.com/media/detail?slug=orexo-interim-report-q4-2025-…
-
Orexo
@OrexoABpubl
Save the date: Orexo R&D Day on March 24
Discover Orexo’s next chapter. Orexo invites investors, analysts and media to an R&D Day in Stockholm. Registration already open. #orexo #amorphox
orexo.com/media/detail?slug=save-the-date-orexo-to-host-r… -
Orexo
@OrexoABpubl
On February 5, we will publish our FY Report 2025, highlighting Q4 and the impact of the Zubsolv® US divestment.
At 2 pm CET, members of the management team will present the report, followed by a Q&A.
Welcome to join. Stay tuned!
Invitation: orexo.com/media/detail?slug=orexo-invites-to-a-presentati…
#orexo -
Orexo
@OrexoABpubl
Wishing Dexcel Pharma USA every success with US commercialization of Zubsolv. The mission to improve lives affected by #opioid dependence continues in strong hands. Thank you to the former #orexo sales team now joining Dexcel.
-
Orexo
@OrexoABpubl
Orexos VD ger i en intervju med @BioStock_News mer färg kring avyttringen av Zubsolv US. Kapitaltillskottet innebär att strategiskt fokus nu helt flyttas till R&D och att fullt kunna dra nytta av AmorphOX-teknologin. biostock.se/2026/01/orexo-saljer-usa-rattigheterna-till-z… #lightweb via @lightweb
-
Orexo
@OrexoABpubl
NEWS 3(3)
Investors, analysts and media are invited to a call on Dec. 23 at 11 am CET.
Read PR for details: orexo.com/media/detail?slug=orexo-enters-into-agreement-w… -
Orexo
@OrexoABpubl
NEWS: Post 2/2
Proceeds strengthen Orexo’s pipeline: Izipry™, OX640, GLP-1 agonists & vaccines via AmorphOX®.
Transaction in numbers:
▶️ USD 91m + USD 4–5m inventory
▶️ Up to USD 16.8m sales-based payments (2026–2027) -
Orexo
@OrexoABpubl
NEWS post 1(3)
Orexo signs agreement with Dexcel Pharma USA to divest US rights to Zubsolv® — our lead #opioid dependence treatment. Continuity for patients secured & many Orexo US colleagues may join Dexcel. Orexo continues OX390 development with BARDA. -
Orexo
@OrexoABpubl
Season’s Greetings ✨
Celebrating 30 yrs since our founding in Uppsala & a strong year of R&D progress, with advances driven by AmorphOX & our BARDA partnership. Looking ahead, we’re excited to unlock the platform’s full potential to continuing making impact for patients #orexo -
Orexo reposted
BARDA
@BARDA
BARDA is partnering with @Orexo US, Inc., a part of @OrexoABpubl, to develop Orexo OX390, a rescue nasal powder for overdoses involving illicit drugs of concern often mixed with fentanyl. See more in our portfolio: medicalcountermeasures.gov/barda/cbrn
-
Orexo
@OrexoABpubl
Medetomidine mixed with fentanyl is fueling a deadly new crisis - life-threatening withdrawal & overdoses. Every second counts. OX390, powered by AmorphOX, aims to give first responders the tools they need. #healthsecurity #opioidcrisis #orexo @BARDA www.nytimes.com/2025/12/15/health/medetomidine-withdrawal…
-
Orexo
@OrexoABpubl
We sat down with Edward Kim, MD, MBA, & CMO @Orexo, to discuss the OX390 program, our collaboration with @BARDA, and the unmet need we aim to address. Here’s the result: orexo.com/media/detail?slug=designing-a-rescue-medication… #orexo #opioidcrisis #amorphox
-
Orexo
@OrexoABpubl
Färsk intervju med Orexo ´s VD Nikolaj Sorensen med fokus på prioriteringar framåt och vad som ska bygga långsiktigt värde. #drugdelivery #amorphox #largemolecules youtu.be/h7KLdcRuSdQ via @YouTube
-
Orexo
@OrexoABpubl
Ta chansen och lyssna på när VD Nikolaj Sorensen höll en presentation idag på Stora Aktiedagarna Stockholm. Tack @aktiespararna för viktigt arrangemang samt @Finwire som agerade moderator. #orexo #opioidcrisis #drugdelivery #amorphox youtu.be/_ysgPjPUM80 via @YouTube
-
Orexo
@OrexoABpubl
Looking forward to having CEO Nikolaj Sørensen present at Stora Aktiedagarna, hosted by @aktiespararna. The company update will take place on November 26 at 2:20 pm CET and can be viewed live ▶️invitepeople.com/public/events/ca68015fc8/pages/cc21d41276 #orexo #drugdelivery #amorphox
-
Orexo
@OrexoABpubl
Our Uppsala lab is My Green Lab certified. Elise Nyhlén, Environmental Lead at Orexo, shared the journey to this sustainability achievement at a company breakfast. More on Orexo´s sustainability work: orexo.com/about-orexo/sustainability/
-
Orexo
@OrexoABpubl
Q3 CEO Interview: Listen to CEO Nikolaj Sørensen summarize the key operational and financial developments, as well as the company’s long-term focus. #orexo youtu.be/mSZADfvz2oo via @YouTube
-
Orexo
@OrexoABpubl
NEWS: Q3 2025▶️Net sales below LY (FX & some lower demand), record-high gross margin & lower OPEX. EBITDA negative (LTIP costs). FY guideline unchanged ▶️ R&D highlights: positive intranasal GLP-1 data, BARDA OX390 deal, OX640 commercial batches, OX124 US progress towards launch.
-
Orexo
@OrexoABpubl
On Wednesday in Sthlm, we explored the realities of patent litigation through #orexo’s win against Sun Pharma in the US — a clear example of how strong IP strategy protects innovation
Thx to our partners Steptoe & Potter Clarkson, who also contributed to insightful conversations -
Orexo
@OrexoABpubl
We’re approaching the release of our Q3 Interim Report on October 23. Investors, analysts, and media are welcome to join the call at 2 PM the same day. orexo.com/media/detail?slug=invitation-to-presentation-of… #orexo
-
Orexo
@OrexoABpubl
📻Nu finns en längre version av intervjun med Orexos VD som adderades till veckans Kort & Lång - analyspodden under måndagen. Den går under poddnamnet Noterat och kan lyssnas på här embed.pod.space/player?episode=noterat/orexo-nikolaj-sore… @dagensindustri
-
Orexo
@OrexoABpubl
Excited to join @OTCMarkets Nordic Investor Days in NYC on Oct 8. Bob DeLuca, who has led our US business since launch will represent Orexo. He has been key in our efforts against the #opioidcrisis. Along with BARDA, we’re now advancing a rescue med mixed overdoses.
-
Orexo
@OrexoABpubl
📻Lyssna på senaste Kort & Lång - analyspodden @dagensindustri och dröj kvar till slutet (50 min+). Då sänds en intervju med VD Nikolaj Sørensen om bl a #orexo s accelererande R&D aktiviteter #opioidcrisis #barda #glp1 #amorphox open.spotify.com/episode/1wxePEDWY9gRjgykoTkEmV
-
Orexo
@OrexoABpubl
Weekend reading: For those who missed our June interview with our SVP and Head of R&D, we’re sharing it again here. An interesting read about AmorphOX - our next-generation powder-based drug delivery technology. orexo.com/media/detail?slug=shaping-the-future-of-drug-de…
-
Orexo
@OrexoABpubl
In H2 2026 we will move the new premises in Uppsala Science Park – a step forward to boost innovation, sustainability & collaboration. State-of-the-art labs, modern offices & a central location will help us grow science, partnerships & talent.
#lifescience #innovation #orexo -
Orexo
@OrexoABpubl
#orexo US will receive an initial $8M from BARDA @ASPRgov to advance OX390, a nasal rescue med. for adulterated overdoses where naloxone isn’t enough. Up to $50.9M in total funding pending milestones & deliverables. Powered by AmorphOX dry-powder tech. Fast -Portable -Lifesaving.
-
Orexo
@OrexoABpubl
We look forward to join this exciting event tomorrow hosted by Biostock. @BioStock_News #orexo #innovation #drugdelivery #amorphox
-
Orexo
@OrexoABpubl
We’re proud our CEO was invited to the @UN Global Compact #ceostudy2025 by @Accenture.
▶️88% of CEOs say the case for sustainability is stronger vs 5 yrs ago
▶️ 97% of CEOs remain committed to the SDGs.
Read the report: unglobalcompact.org/library/6295 #orexo -
Orexo
@OrexoABpubl
We're conducting an Investor & Analyst Survey, which we're also sharing with our community on X.
This short, anonymous survey aims to further clarify our communication with the financial market. It takes less than 5 minutes to complete.
Thx IR@orexo▶️
www.orexo.com/ir-questions/ -
Orexo
@OrexoABpubl
We’re pleased to once again attend @ParetoSec Healthcare Conference, targeting institutional investors. On the day, Robert Rönn, SVP & Head of R&D, will present our latest developments within product #innovation supported by our AmorphOX® technology.
#orexo #largemolecules -
Orexo
@OrexoABpubl
Orexo Golf 2025 – the battle for the trophy is over!
In glorious sunshine @ Åkersberga Golf Club, this year’s champion was crowned - congratulations to Jonas Sävmarker. Now it’s time to recharge for the 2026 season & we hope to see even more enthusiasts on the course next year -
Orexo
@OrexoABpubl
Bra intervju med Robert Rönn SVP & Head of R&D där han ger mer färg på en eventuell fortsatt utveckling av ett intranasalt semaglutidläkemedel #glp1. www.placera.se/telegram/orexo-humanstudie-nasta-stora-ste…
-
Orexo
@OrexoABpubl
NEWS: Orexo’s AmorphOX® technology shows promising data in a preclinical study with #semaglutide:
✅ Higher bioavailability vs. oral tablets
✅ Stabilizes #peptides
✅ Potential for intranasal #glp-1 delivery
▶️orexo.com/media/detail?slug=orexos-amorphox-technology-ma… -
Orexo
@OrexoABpubl
View presentation from @DNBCarnegie Small Cap Day. The focus was on long-term value drivers in our R&D business, where the AmorphOX technology plays a central role, as well as our growing commitment to #opioid dependence #ox124 #ox390 #orexo
youtu.be/ctkLfoowlE0 via @YouTube -
Orexo
@OrexoABpubl
👉 For biotech innovators, the American market offers huge opportunity but strong IP is the key to survival. Learn more @NLSDays. #orexo #innovation
orexo.com/media/detail?slug=seminar-ip-that-matters-behin… -
Orexo
@OrexoABpubl
Today at @DNBCarnegie SmallCapDay, Orexo´s CEO, among other things, highlighted the AmorphOX® technology & its refined strategy▶️to focus on large molecules & intranasal rescue medications to address large unmet needs. Full presentation soon available on demand. #drugdelivery
-
Orexo
@OrexoABpubl
We look forward to attending @DNBCarnegie Small Cap Day next Monday (Sep 1). Our CEO will share a company update, and those unable to join in person can follow the event live here: qcnl.tv/p/1eyViEyIJ9YxwDzeBfTWWQ #orexo
-
Orexo
@OrexoABpubl
The International Overdose Awareness Day is approaching. On that day around 140 people in the US will die of an overdose caused by opioids.@ Orexo our mission is to save lives & empower people to kickstart their recovery through pioneering & holistic treatment solutions #ioad2025
-
Orexo
@OrexoABpubl
Orexo runs the🌍only commercial production line for dry powder epinephrine, using the only available nasal powder device. The facility has capacity to accelerate production of nasal rescue meds, powered by the AmorphOX technology. Below: subsite for OX640 commercial production.
-
Orexo
@OrexoABpubl
Latest update 📽️. View video where Orexo’s CEO summerizes highlights & challenges in Q2 & where the focus lays ahead. #outlookreaffirmed youtu.be/7uXk15xTaXo
-
Orexo
@OrexoABpubl
#orexo Q2 Net Sales down mainly due to FX & one-time rebate. EBITDA negative but would’ve been positive excl. rebate. Cash position slightly up.
Outlook reaffirmed
Pipeline
• OX124 ready for commercial mfg
• Strong partner interest in OX640
• AmorphOX can stabilizes vaccines -
Orexo
@OrexoABpubl
Powder-based #drugdelivery is transforming medicine.
With AmorphOX®, Orexo leads the way in nasal delivery of stable, fast-acting therapeutics — no cold chain needed to maintain efficacy.
Learn how we're shaping the future: 👉orexo.com/media/detail?slug=shaping-the-future-of-drug-de…
#pharma #innovation #biotech -
Orexo
@OrexoABpubl
❤️🤍💙As we celebrate the #independenceday2025 let's take a moment to reflect on the ongoing opioid epidemic. At Orexo we are committed making a difference for those affected through innovative treatments. Together we can overcome the challenges & build a brighter future for all
-
Orexo
@OrexoABpubl
Join us on July 16 at 2 pm CEST for a live presentation of Orexo’s Q2 Report. Get the latest updates & insights, followed by a Q&A.
👉 Report published at 8 am CEST the same day.
#opioidcrisis #drugdevelopment #amorphox
+ info shorturl.at/CHauI -
Orexo
@OrexoABpubl
This wknd 2(2): #orexo SVP & Head of RnD & our Scientific Dir. also attended #eaaci2025. Both presented a research poster ‘Epinephrine Nasal Powder – a sustainable and reliable alternative for the treatment of #anaphylaxis’, which highlighted OX640´s superior stability profile.
-
Orexo
@OrexoABpubl
This wknd 1(2): We were delighted to have Dr. Anne Ellis, Prof. & Chair of the Division of Allergy & Immunology @Queen’s University, CA, presenting positive data from the 2nd OX640 clinical study — e.g. highlighting its efficacy also in patients with allergic rhinitis #eaaci2025
-
Orexo
@OrexoABpubl
A key part of Orexo’s growth strategy is to capitalize on our next-generation drug delivery technology — AmorphOX. This scalable platform offers multiple opportunities, and partnerships can generate substantial value for all companies involved.
-
Orexo
@OrexoABpubl
Orexo - Aktiedagarna @aktiespararna 10/6:
▶️Lång erfarenhet av produktutveckling för globala marknader
▶️Kassagenerator i USA #opioidkrisen
▶️Ledande pulverteknologi #amorphox #pipeline
▶️Tydlig tillväxtstrategi
youtu.be/z8H3H_mfl1Y via @YouTube -
Orexo
@OrexoABpubl
På tisdag - 10 juni - kan du lyssna på när VD Nikolaj Sørensen presenterar #orexo @aktiespararna #aktiedagen. Fokus kommer ligga på den senaste utvecklingen inom US Commercial samt Product Development #amorphox och strategin framåt för att driva tillväxt ▶️www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm…
-
Orexo
@OrexoABpubl
Throwback to last week´s presentations ▶️
1️⃣CEO Nikolaj Sorensen at ABGSC, talking about Q1 developments & priorities to drive growth
2️⃣SVP & Head of R&D Robert Rönn & Maria Alriksson CEO @Abera presented the collab developing nasal powder-based vaccines using AmorphOX. #orexo -
Orexo
@OrexoABpubl
🎙️ Lyssna på VD Nikolaj Sørensen från ABGSC investerardagar.
Fokus:
▶️ USA-närvaro & opioidkrisen
▶️ AmorphOX – skalbar pulverteknologi
▶️ Pipeline-projekt
▶️ Finansiell utveckling
▶️ Strategiska prioriteringar
#orexo
youtu.be/R5znYe6xN4s via @YouTube -
Orexo
@OrexoABpubl
IR-presentation. Vi ser fram emot att delta på @ABGSC investerardagar 13-14 maj. Imorgon kl 8.45 ger VD Nikolaj Sørensen en bolagspresentation. För dem som ej delar på plats kommer en PDF läggas upp på webben. En inspelad version blir tillgänglig inom kort. STAY TUNED. #orexo
-
Orexo
@OrexoABpubl
Orexo is delighted to welcome Friedrich von Bohlen as chairman of our board following his appointment at the AGM on 8 May. We’ll be publishing an interview with Friedrich on our website soon, but in the meantime, read more in our PR: orexo.com/media/detail?slug=orexo-friedrich-von-bohlen-un…
-
Orexo
@OrexoABpubl
Q1 2025 Interview with Orexo CEO Nikolaj Sørensen | Insights & Triggers youtu.be/DsVNMN8XMyU via @YouTube
-
Orexo
@OrexoABpubl
Yesterday, Orexo announced its Q1 interim report – 'Stable commercial business in a volatile market.' The video below summarizes our financial and operational developments, as well as how we are mitigating external uncertainties.
The full report ▶️ www.orexo.com. -
Orexo
@OrexoABpubl
Nyligen meddelade vi framsteg i samarbetet med Aberas där vi siktar på att utvecka nya vacciner. Nyfiken på att veta mer? Kom och lyssna när #orexo s forskningschef Robert Rönn, tillsammans med Aberas VD Maria Alriksson håller en presentation. Anmälan: uppsala-business-park.confetti.events/life-after-work
-
Orexo
@OrexoABpubl
We are approaching announcement for the Q1 Interim Report. On May 6 at 8 am CEST we will share the latest operational & financial developments. Later that day investors, analysts & media are invited to join our quarterly call. #orexo For details ▶️: orexo.com/media/detail?slug=invitation-to-presentation-of…
-
Orexo
@OrexoABpubl
#orexo announce progress in the collab. with Abera Bioscience with the ambition to develop vaccines of the future. In-vivo study data shows the influenza vaccine is effective both as liquid & when formulated as a powder using the AmorphOX technology. orexo.com/media/detail?slug=press-release
-
Orexo
@OrexoABpubl
Tomorrow, on April 10, #orexo’s CEO, is attending in-person to speak at this prestigious invitation-only event in Stockholm, Sweden, about the challenges and opportunities of being a commercial-stage pharmaceutical company with an international footprint.
-
Orexo
@OrexoABpubl
@ Orexo we’re delighted to welcome talented students as part of our goal to bridge science between industry & academia. Carl Lagergren&Gustav Holmberg, Chemical engineering students, @Uppsala University, are researching our powder-based technology, AmorphOX®, for their MSc thesis
-
Orexo
@OrexoABpubl
Orexo is inviting its shareholders to attend the 2025 Annual General Meeting. Join us in Uppsala on May 8 at 4 PM. To read the Notice and the Nomination Committee's proposals + all other related doc., visit the Corporate Governance section of our website ▶️orexo.com/who-we-are/governance/general-meetings/
-
Orexo
@OrexoABpubl
Weekend reading: Orexo's Annual & Sustainability Report for 2024 is out.
The report provides valuable insights into areas such as operations, markets, business ethics, governance & control. It also takes a deep dive into our financial performance. ▶️orexo.com/media/detail?slug=orexo-publishes-the-annual-an… #orexo -
Orexo
@OrexoABpubl
This team is about to put some productive days behind @BioEuropeSpring. It's been filled with valuable meetings with potential partners for our scalable drug delivery technology, AmorphOX, & our most exciting pipeline asset OX640, a nasal powder-based epinephrine product. #orexo
-
Orexo
@OrexoABpubl
Idag presenterade Orexos VD på Carnegies Hälsovårdsdag. Lyssna på presentationen nedan som följs av en lika lång Q&A som leddes av CARs Healthcare analytiker Klas Palin. #orexo #opioidcrisis #amorphox youtu.be/ZDTax5S9k5U via @YouTube
-
Orexo
@OrexoABpubl
📹Get to know Orexo: This week we look forward to have CEO Nikolaj Sørensen presenting at IR Seminars hosted by Carnegie Investment Bank. Stay tuned.
#orexo #opioidcrisis #drugdelivery ”wemakeadifference" -
Orexo
@OrexoABpubl
Kom och lyssna på när Orexos VD Nikolaj Sørensen håller en kort presentation om bolagets utvecklingsresa - från renodlat R&D bolag till fullfjädrat läkemedelsbolag.
När: Torsdag 27 Feb kl 8 i Uppsala Business Park.
För mer info & bokning: uppsala-business-park.confetti.events/community-breakfast… -
Orexo
@OrexoABpubl
By leveraging the strengths of our next-generation technology - AmorphOX, partners can unlock the full potential of their molecules, bringing innovative treatments to market faster & more efficiently. Below are some challenges that can be solved with AmorphOX. #orexo #innovation
-
Orexo
@OrexoABpubl
Our team recently attended the Leadership Fair in Sthlm, gaining valuable insights & inspiration to support their leadership roles. The fair also provided to connect with industry leaders, share knowledge, and stay ahead of trends as we work to develop next wave of medications.
-
Orexo
@OrexoABpubl
Congrats @AberaBioscience on the promising data from their first in-vivo study with a new #influenza vaccine candidate. @Orexo we look forward to the results from our joint study developing an influenza vaccine based on our powder-based technology AmorphOX aberabio.com/first-study-on-new-influenza-vaccine/
-
Orexo
@OrexoABpubl
News: Today we published the FY Report, focusing on developments in Q4. It was an intensive period with mixed developments, setting the stage for an exciting and eventful time ahead. In CEO Comments in Brief below CEO Nikolaj Sorensen summarizes the highlights of the quarter.
-
Orexo
@OrexoABpubl
On February 6 @ 8 am CEST we will announce the Q4 Interim Report. On the same day, at 2 pm, we invite investors, analysts & media to join a presentation, where our CEO & CFO will provide an operational and financial update. To join view here: orexo.com/media/detail?slug=invitation-to-presentation-of…
-
Orexo
@OrexoABpubl
Excited to share positive topline data from the 2nd clinical study with our nasal rescue drug OX640. In allergic rhinitis patients, the absorption was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with airway symptoms. #orexo
-
Orexo
@OrexoABpubl
Season's Greetings from Orexo. We’d like to thank all our stakeholders for your trust and support this year. Together we can keep making a difference for patients, communities and societies in 2025. Wishing you & your loved ones a joyful holiday season & prosperous New Year.
-
Orexo
@OrexoABpubl
NEWS 🌟: We're excited to welcome Dr. Friedrich von Bohlen to the #orexo Board. With 25+ years in biotech, he’s been key in growing several companies as co-founder, CEO, & Chairman. His expertise & network will help accelerate Orexo's strategic growth & boost AmorphOX’s potential
-
Orexo
@OrexoABpubl
Samarbetet med Abera trevligt återgivet av @LifeSciSwe www.lifesciencesweden.se/article/view/1136308/deras_samar… #orexo
-
Orexo
@OrexoABpubl
NEWS: In line with the AmorphOX strategy to broaden the use of our drug delivery technology we today announce the collab with Abera. With them, we intend to develop a powder-based nasal vaccine with clear advantages mainly in terms of stability #orexo ▶ orexo.com/media/detail?slug=orexo-enters-into-collaborati…
-
Orexo
@OrexoABpubl
Finally, the patent dispute with Sun Pharmaceutical is resolved. The deal eliminates the risk of Sun launching generics of our lead drug in the US next year. If Sun chooses to launch, it can NOT happen before Sep. 2030. #orexo PR ▶ orexo.com/media/detail?slug=orexo-resolves-zubsolv-us-pat… #opioidcrisis
-
Orexo
@OrexoABpubl
Today we announce the rights to commercialize the digital therapy for depression - Deprexis - in the US have returned to GAIA. The termination will not have any impact on the cash position but will result in an impairment cost of approx. SEK 70 m in Q4. ▶
orexo.com/media/detail?slug=orexo-and-gaia-agree-to-termi… -
Orexo
@OrexoABpubl
🎞 För er som inte lyssnade live i går när VD Nikolaj Sørensen presenterade på Carnegie Småbolagsdag så går den att se On Demand här ▶ @EP_Access youtu.be/4RdEP9nxV50 via @YouTube
-
Orexo
@OrexoABpubl
Thanksgiving is an exciting time, but the pressures of the holiday season can be hard, especially for those facing unseen challenges. This year, let’s be grateful for what we have, but also extend our compassion to others. Wishing a peaceful Thanksgiving from all of us at Orexo.
-
Orexo
@OrexoABpubl
We are glad to announce our CEO, Nikolaj Sorensen, will be presenting at the investor conference - Carnegie Bolagsdag - that takes place in Sthlm, Sweden, on November 28. If you won’t be attending in person, you can view the presentation live ▶: api.screen9.com/preview/T-ZF7hR1CrIOXqWZiuPCIbJbihfW5mV4u… #orexo
-
Orexo
@OrexoABpubl
🎥Check out an interview with Bob DeLuca, President of Orexo US, as he discusses how we’re advancing the fight against the #opioidcrisis with innovative therapies & the focus ahead. Thanks to @OTCMarkets for hosting the IR event. #innovation #amorphox youtu.be/4vnLYpcPNWs
-
Orexo
@OrexoABpubl
Our President of Orexo US Inc. will be attending the OTC Markets Swedish Investor Day in NYC tomorrow. He’ll be presenting an overview of Orexo’s latest developments & growth strategies @ 1:45 PM EST.
FOR LAST MINUTE REGISTRATION (IRL) ▶
www.eventbrite.com/e/swedish-investor-day-tickets-1016846…
@OTCMarkets -
Orexo
@OrexoABpubl
Wrapping up 3 exciting days at #bioeurope! Had valuable discussions, insightful meetings, & inspiring networking. Thrilled to showcase our next-gen. #drugdelivery platform, AmorphOX, & share updates on our epinephrine product OX640. Thanks to everyone we connected with! #orexo
-
Orexo
@OrexoABpubl
At #bioeurope next week we will showcase our next-generation drug delivery platform, AmorphOX, & share exciting developments from our pipeline based on this cutting-edge powder-based technology. Access to the BD team ▶ orexo.com/partnerships/ #biologics #ox640 #orexo
-
Orexo
@OrexoABpubl
🔊Yesterday we published the Q3 report. A quarter that was characterized by both setbacks & achievements. In this interview with Life Science analyst Klas Palin @Carnegie, CEO Nikolaj Sorensen summarizes the latest developments and the way forward #orexo
youtu.be/rgbfB6zQrT4 -
Orexo
@OrexoABpubl
🚨 NEWS: We're excited to announce testing of OX640, our powder-based epinephrine product for #anaphylaxis, in participants with allergic #rhinitis. This study is a key step in meeting development & regulatory requirements on the journey towards approval. #allergyresearch #orexo
-
Orexo
@OrexoABpubl
Today we are happy to have our colleague Jonas Sävmarker attending the MVIC Symposium. His presentation will delve into the innovative processes and formulations of #amorphox - our powder technology for innovative drug delivery of both small and large molecules. #orexo #pipeline
-
Orexo
@OrexoABpubl
This #worldmentalhealthday, the focus is on healthy work environments. At Orexo, we believe in the power of inclusive, healthy workplaces and it’s an integral part of our sustainability strategy. Learn more ▶ orexo.com/sustainability/focus-areas/
-
Orexo
@OrexoABpubl
The Nomination Committee for the upcoming Annual General Meeting has been established. The committee holds 34% of the votes and will prepare proposals for the AGM scheduled for May 8, 2025. Read the press release here: orexo.com/posts/2024-10-04-orexo-s-nomination-committee-f…
-
Orexo
@OrexoABpubl
Yesterday we had the pleasure attending Pareto's annual investor event (HC sector). A day mixed with 1-1 meetings & a presentation held by our SVP & Head of R&D Robert Rönn who, e.g., talked about the wide applicability of the AmorphOX technology ▶ #peptides #biologics #orexo
-
Orexo
@OrexoABpubl
The US opioid epidemic isn’t just about young people. In a News Article, we’re focusing on why increasing numbers of older adults in the US are misusing opioids & developing substance use disorders. Discover more: orexo.com/posts/2024-09-12-opioid-misuse-and-overdose-in-… #opioidcrisis
-
Orexo
@OrexoABpubl
It’s World 🌍Suicide Prevention Day. @Orexo, we know that mental illness & substance use disorder can put people @risk. The number of suicides related to opioids, or narcotic painkillers, have doubled over the last years. If you, or someone you know is struggling, speak out today
-
Orexo
@OrexoABpubl
We look forward to also this year attend the 15th Annual Healthcare Conference hosted by @ParetoSecSE on Sep 19. On the day Orexo´s SVP and Head of R&D will give a company presentation. For more information see below or reach out to ir@orexo.com #amorphox #pipeline #ox640
-
Orexo
@OrexoABpubl
On the International Overdose Awareness Day it is an opportunity for people across the globe to reflect on the many lives being destroyed by opioids. In the US opioids & not at least synthetic such are behind the vast majority of the fatal overdoses #rescuemedications #highdose
-
Orexo
@OrexoABpubl
Look forward to have SVP & Head of R&D, Robert Rönn, to talk about OX640, our needle-free epinephrine medication with nasal delivery, in Copenhagen on Aug 28. Thx to AmorphOX®, it has the potential to significantly increase the stability & shelf-life vs current treatments. #orexo
-
Orexo
@OrexoABpubl
Honored to be mentioned in SwedenBIO's article on industry growth, as we are one of the few 🇸🇪 life science companies that have transitioned from being a pure R&D company to also commercialize drugs #thrivingecosystem press.swedenbio.se/posts/pressreleases/swedish-and-danish…
-
Orexo
@OrexoABpubl
Thx to an announcement from the FDA on Friday, when a competitor to our OX640 product was given an NDA green light, the #anaphylaxis market is on the verge of a paradigm shift. When needle-free treatments can replace today's auto-injectors MORE LIVES CAN BE SAVED. About OX640⏬
-
Orexo
@OrexoABpubl
Federal departments and agencies need to do more to stop the supply of synthetic opioids, according to President Biden’s new National Security Memorandum. In 2023, the DEA seized 75 million pills containing fentanyl.
Read more about what’s happening: orexo.com/news-room/pressreleases-and-news/2024-05-07-fen… -
Orexo
@OrexoABpubl
It’s National Parents’ Day in the US this Sunday, 28 July. At Orexo, we know that families affected by substance misuse may be struggling while others are celebrating. We also know that help can make all the difference. Read Dominique’s story here: blog.orexo.com/2022/08/31/dads-overdose-now-i-know-its-no…
-
Orexo
@OrexoABpubl
It has been a busy week with the publication of our Q2 report & that the FDA, w/r/t the OX124 filing, requires additional technical data & data from a new HF study (the latter finalized in July). For more information listen to the Q2 call held yesterday 🔉ir.financialhearings.com/orexo-q2-report-2024
-
Orexo
@OrexoABpubl
We are thrilled that our sustainability work once again has been recognized. This time by @ecovadis, one of the world's most trusted sustainability assessment providers. Among the 70.000 businesses reviewed annually #orexo AB is ranked among the top 5%. orexo.com/posts/2024-07-10-orexo-ab-s-sustainability-work…
-
Orexo
@OrexoABpubl
🔉On July 17 at 8 am CET we will publish the Q2 Interim Report. The same day at 2 pm you are welcome to join a presentation where CEO+CFO will take you through the latest operational & financial developments. STAY TUNED and for details view ▶ orexo.com/posts/2024-07-08-orexo-invitation-to-presentati… #orexo
-
Orexo
@OrexoABpubl
“If I could save one child, it’s worth it”. A mom whose son died from fentanyl poisoning spoke about drug dangers at an awareness event last weekend. She is one of a growing number of people who know that just one pill can kill. Find out more: www.wect.com/2024/06/29/if-i-could-save-one-child-its-wor…
-
Orexo
@OrexoABpubl
When Jonas Sävmarker joined Orexo, his goal was to create a treatment to help save the lives of people suffering from opioid overdoses. His research pioneered AmorphOX®, Orexo’s world-class drug delivery platform.
Meet Jonas, the man behind the science: orexo.com/about-us/career/get-to-know-orexo/ -
Orexo
@OrexoABpubl
Utbredningen av syntetiska opioider (nitazener) ökar i Europa. Även dem som är betydligt starkare än #fentanyl. En effekt av att inflödet av heroin till EU minskat markant sedan Afaganistan införde förbud av odling av vallmo i april 2023. #orexo
images.app.goo.gl/dzjLbgEY4BYnc7qX9 -
Orexo
@OrexoABpubl
4 in 10 teenagers in Italy take drugs, according to a government report. Synthetic fentanyl has caused numerous deaths in Europe in the last few years, incl Italy. Highdose rescue medication can overcome potent fentanyl analogs, wherever they’re being used news.italy24.press/local/1867919.html
-
Orexo
@OrexoABpubl
🔊A recorded presentation held at the Life Science Investor Forum today is now available here ▶
onlinexperiences.com/Launch/Event.htm?ShowKey=258086&Disp…. Listen in & also take part when Brad Sorensen, Senior Equity Analyst with Zacks Small-Cap Research hosts a Q&A chat with CEO Nikolaj Sorensen. #orexo -
Orexo
@OrexoABpubl
Fred Nyberg, Professor in Biological Research on Drug Dependence at Uppsala University, joined us recently on an internal meeting to talk about the prevalence of synthetic opioids with a focus on the US, why they are life-threatening, and the need for more powerful overdose drugs
-
Orexo
@OrexoABpubl
🔊Join us tomorrow at 11.30 am EST when CEO Nikolaj Sorensen will attend an IR conference hosted in collab with #otcqx Market where Orexo´s ADR is available. The event will be moderated by Brad Sorensen, Senior Equity Analyst with Zacks Small-Cap Research
www.virtualinvestorconferences.com/events/event-details/l… -
Orexo
@OrexoABpubl
#orexo has long experience in successful collaborations, which has enabled the development & launch of novel products, offering improved treatment options for patients worldwide. Last week we had these colleagues at the #biointernational Convention #bio2024
-
Orexo
@OrexoABpubl
A person who uses opioids may become isolated because of their experiences of stigma & feel driven to take more drugs to manage their loneliness. In a 2022 blog piece Dr Geri-Lynn Utter, PsyD, explores stigma and how to support patients who are struggling: blog.orexo.com/2022/10/10/dr-geri-lynn-utter-psyd-whats-s…
-
Orexo
@OrexoABpubl
🔉Listen to a company presentation that Carnegie (@EP_Access) published today under the umbrella of a digital healthcare event. If you are new to #orexo its a good opportunity to learn more about us in terms of strategy, market, products & pipeline.
youtu.be/I_mS1eB5Yc4 -
Orexo
@OrexoABpubl
Partnerships are key to our success. Delighted to have this team attending the Bio International Convention. Networking is on the top of the agenda with a focus on our development pipeline and not at least the scalable drug delivery platform AmorphOX #orexo #ox640 #amorphox
-
Orexo
@OrexoABpubl
#esg investments continue to grow rapidly. This week, #orexo's IR & Comm Director, Lena Wange, participated in @Solberg Insights along with representatives from @SSAB_AB & @TredjeAPfonden. #sustainability issues and #csrd were on the agenda. #sdg3 #opioidcrisis #impactful
-
Orexo
@OrexoABpubl
Accidental overdoses in young people are rising in the US, caused by counterfeit pills contaminated with synthetic opioids. @Orexo, we know just a single pill can kill. HCPs working with young people need to explain the risks and how to stay safe. #ox124 www.medpagetoday.com/special-reports/features/110186
-
Orexo
@OrexoABpubl
Podden ute🔽Förutom en inledande presentation av #orexo står på agendan
1️⃣huvudläkemedlet mot opioidberoende (=viktig kassadrivare)
2️⃣formuleringsteknologin AmorphOX
3️⃣OX124 överdosläkemedlet som närmar sig ett FDA godkännande
4️⃣OX640 lovande projekt vid allergiska reaktioner
DNB Carnegie Access
@CarnegieAccess
#penserpodden 285! Kassakor och tillväxtpotential!
Vi kickstartar veckans poddavsnitt med besök av Orexos VD Nikolaj Sorensen. Bolagets kassako Zubsolv bekämpar opioiddrogberoende och parallellt utvecklar man nya läkemedel genom sin plattform AmorphOX. Nikolaj uppdaterar oss med sin syn på potentialen för Zubsolv, pågående rättegång och nästa marknadslansering.
Vi följer upp detta med analytiker Ludvig Svensson som ger oss investeringscaset i Integrum AB. Familjen Brånemark är pionjärer inom titanimplantat och vi får höra mer om marknadspotentialen för Integrums produkt OPRA-systemet i USA och övriga marknader.
Avslutningsvis ger Klas Palin investeringscaset i Initiator Pharma, ett kostnadseffektivt läkemedelsbolag som utvecklar preparat inom sexuell dysfunktion.
Lyssna in här eller där poddar finns:
Spotify: open.spotify.com/episode/6VJOlLUw8V7k8Fh6fFSrMj
SoundCloud: soundcloud.com/user-326114081/avsnitt-285-kassakor-och-ti…
Apple Podcast: podcasts.apple.com/se/podcast/avsnitt-285-kassakor-och-ti…
$INTEG.B $INIT $ORX -
Orexo
@OrexoABpubl
I förmiddags besökte vi @EP_Access (nu del av Carnegie) för att göra poddinspelning. @AlexanderGust höll i taktpinnen & Klas Palin, analytiker, gjorde bra inspel i samtalet med #orexo s VD Nikolaj Sørensen. STAY TUNED - avsnittet går live senare i em. 🔉📻
-
Orexo
@OrexoABpubl
This morning, at our weekly internal breakfast, we had the privilege of listening to our CEO Nikolaj Sørensen, who presented the latest developments in Q1 & where our focus should be in the short and medium term. #opioidcrisis #amorphox #ox124 #ox640
-
Orexo
@OrexoABpubl
Today we published the Q1 2024 Interim Report. Watch here orexo.com/investors/ as Nikolaj Sørensen, President and CEO, summarizes the quarter and Orexo's focus moving forward.
-
Orexo
@OrexoABpubl
Why are young people at such high risk of dying from a drug overdose? Today, on National Fentanyl Awareness Day, our spotlight is on young people. Find out here: orexo.com/posts/2024-05-07-fentanyl-awareness-day-the-syn…
#nationalfentanylawarenessday #justsayknow -
Orexo
@OrexoABpubl
We will publish our Q1 Report on May 8 at 8 am CET. At 1 pm analysts, investors & media are more than welcome to join a call where our CEO & CFO will take you through Q4, the latest developments financially & operationally & our focus going forward. #orexo orexo.com/posts/2024-05-02-invitation-to-presentation-of-…
-
Orexo
@OrexoABpubl
#fentanyl is so powerful that only a tiny amount, can be deadly. Every family is different, but if you or your loved one is struggling, remember you can get better with the right help. People do overcome their #addiction. Read Marguerite’s recovery story blog.orexo.com/2021/09/16/marguerite/
-
Orexo
@OrexoABpubl
Fred Nyberg, Professor of Addiction Medicine @uppsalauni gave an interesting lecture at the Sigtuna Days on Friday about the need for more powerful overdose drugs in Sweden. Especially in the wake of there are signs of increased use of synthetic opioids also in the EU #opioids
-
Orexo
@OrexoABpubl
NEWS: Proud to announce we continue to improve the IP rights in the US for OX640, our needle-free, powder-based adrenaline product, with the potential to provide significant benefits to patients and healthcare systems worldwide. Read PR ▶ orexo.com/posts/2024-04-17-orexo-extends-patent-protectio… #anaphylaxis
-
Orexo
@OrexoABpubl
Have you noticed how normalized alcohol is in many communities?
It’s easy to drink more than we realize. In 2022, 60.3 million people in the US engaged in binge drinking. If you’re struggling, check Dr Geri-Lynn Utter’s (PsyD) advice on overcoming stigma: blog.orexo.com/2022/10/10/dr-geri-lynn-utter-psyd-whats-s… -
Orexo
@OrexoABpubl
Svensk narkotikapolitik: Intressant ledarartikel i @altingetse skriven av Prof. och beroendeforskaren Fred Nyberg om behovet av kraftfullare överdosläkemedel även i Sverige. Artikeln är skriven i ljuset av att naloxon blir receptfritt. #opioidkrisen
www.altinget.se/omsorg/artikel/motgiftet-naloxon-blir-rec… -
Orexo
@OrexoABpubl
Today, we published our 2023 ASR, encapsulating the past year's milestones & providing in-depth financial insight. In addition, our CEO got more space to give his perspective on developments & the way forward to becoming a much broader & stronger company. orexo.com/posts/2024-03-28-orexo-publishes-the-annual-and…
-
Orexo
@OrexoABpubl
Glad to announce successful closing of a secured SOCIAL bond. Proceeds will be used for the refinancing of the current bond & enabling us to continue providing innovative treatment solutions (e.g. OX124) for those who need them most. orexo.com/posts/2024-03-13-orexo-successfully-issues-seni…
-
Orexo
@OrexoABpubl
“As a leader, I always make sure everyone has the right environment to shine, regardless of their gender, ethnicity, or beliefs.” Cecilia Coupland, SVP and Head of Operations at Orexo, shares her views on leadership for IWD 2024 here: t.ly/zbtQc
#iwd2024 -
Orexo
@OrexoABpubl
NEWS: We have established a social framework enabling us to finance our operations by issuing social bonds. A framework reviewed and approved by Morningstar Sustainalytics.
Read more in the press release here: t.ly/4DODb
#healthcareforall #sgd3 #socialbonds -
Orexo
@OrexoABpubl
Check out the Merck Manual (t.ly/GllPp) where Martin Jönsson, m.sc Pharm, was interviewed about our nasal powder epinephrine product for allergic attacks, OX640, highlighting its stability superiority over other development products.
#aaaai24 -
Orexo
@OrexoABpubl
Today we attended the Carnegie Healthcare Seminar targeting institutional investors. At the event our CEO gave a company update and participated in 1-1 meetings. To view the presentation in PDF format go to reports on the website ▶ orexo.se/investerare/rapportarkiv/
-
Orexo
@OrexoABpubl
This weekend we attended the AAAAI conference in Washington, DC.
OX640, our epinephrine rescue medication for allergic reactions was presented and Robert Rönn, Head of R&D, reports on the well-attended presentation, exciting follow-up questions and a great interest in OX640. -
Orexo
@OrexoABpubl
A sustainable future requires joint responsibility for the environment.
Next month, our 2023 Sustainability Report will be published, until then you can read more about environment and climate change and our sustainability strategy on www.orexo.com/sustainability. -
Orexo
@OrexoABpubl
Trevlig läsning i Life Science Sweden 👍. #orexo #amorphox #biomolecules www.lifesciencesweden.se/article/view/1080894/orexo_och_s…
-
Orexo
@OrexoABpubl
NEWS: For AmorphOX a core strategy is to expand the use of our drug delivery platform to be tested with molecules controlled by other companies. Now the feasibility study conduced with Sobi is advancing to incl. formulation optimization & stability studies orexo.com/posts/2024-02-12-orexo-and-sobi-agree-to-advanc…
-
Orexo
@OrexoABpubl
Today, we published the Interim Report for Q4, incl. the FY numbers. In this video: orexo.se/media/ifhpfswt/orexo-q4-2023-run-through.mp4, Nikolaj Sørensen, CEO, summarizes the quarter and what he looks forward to in 2024.
Read the full report here: orexo.com/media/520iybfq/orexo-interim-report-q4-2023-inc… -
Orexo
@OrexoABpubl
NEWS: The Q4 Interim Report is out. Thanks to growing net revenues and lower costs, EBITDA came in at SEK 12 m, setting the target of a positive EBITDA FY 2024. For details ▶ bit.ly/3StIqVrby or join our call today at 2 pm CET. #orexo
-
Orexo
@OrexoABpubl
Glad to announce study data for OX640, #orexo´s nasal epinephrine powder product, will be presented @ the @AAAAI_org Annual Meeting in DC, by our advisor Dr Anne K Ellis, Prof. & Chair of the Division of Allergy & Immunology @ Queen’s University, Ontario orexo.com/posts/2024-02-06-orexo-s-ox640-development-resu…
-
Orexo
@OrexoABpubl
“It’s not like the first time.” This is the reason thousands of people keep taking opioids. That, & their addiction. A disease so powerful it keeps people wanting more. At Orexo, we’re developing a high-dose naloxone rescue medication to save more lives ▶ orexo.com/pipeline/
-
Orexo
@OrexoABpubl
On Feb. 8, @8 am CET we will disclose our Q4 Report, with the latest development financially & operationally. At 2 pm analysts, investors & media are WELCOME to join a call where our CEO & CFO will take you through Q4 & our focus going forward. #orexo orexo.com/news-room/pressreleases-and-news/2024-01-30-inv…
-
Orexo
@OrexoABpubl
Only 1 out of every 5 adults with #opioid use disorder is getting the right medication, according to a study published in 2023. Learn more: bit.ly/3SmpV6vAt
▶ At #orexo, we believe everyone has the right to safe, effective and stigma-free medication assisted treatment. -
Orexo
@OrexoABpubl
Our people are our strength.🦾
At Orexo,we value one another’s contributions as we understand that joint efforts are the key to our company’s success.
Read more about our view of sustainable employees and our sustainability strategy on www.orexo.com/sustainability. -
Orexo
@OrexoABpubl
🍏As we start the new year, we’re thinking about the many people in recovery who may be finding the holidays a difficult time. Check out this blog for Geri-Lynn’s top tips for taking care of your well-being during the festive season: blog.orexo.com/2023/12/20/taking-care-of-your-well-being-…
-
Orexo
@OrexoABpubl
🌟1 of the favorite breakfasts in 2023 was when we celebrated 10 years with our lead product in the US. Colleagues shared everything from the history to FDA approval, manufacturing & getting the US subsidiary in place. And not at least the difference we are making for people.
-
Orexo
@OrexoABpubl
🎇As we approach the year’s end, we’d like to thank everyone who’s been part of our 2023 #orexo story.
We’re proud of our achievements & we’re looking forward to an exciting 2024.
Discover the difference we’re making to patients & much more here👉: orexo.com -
Orexo
@OrexoABpubl
The holiday season can be a time of joy, but it can also bring added pressures. In this blog, Dr. Geri-Lynn Utter shares her thoughts on how to get through the holiday season without turning to drugs and alcohol.
Read it here: blog.orexo.com/2023/12/20/taking-care-of-your-well-being-… -
Orexo
@OrexoABpubl
At Orexo, we were excited to hear Daniel Karlsson (Oxygroup) speak to us about AI at a meet-up recently. AI offers significant opportunities to support our R&D and commercialization activities as well as to help us grow more efficient. #innovation #development #employees
-
Orexo
@OrexoABpubl
Access to healthcare is essential to improve treatment outcomes and fundamental to an equitable society. We are determined to contribute to UN sustainable development goal 3.5 – to strengthen the prevention and treatment of substance abuse.
Read more on orexo.com/sustainability -
Orexo
@OrexoABpubl
It is an honor to have our US President, Bob DeLuca, visit 🇸🇪. Today, he met with some analysts in Sthlm, & at EPB, he gave an interview talking about the OUD market & how his team is preparing bringing out a broader product portfolio to patients. #orexo youtu.be/AVgO6_Pb2k4
-
Orexo
@OrexoABpubl
With OX124, our high-dose rescue medication for opioid overdose, we are meeting a great need of more powerful solutions. Today we announced FDA has accepted our NDA filing and if approved US launch will be initiated late 2024. PR ▶shorturl.at/stF57
-
Orexo
@OrexoABpubl
To operate in the pharmaceutical industry and market controlled substances carry great responsibilities.
Read more about how we prioritize responsible business and our sustainability strategy on www.orexo.com/sustainability.
#sustainability #responsiblebusiness #sgd12 #sgd8 #sgd3 -
Orexo
@OrexoABpubl
At Orexo, we have taken significant steps to strengthen our sustainability work in recent years. Read about our sustainability approach in the slides below:
www.orexo.com/sustainability -
Orexo
@OrexoABpubl
Partnerships are crucial to our success. We are delighted to see these colleagues attending the Bio Europe conference. Thank you for sharing the picture and we wish you a fruitful time in Munich. #bioeurope2023 #amorphox #orexo
-
Orexo
@OrexoABpubl
Kvartalsintervju med Klas Palin analytiker på Erik Penser Bank om den senaste utvecklingen och prioriteringarna framåt. @EP_Access #orexo youtu.be/vbFif-AftAY via @YouTube
-
Orexo
@OrexoABpubl
Today, we published the Q3 Interim Report. Below, Nikolaj Sørensen, CEO, summarizes the quarter and what he looks forward to in 2024.
Read the full report here: orexo.com/media/bboge2lx/orexo-q3-2023-interim-report.pdfThis media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
Orexo welcomes Robin Evers as new member of the board ▶ orexo.com/news-room/press-releases-and-news/2023-10-27-or… #orexo
-
Orexo
@OrexoABpubl
New nomination committee appointed representing our largest shareholders:
▶Henrik Kjaer Hansen (chairman , appointed by Novo Holdings)
▶Claus Berner Møller (appointed by ATP)
▶Robert Florczykowski (appointed by Third Dot)
▶James Noble (chairman of the board)
PR on the web -
Orexo
@OrexoABpubl
We had a great time at the esteemed World Vaccine Congress Europe 2023. And we’re excited to be bringing fresh ideas and thinking to #orexo as we continue our pharmaceutical research and development to make a difference to people’s lives. #wvceu @vaccinenation
-
Orexo
@OrexoABpubl
The MODIA (24/7 CBT therapy) study did not meet the endpoint to prove therapy along with medication is superior to reducing illicit use of opioids vs CAU. However, it showed frequent visits with HCPs strongly impact reducing misuse of illicit opioids. PR ▶www.orexo.com/posts/2023-10-11-orexo-announces-data-from-…
-
Orexo
@OrexoABpubl
Orexos R&D-chef Robert Rönn möter EPBs analytiker Klas Palin. Intervjun fokuserar på den nya formuleringsteknologin amorphOX & dess skalbarhet i form av substanser & adminstrationsvägar men oxå vikten av starkt IP skydd genom hela utvecklingen #orexo
youtu.be/iIDq_5ZMUKU -
Orexo
@OrexoABpubl
"This is a privileged journey for me, to be able to fight the opioid epidemic.” For Robert DeLuca, President of #orexo US, celebrating 10 years since ZUBSOLV® was launched on the US Pharma market is about so much more than financial & strategic successes👉 www.orexo.com/posts/2023-09-29-orexo-is-celebrating-10-ye…
-
Orexo
@OrexoABpubl
Last week our CEO Nikolaj Sørensen presented @BioStock_SWE Investor Meeting. For those who did not attend we now have a recorded version to share. #orexo #uscommercial #pipeline youtu.be/Xz_O17u5uHs via @YouTube
-
Orexo
@OrexoABpubl
Are you a driven pharmacy or engineering student passionate about innovative technologies to develop improved drugs? Catch the opportunity & apply for this MASTER THESIS project, where you will be part of our skilled R&D team in Uppsala, Sweden. #orexo orexo.workbuster.com/jobs/255629-master-thesis-in-vitro-s…
-
Orexo
@OrexoABpubl
Today we announced our NDA submission to the FDA for OX124, a high-dose rescue medication for #opioid overdose. With the filing, we are making progress in expanding our US commercial portfolio to meet the significant & growing need for more powerful rescue medications. #orexo
-
Orexo
@OrexoABpubl
Throwback from yesterday. SVP & Head of R&D Robert Rönn presenting @ParetoSecSE Healthcare Conference. Below he highlight the strong stability data displayed for OX640, our powder-based nasal epinephrine product, in comparision to Epipen. #amorphox #orexo
-
Orexo
@OrexoABpubl
#orexo PATENT WIN: Orexo´s IP partner since 20 years @PotterClarkson reflects on new trends & the importance of having well drafted & comtemplated patent applications at the time for filing. www.potterclarkson.com/insights/another-us-patent-litigat…
-
Orexo
@OrexoABpubl
We look forward to attending the Pareto Securities 14th Annual Healthcare Conference in Stockholm, Sweden, tomorrow, targeting institutional investors. It will be a day blended with 1-1 meetings and a company presentation. @ParetoSecSE #orexo #amorphox #opioidcrisis
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen inleder veckans #penserpodden. Gå in och lyssna för att lära känna vårt bolag och vad som ska driva tillväxt framåt. #orexo #usmarket #rnd ‘Avsnitt 248: Life Science-tema med spännande bolagspitchar’ is on #soundcloud on.soundcloud.com/k4zCd
-
Orexo
@OrexoABpubl
#internationaloverdoseawarenessday. Why are so many people dying from #opioid overdoses in the US? We asked Michael Brown, i.a. Global Director of Counter Narcotics Technology for Rigaku Analytical Devices. Discover what he said: blog.orexo.com/2023/08/31/international-overdose-awarenes…
-
Orexo
@OrexoABpubl
Kul att få gästa #penserpodden nu på morgonen som i veckans avsnitt har tema Life Science. Podden räknar med att gå Live i eftermiddag. STAY TUNED. #orexo @EP_Access
-
Orexo
@OrexoABpubl
The IP protection for OX640-a nasal powderbased epinephrine product for allergic attacks-is expanding. The new patent covers the important US market until 2041. As multiple other patents are filed we expect the IP protection to continue to grow globally🌍shorturl.at/gvAW3
-
Orexo
@OrexoABpubl
De senaste åren har #orexo gjort en hel del framsteg inom hållbarhetsområdet. Framför allt drivet av en ambition att vara med & bidra till ett hållbart samhälle men också styrt av legala krav & ett ökat intresse från investerare. Vill du veta mer? Se nedan
www.apotekarsocieteten.se/produkt/hallbarhet-fran-det-min… -
Orexo
@OrexoABpubl
Trevlig läsning i senaste numret av @aktieaspararna. Avser perioden 10 maj - 10 augusti. #orexo
-
Orexo
@OrexoABpubl
Idag ger VD Nikolaj Sørensen en uppdatering av verksamheten på Erik Penser Banks Bolagsdag. Presentationen börjar kl 14:15 och kan ses här ▶ www.youtube.com/watch?v=IvzrtRE74wo
-
Orexo
@OrexoABpubl
Uppsala Nya Tidning - @untse - om #orexo´s seger i patenttvisten tidigare i sommar och vad det innebär för bolaget framåt. 🔆#r&D #pipeline #opioidcrisis
unt.se/nyheter/ekonomi/artikel/uppsalaforetag-vann-mot-gl… -
Orexo
@OrexoABpubl
News: The win in the patent litigation appealed. As the decision from the District Court in NJ was completely in Orexo’s favor on both infringement & validity we remain confident the Appeal court will come to the same conclusion. orexo.com/posts/2023-07-24-orexo-s-patent-win-for-zubsolv…
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen summerar andra kvartalet och prioriteringarna framåt i en intervju med Erik Penser Banks analytiker Klas Palin @EP_Access #orexo youtu.be/OOwuA10RG04 via @YouTube
-
Orexo
@OrexoABpubl
Patent litigation win & strong financial development are the key highlights for the second quarter. View the Q2 Interim Report here www.orexo.com/posts/2023-07-18-orexo-q2-2023-interim-report
-
Orexo
@OrexoABpubl
Next week on July 18, at 8 am we will publish the Q2 Interim Report. In the afternoon, at 3 pm, analysts, investors & media are welcome to join a call where our CEO & CFO will take you through the latest development. #orexo STAY TUNED
-
Orexo
@OrexoABpubl
Pleasant reading in @Law360. It concludes the outcome of the #patent litigation against one of the world´s largest pharma companies. We are thrilled that we yet another time succeeded in defending our IP rights linked to our lead pharma product. #orexo www.law360.com/articles/1695624/sun-infringes-orexo-s-opi…
-
Orexo
@OrexoABpubl
Vinsten i patenttvisten och fokus framåt i närtid - VD Nikolaj Sorensen intervjuas av Klas Palin, Life Science analytiker på Erik Penser Bank. #orexo
@EP_Access youtu.be/06mvpbGRFPw via @YouTube -
Orexo
@OrexoABpubl
NEWS: The District Court in NJ, US, has announced Orexo´s win in the patent litigation. ⭐ Thanks to ALL shareholders for your strong support during this period. Now we can fully focus on continuing growing our business. orexo.com/posts/2023-07-01-orexo-wins-patent-litigation-f…
-
Orexo
@OrexoABpubl
Synthetic drugs are simple to manufacture, profitable & easy to distribute. The International Day against Drug Abuse & Illicit Trafficking (June 26) sheds some light on all these people who have become dependent on drugs. #sdg3 #orexo www.un.org/en/observances/end-drug-abuse-day
-
Orexo
@OrexoABpubl
🔊View the recorded version of the presentation our CEO held at the Life Science Investor Forum last week. Go to the link ▶ onlinexperiences.com/scripts/Server.nxp?LASCmd=L:0&AI=1&S… #otcmarkets #uscommercial #pipeline #drugdelivery
-
Orexo
@OrexoABpubl
Today at 3.30 pm CET our CEO will give a company presentation at Life Science Investor Forum an event hosted in collaboration with US based OTC Market. #adr #orxoy www.virtualinvestorconferences.com/events/event-details/l…
-
Orexo
@OrexoABpubl
What makes OX640 so special? In this interview, Robert Rönn, SVP & Head of RnD, shares why OX640, an innovative nasal epinephrine pharmaceutical candidate, has the power to transform lives. www.orexo.com/posts/2023-06-19-ox640-shaping-the-future-o…
-
Orexo
@OrexoABpubl
Yesterday CEO Nikolaj Sorensen presented at @ABGSC Life Science Seminar in Sthlm, Sweden. View an excerpt from the presentation about the potential with OX640 - our drug candidate for allergic reactions. #orexo
This media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
#orexo is a commercial stage pharma company. At Erik Penser Bank´s Bolagsdag hosted last week our CEO joined a panel session discussing opportunities & challenges entering the US market. View here: youtu.be/6TlvYNg5tE8 via @YouTube
-
Orexo
@OrexoABpubl
Nu kan du lyssna på presentationen på Erik Penser Banks Bolagsdag som hölls förra veckan. Då ESG-frågor blir allt viktigare vid investeringar uppmanade EPB bolagen även ge en uppdatering inom detta område. @EP_Access #esg #orexo 🌎 youtu.be/Xry8mI5tAok
-
Orexo
@OrexoABpubl
Glad to have these colleagues presenting the amorphOX® drug delivery platform at the Novel Nasal Formulation & Delivery Summit, in San Diego, US.
-
Orexo
@OrexoABpubl
Tomorrow we will join Bolagsdagen hosted by Erik Penser Bank. An IRL event with more than 300 participants + 60 presented companies. Our CEO will give a business update and also attend a panel session focusing on commercialization. @EP_Access www.penser.se/nyheter-evenemang/
-
Orexo
@OrexoABpubl
Our partner @gesynta Pharma is developing a novel treatment for #endometriosis (phase II). Today they announces the drug candidate has received an INN name - vipoglanstat- by @WHO. This is yet another preparatory step closer market approval. BIG Congrats!
www.gesynta.se/news-media/gesynta-pharmas-drug-candidate-… -
Orexo
@OrexoABpubl
In an effort to reduce waiting times and being able to help more people suffering from mental illness, @NHSEngland will give access to 9 digital therapeutics. #deprexis #mentalhealth #digitalhealth www.bollyinside.com/news/health-news/england-approves-onl… via @bollyinsidenews
-
Orexo reposted
Matthias Zenker, MD
@matthiaszenker
Woderful news - what a team effort, thanks to everybody involved for making this partnership possible. #dtx #diga #digitaltherapeutics #gaia #chugaipharmagermany
-
Orexo
@OrexoABpubl
“#fentanyl is in everything & it’s killing so many people.” This #nationalfentanylawarenessday Elissa reflects on what it was like being addicted to alcohol & opioids, & how even the dealers don’t know what’s in the drug supply anymore #opioidcrisis #orexo blog.orexo.com/2023/05/09/fentanyl-awareness-day-2023-fen…
-
Orexo
@OrexoABpubl
Building on the successes of the recent Bio-Europe event, Orexo was delighted to also attend the #asiabio event in Singapore that took place recently. Coming together at events like this inspires & enables the innovation that drives progress. #drugdelivery
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen möter analytikern Klas Palin i EP Banks nya studio. På 10 min summeras utvecklingen i Q1 med fokus på produkter på marknaden & RnD. Dessutom ges en uppdatering kring pågående patenttvist + prioriteringar framåt #orexo
youtu.be/XVV-GkJtFCQ via @YouTube -
Orexo
@OrexoABpubl
Focusing operations on Orexo´s strengths - The Q1 Interim Report is published. Read about the latest development and our priorities going forward here: www.orexo.com/posts/2023-04-27-orexo-interim-report-q1-2023 #opioidcrisis #develpment
-
Orexo
@OrexoABpubl
Tomorrow at 8 am we publish our Q1 Interim Report. In the afternoon investors, analysts & media are invited to join a call where our CEO & CFO are presenting the latest development. For call in details view www.orexo.com/posts/2023-04-20-invitation-to-presentation…
-
Orexo
@OrexoABpubl
In below podcast our colleague Mikaela Odlander, along with Edward Kliphuis @Sofinnova, are discussing the potential with digital therapeutics but also the challenges entering the US market. #digitalhealth
www.bblsa.com/investing-and-development-in-health-tech-di… -
Orexo
@OrexoABpubl
Today we are hosting our AGM @ our headquarters in Uppsala, also home to Sweden’s oldest university (image). Thank you to our shareholders for your support as we continue delivering on our purpose to improve the lives of people suffering with #opioid use disorder & #mentalillness
-
Orexo reposted
Matthias Zenker, MD
@matthiaszenker
Evidence based, effective and scalable help for a massive health burden. Promise kept, #digitaltherapeutics. And thank you @OrexoABpubl for being an advocat for real #dtx
Orexo
@OrexoABpubl
This Alcohol Awareness Month we’re highlighting the problem of Alcohol Use Disorder, which according to NIAAA affected 29.5 million Americans aged 12+ in 2021. vorvida® is a personalized digital therapy that’s scientifically proven to help adults with AUD. us.vorvida.com
-
Orexo
@OrexoABpubl
This Alcohol Awareness Month we’re highlighting the problem of Alcohol Use Disorder, which according to NIAAA affected 29.5 million Americans aged 12+ in 2021. vorvida® is a personalized digital therapy that’s scientifically proven to help adults with AUD. us.vorvida.com
-
Orexo
@OrexoABpubl
Med anledning av dagens PM intervjuades Orexos VD av Klas Palin, life science analytiker på EP Bank. Förutom info kring NDA-ansökan ges kommentarer om marknaden för överdosläkemedel med fokus på konkurrens & differentiering #us #ox124
Orexo youtu.be/Nh1QxThuu2E via @YouTube -
Orexo
@OrexoABpubl
Today we have announced an updated timeline for OX124 - our high-dose rescue medication for #opioid #overdose. As Orexo will resubmit the NDA, an FDA approval is expected in H2 2024. Read the PR here www.orexo.com/posts/2023-04-03-orexo-shares-new-timeline-… #opioidcrisis
-
Orexo
@OrexoABpubl
The Annual & Sustainability Report is out. Nice reading as it gives a deeper knowledge about #orexo in terms of:
✅Strategic agenda
✅Business model
✅Operations
✅Corporate governance
✅Sustainability agenda
✅In-depth financial info
Go to report: orexo.com/media/l53fx341/orexo_annual-and-sustainability-… -
Orexo
@OrexoABpubl
PARTNERSHIPS ARE KEY FOR OUR SUCCESS. This week we are glad to have our business development team, represented by Petter Wereén and Robert Coburn, in Basel, Switzerland, to participate in #bioeuropespring. #amorphox #ox640 #drugdelivery
-
Orexo
@OrexoABpubl
March 28 is the new date for publication of our Annual Report for 2022, also incl our Sustainability Report. Earlier communicated date was March 24. The change is due to prolonged audit of the ESEF (electronic) reporting. #orexo
-
Orexo
@OrexoABpubl
Brief interview with CEO Nikolaj Sørensen, conducted at the Stockholm Corporate Finance Life Science Seminar last week. On the agenda:
▶ The DTx venture
▶ US Pharma sales development
▶ Investment themes
www.youtube.com/watch?v=F4KomrPj704&list=PLIXgZaftxCZ78XE… -
Orexo
@OrexoABpubl
Last week our CEO presented at Stockholm Corporate Finance Life Science Day. View the full presentation below incl. a Q&A session hosted by @cstjerngren.
#opioidcrisis #digitaltherapies #pipeline
financialhearings.com/event/46590 -
Orexo
@OrexoABpubl
This #internationalwomensday, Geri-Lynn Utter, PsyD, & Medical Science Liaison at #orexo is speaking at the Women’s Centre of Montgomery County’s event, Still I Rise. We’re delighted that she’s sharing her expertise today to stand up for women.
www.eventbrite.com/e/still-i-rise-a-celebration-of-courag… -
Orexo
@OrexoABpubl
Well deserved. Big congrats to the GAIA team. 🏅
Matthias Zenker, MD
@matthiaszenker
Proud - first #digitaltherapeutics company ever becoming a fully accredited member of one of the leading associations of research-based pharmaceutical companies in the world. 2+ decades of real R&D recognized. #dtx #diga #pdtx #sciencedoesmatter
-
Orexo
@OrexoABpubl
Deprexis on the UK-based National Institute for Health & Care Excellence (NICE) list when recommending DTx interventions for the treatment of #depression.
@Ethypharm @GAIA_COM #digitalhealth
www.wandsworthtimes.co.uk/news/national/23354197.apps-onl… -
Orexo
@OrexoABpubl
Recently we welcomed our US colleague Bob DeLuca, President of #orexo US Inc, to our headquarter in Uppsala, Sweden. Below he attended an internal meeting talking about the new US legislation and its positive impact on access to care for people with #opioid #dependence.
-
Orexo reposted
Opioid overdose 1st Responders
@BroochOpioidEMS
Orexo, leveraging drug delivery tech, seeks FDA approval of nasal high-dose opioid rescue naloxone medicine www.fiercepharma.com/pharma/orexo-leveraging-drug-deliver…
-
Orexo
@OrexoABpubl
Best of luck @matthiaszenker at this important seminar! Germany is the leading example in embracing evidence-based DTx & many of GAIA´s products have been added to the DIGA list. #orexo #dtx #digitaltherapeuitcs
Matthias Zenker, MD
@matthiaszenker
See you soon, everybody - and let's hope for better weather than early January at the West Coast:) #digitaltherapeutics #diga #dtx
-
Orexo
@OrexoABpubl
Life Science Sweden om att vi lämnat in en FDA-ansökan om att få OX124 - vårt överdosläkemedel - godkänt i USA. @LifeSciSwe #orexo
www.lifesciencesweden.se/article/view/895886/fdaansokan_i… -
Orexo
@OrexoABpubl
#orexo has filed a New Drug Application to the FDA for OX124, our life-saving medication that reverses the effects of powerful synthetic opioids. We’re dedicated to saving lives for vulnerable & often stigmatized patients, & now we’re one step closer ▶ orexo.com/news-room/press-releases-and-news/2023-02-03-or…
-
Orexo
@OrexoABpubl
Klas Palin, hälsovårdsanalytiker på Erik Penser Bank, i en lång intervju med VD Nikolaj Sørensen. På agendan: Operationell & finansiell utvecklingen i kv 4, status i pågående patenttvist & fokus framåt. @EP_Access
youtu.be/3_MxUbgYBiI via @YouTube -
Orexo
@OrexoABpubl
O4 Report - Important steps forward in a challenging environment. Read the PR here: orexo.com/investors/regulatory-press-releases/2023-01-26-…
To just view the presentation at 2 pm and ask Qs via the chat function use this link, which is the same as mentioned in earlier communication ir.financialhearings.com/orexo-q4-2022/register -
Orexo
@OrexoABpubl
Our Q4 Report will be published tomorrow at 8 am CET. In the afternoon at 2 pm investors, analysts & media are much welcome to join a call where our CEO & CFO will present the latest development and key priorities going forward. For call in details ▶ orexo.com/news-room/press-releases-and-news/2023-01-18-in…
-
Orexo
@OrexoABpubl
New BLOG post out: “We lost our youngest son, Charlie, to a single counterfeit Percocet.” Discover what happened when Edward Ternan discovered the trade in fake pills following his son’s tragic overdose. #opioidcrisis #fentanyl #ox124 blog.orexo.com/2023/01/20/charlies-overdose-why-we-need-t…
-
Orexo
@OrexoABpubl
NEWS: 2 exploratory feasibility studies initiated, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals & vaccines. The studies are conducted in collaboration with international biopharma & vaccine companies orexo.com/posts/2023-01-09-orexo-initiates-exploratory-fe… #research
-
Orexo
@OrexoABpubl
Season’s greetings to our community followers and not at least our employees and other stakeholders who are key for our success. Ahead of the season holiday #orexo has donated to the UNHCR to help those in need #westandwithukraine
-
Orexo
@OrexoABpubl
Edward Kim, M.D. and new CMO at #orexo. Here Edward shares his reasons for joining Orexo and how he’s supporting the company in its core mission to combat the US #opioidcrisis #modia #accesstocare Read the in-depth interview here ▶ www.orexo.com/posts/2022-12-22-edward-kim-m-d-chief-medic…
-
Orexo
@OrexoABpubl
#orexo to Webcast Live at virtualinvestorconferences.com tomorrow, Dec. 15 at 9.30 am ET (3.30 pm CET). The event is hosted along with @OTCMarkets where US investors can trade in the company´s ADR. To view the presentation to be held by our CEO use this link www.virtualinvestorconferences.com/events/event-details/k…
-
Orexo
@OrexoABpubl
We talked to Megan Coder, founder of the Digital Therapeutics Alliance and today Chief Policy Officer, about the power of DTx - the new clinically proven treatment solutions. Read the interview▶ orexo.com/posts/2022-12-09-digital-therapeutics-the-futur… @meganecoder @dtx_alliance #digitalhealth #accesstocare
-
Orexo
@OrexoABpubl
Epinephrine is the 1st-line treatment for #anaphylaxis. If you’re someone who can’t go anywhere without your auto-injector, it can be more than just an inconvenience. OX640, #orexo s nasal epinephrine project is stable in any life situation. Discover more: orexo.com/news-room/press-releases-and-news/2022-06-29-an…
-
Orexo
@OrexoABpubl
View the presentation held at @aktiespararna Stora Aktiedagen yesterday, focusing on
▶ Our core mission
▶ The commercial opportunity in the US
▶ Versatile proprietary drug delivery technology
▶ Profitability in sight
#orexo
youtu.be/bZR0V2pi_8s via @YouTube -
Orexo
@OrexoABpubl
Today at 12-12.30 pm our CEO Nikolaj Sørensen will present @aktiespararna Stora Aktiedagen in Stockholm, Sweden. After the presentation a Q&A will be hosted. To view live ▶ www.aktiespararna.se/tv/live. A recorded version will be available later this week. Welcome to join us #orexo
-
Orexo
@OrexoABpubl
Good interview with M.D. Joe Volpicelli, who has>40 years of experience from treating SUD patients of which many within the Veteran Affairs setting. E.g he ranks DTx & specifically deprexis as new important tools to improve veterans health outcomes #orexo link.medium.com/zxIRlMJTevb
-
Orexo
@OrexoABpubl
Thanksgiving Day is a good opportunity for celebration. Today our thoughts are with all the people who are suffering with substance abuse disorder & #mentalillness. By showing kindness to those in need, together we can make a difference. #thanksgiving
-
Orexo
@OrexoABpubl
Last Week, #orexo participated in UTNARM, a career fair for engineering and science students at Uppsala University, Sweden. Mikael Persson, Pontus Riarbäck & Karl Johansson report on many rewarding conversations with ambitious students. @UU_university
-
Orexo
@OrexoABpubl
Klas Palin Life Science analyst Erik Penser Bank intervjuar Orexos VD Nikolaj Sørensen om utvecklingen i Q3 samt vägen framåt. #opioidcrisis #digitalhealth #pipeline @EP_Access
youtu.be/4hjytghp6WU via @YouTube -
Orexo
@OrexoABpubl
Last week we put yet another Q behind. In Q3 we saw an improved EBITDA, driven by strong profit contribution from US Pharma & lower DTx costs. Operationally, we delivered on our future growth drivers in our pipeline OX124/OX640/MODIA. For CEO Comments: orexo.com/about-us/ceo-comments/
-
Orexo
@OrexoABpubl
Tomorrow at 8 am CET we will go out with our Q3 Interim Report. In the afternoon, at 2 pm, analysts, investors & media are welcome to join a call where the latest development and the way going forward will be presented. To join view here ▶ orexo.com/news-room/press-releases-and-news/2022-10-25-in…
-
Orexo
@OrexoABpubl
NEWS: Last patient enrolled in the MODIA® study. Data from the trial, which is expected mid-2023, will serve as a base applying for a prescription digital therapeutics clearance by the FDA. #opioiddependence #mat orexo.com/posts/2022-10-28-orexo-announces-last-patient-e…
-
Orexo
@OrexoABpubl
Today we welcome Ed Kim, M.D, as our new Chief Medical Officer. He will lead the 🇺🇸 Medical Affairs Department concentrating on commercial products in pharmaceuticals & digital therapeutics, and additionally he will work closely with the R&D team in 🇸🇪. orexo.com/news-room/press-releases-and-news/2022-10-26-or…
-
Orexo
@OrexoABpubl
Good news from the payer side of the DTx market that much likely can spark the uptake of this new innovative solutions that has the potential to increase access to evidence-based psychosocial support. www.statnews.com/2022/10/19/highmark-insurers-decision-to…
-
Orexo
@OrexoABpubl
Our partner Gesynta Pharma is now preparing to initiate a phase 2 trial for OX-MPI in patients suffering from #endometriosis. If they succeed all the way they will meet a great need as 10% of all women in reproductive age suffer from this chronic disease. orexo.com/news-room/press-releases-and-news/2022-10-20-or…
-
Orexo
@OrexoABpubl
Pharm sci 360 conference in Boston. Jonas Sävmarker, Project chief designer, and Jonas Rudén, Senior formulation scientist, in front of the poster showcasing R&D findings related to the development of OX124 and amorphOX®. #orexo @AAPSComms #pharsci360 #drugdelivery #opioidcrisis
-
Orexo reposted
Andrew Steen
@steen1969
"The partnership between @TrinityHealthND and @OrexoABpubl may be an example of how #digitaltherapeutics can be especially beneficial for healthcare systems serving rural areas. www.managedhealthcareexecutive.com/view/trinity-health-to…" via @MHExecutive.
-
Orexo
@OrexoABpubl
Med anledning av att vi idag kommunicerat positiv data från vår kliniska fas 1 studie för OX640 så kan vi här dela en färsk intervju med VD Nikolaj Sørensen med fokus på bl a klinisk data, konkurrensbild och vägen framåt. youtu.be/OPcxE0Z3tNM via @YouTube
-
Orexo
@OrexoABpubl
Dagens @LifeSciSwe skriver om framgångarna med OX640 studien och citerar Robert Rönn SVP & forskningschef: "Studieresultaten är verkligen spännande och jag ser fram emot den fortsatta utvecklingen av denna viktiga och differentierade produkt"
www.lifesciencesweden.se/article/view/873191/lovande_data… -
Orexo
@OrexoABpubl
NEWS: Once again, the R&D team at #orexo has timely delivered on yet another significant company milestone, by showing positive data from the phase 1 clinical study for OX640 - our nasal epinephrine rescue medication for allergic reactions. www.orexo.com/posts/2022-10-11-orexo-announces-positive-d…
-
Orexo
@OrexoABpubl
🌍“Often people don’t realize that they’re behaving negatively towards someone else.” This #worldmentalheathday, Clinical Psychologist Geri-Lynn Utter shares her thoughts on stigma and how to deal with it. View more on our blog portal here blog.orexo.com/2022/10/10/dr-geri-lynn-utter-psyd-whats-s…
-
Orexo
@OrexoABpubl
At NLS Days, we co-hosted the US Pavilion. Along with our partners we showed good examples of how US-Nordic partnerships are shaping the future of healthcare through dedication & innovation.⏬ Robert Rönn Head of R&D in a sit-down with the US Ambassador of 🇸🇪, Erik D Ramanathan
-
Orexo
@OrexoABpubl
Very proud that our talented colleague Tanya Hughes, Director of Payer Channel Marketing, recently presented at an event hosted by the industry organization @dtx_alliance. Tanya is key in our efforts to drive awareness and building knowledge around our evidence-based DTx products
-
Orexo
@OrexoABpubl
Crossing the Atlantic building🆙a US commercial platform paved the way for a broader & stronger #orexo. Today we are about to become a leader in providing new innovative treatment solutions for patients suffering from opioid dependence in the US. Meet us @ US Pavillion @NLSDays
-
Orexo
@OrexoABpubl
#orexo looks forward to being part of the US Pavillion exhibition at NLS Days, Sep. 28-29. Along with our co-hosts, we are sharing learnings and insights about how our industry can grow even stronger by approaching the US market through green-field establishment or partnership.
-
Orexo reposted
Sid Shah
@Sid_Healthcare
Partnership Aims to Enhance Patient Access to #digitaltherapeutics - new collaboration between Trinity Health and @OrexoABpubl US aims to increase patient #access to #dtx to treat #depression and #alcoholabuse in North Dakota and Montana mhealthintelligence.com/news/partnership-aims-to-enhance-…
-
Orexo
@OrexoABpubl
Klas Palin analytiker på Erik Penser Bank intervjuar Orexos VD om den senaste utvecklingen inom digitala behandlinar med fokus på att Trinity Health nyligen påbörjat lanseringen av vorvida & deprexis #orexo
www.youtube.com/watch?v=a1HSWhsLBws -
Orexo
@OrexoABpubl
In 2013 #orexo launched its lead product for opioid dependence on the US market. Since then, total net sales have reached a level of > SEK 4 billion. Learn more about market priorities in 2022 & long-term achievements for the US Pharma segment ▶
orexo.com/operations/us-pharma/ -
Orexo
@OrexoABpubl
Patric Stenberg, CEO, Gesynta Pharma, commenting on the strategy going forward for OXMPI. “We are now looking forward to using the valuable insights from this study to progress GS-248/OXMPI in other indications of high unmet need, e.g. endometriosis”. ▶ www.gesynta.se/news-media/gesynta-pharma-presents-results…
-
Orexo
@OrexoABpubl
Glad to tell patients suffering from depression & excessive drinking in North Dakota & Montana will get access to evidence-based psychosocial support - 24 hrs a day. A true milestone based on an extensive collab. with Trinity Health #dtx #vorvida #deprexis www.orexo.com/posts/2022-09-07-orexo-s-partner-trinity-he…
-
Orexo
@OrexoABpubl
Today Robert Rönn, SVP & Head of R&D at #orexo looks forward to present our novel and proprietary drug delivery platform - amorphOX®, at the Drug Formulation & Bioavailability Conference in Copenhagen, Denmark. #innovation #research #intellectualproperty
www.formulationsbioavailability.com/arrangement/page.xhtm… -
Orexo
@OrexoABpubl
#orexo först ut bland bolagen som diskuteras i det färska avsnittet av #penserpodden (+19 minuter in i sändning). Klas Palin @EP_Access drar investment caset och @DLjungstrom håller i taktpinnen. #transformation #mentalhealthmatter #digitalhealth
DNB Carnegie Access
@CarnegieAccess
#penserpodden 193! Penserpodden passerade i dagarna 2 000 000 spelningar. Vi firar vårt jubileum genom ett göra ett avsnitt av vår signaturpodd - Booonanza. Analytikerna uppdaterar oss om vad som händer hos 23 utvalda bolag.
👂Lyssna här: soundcloud.com/user-326114081/avsnitt-193-jubileumsboonanza -
Orexo
@OrexoABpubl
For #orexo a strong patent portfolio that covers all existing products and pipeline projects is central for the business. Today we are glad to announce the European Patent Office has granted the first European patent for OX640 - our #adrenaline product ▶ orexo.com/news-room/press-releases-and-news/2022-09-01-fi…
-
Orexo
@OrexoABpubl
“It’s crazy how such a little amount of fentanyl can kill you.” Dominique’s Dad suffered with opioid #addiction from the age of 9. She reflects on what life was like for her growing up with addicted parents and what happened on the day he #overdose d:
blog.orexo.com/2022/08/31/dads-overdose-now-i-know-its-no… -
Orexo
@OrexoABpubl
Today at 4.25 pm CET we look forward to join @aktiespararna s Life Science event where our CEO will give a brief presentation that will be followed by a Q&A session. You are much welcome to view here ▶ us02web.zoom.us/j/86503295901
-
Orexo
@OrexoABpubl
Idag har Erik Penser Bank & deras välrenommerade life science analytiker Klas Palin tagit upp bevakning på #orexo. Klas har sedan länge omfattande kännedom om vårt bolag & vår marknad och vi ser fram emot ett förnyat samarbete. Läs initieringsanalysen här: orexo.se/investerare/analytiker/
-
Orexo
@OrexoABpubl
USA: Marknadsföring på sociala plattformar får fler att komma över falska receptbelagda läkemedel som sägs lindra #ångest. De flesta innehåller #fentanyl med dödliga konsekvenser som följd. Utveckl. drabbar särskilt de unga. Läs mer i helgens @SvD esvd.svd.se/shared/article/drogen-fentanyl-den-farligaste…
-
Orexo
@OrexoABpubl
On our website you can view a brief interview with our business area leaders, conducted during early spring time. Below Dennis Urbaniak, EVP Digital Therapeutics, about what he would like to achieve in a 5 year horizon? #leadership #digitalthealth #transformation
-
Orexo reposted
Life Science Sweden
@LifeSciSwe
Snabb upplösning, men med bibehållen stabilitet. Forskningschefen Robert Rönn berättar om den nya drug delivery-plattform från @OrexoABpubl och hur man löser problematiken hos amorfa material.
www.lifesciencesweden.se/article/view/861095/amorfa_mater… -
Orexo
@OrexoABpubl
Soon a week ago. #orexo/#deprexis + Veterans Affairs #depression #digitalhealth
-
Orexo
@OrexoABpubl
Dagens @SvDNaringsliv - en sammanfattning av Q2s finansiella utveckling. #orexo
-
Orexo
@OrexoABpubl
Färsk intervju där hälsovårdsanalytikern Klas Palin på Erik Penser Bank för en dialog med #orexos VD Nikolaj Sorensen om den senaste utvecklingen i Q2 och om den senaste framgången med Veterans Affairs.
youtu.be/yA0qm_QRhWI via @YouTube -
Orexo
@OrexoABpubl
Today we put yet another Q behind us. Q2 was characterized by improved financial development, thanks to FX tailwinds, favorable payermix & good cost control. Operationally, we took important steps ahead across the full business line. FMI read CEO comments: rb.gy/bk7p7y
-
Orexo
@OrexoABpubl
Tomorrow #orexo will announce the Q2 Interim Report. At 2 pm CET investors, analysts and media are welcome to join a call where the latest development will be presented. Also a Q&A will be hosted. For more information view ▶ www.orexo.com/posts/2022-07-06-invitation-to-presentation…
-
Orexo reposted
Matthias Zenker, MD
@matthiaszenker
These are truely fantastic news - congratulations to the @OrexoABpubl team and the VA for making it possible that so many in need get the help of a proven effective #digitaltherapeutic #deprexis !
Orexo
@OrexoABpubl
Today we are glad to tell that our scientifically proven digital therapy deprexis® will be reimbursed under the
US Veterans Affairs Federal Supply Schedule. #orexo #depression Read PR: www.orexo.com/posts/2022-07-13-orexo-s-digital-therapy-de… -
Orexo
@OrexoABpubl
Today we are glad to tell that our scientifically proven digital therapy deprexis® will be reimbursed under the
US Veterans Affairs Federal Supply Schedule. #orexo #depression Read PR: www.orexo.com/posts/2022-07-13-orexo-s-digital-therapy-de… -
Orexo
@OrexoABpubl
Our partner Gesynta Pharma is developing a novel medicine for systemic sclerosis & for which they have been granted ODD by FDA. Today they announce the completion of patient enrollment in the phase 2 study. Top-line data is expected during the fall www.gesynta.se/news-media/gesynta-pharma-completes-patien…
-
Orexo reposted
BiotechTechNow
@MedTechNow_
R&D
~@AMRAMedical continues to advance #fshd research with whole-body #mri measurements
~@OrexoABpubl's nasal adrenaline rescue medication OX640 enters clinical development
~@iitmadras #researchers develop #ai tool to identify #cancer-causing #genes -
Orexo
@OrexoABpubl
#orexo is proud of being one of the few R&D companies in the Nordics that has crossed the Atlantic and built up a commercial platform on the worlds largest pharma market - the US. In ⬇ article our CEO gives some strategic learnings about market entrance
nordiclifescience.org/business-qa-the-four-ps-of-market-e… -
Orexo
@OrexoABpubl
Today we are glad to announce the first clinical trial has been initiated for OX640 – a nasal rescue medication for allergic reactions. If reaching approval the medicine will target a global growing market today amounting to USD 2 billion.
#r&D #innovation #amorphox #orexo -
Orexo
@OrexoABpubl
NEWS Release: Anaphylaxis: Symptoms, causes and treatment challenges. Explore here: www.orexo.com/posts/2022-06-29-anaphylaxis-symptoms-cause…
#epinephrine #autoinjector #orexo #ox640 -
Orexo
@OrexoABpubl
It’s always a good time to check that your #epinephrine #autoinjector is in date and that you, and your loved ones, feel confident with how to use it.
At #orexo, we’re developing a needle free, fast & reliable treatment for allergic reactions - OX640 ▶
orexo.com/pharmaceutical/ox640/ -
Orexo
@OrexoABpubl
Economic disruptions due to COVID-19, such as job loss, led to a sharp decrease in #addiction treatment among people in the age of 18-29 and with commercial insurance. These conclusions are made in a study conducted by the Johns Hopkins Children's Center www.medindia.net/news/covid-19-pandemic-affected-access-t…
-
Orexo
@OrexoABpubl
🎥DISCOVER OUR STORY
💠Where have we come from?
💠How have we evolved?
💠What motivates us to do what we do?
To learn more about #orexo view www.orexo.com
#transformation #leadership #opioidcrisis #whatwedomatters
player.vimeo.com/video/716308536?h=0968e33913&badge=0&aut… -
Orexo reposted
Families Against Fentanyl
@FafFentanyl
ICYMI: @cleveland19news coverage of the #weareapald Ohio rally: “Families Against Fentanyl founder James Rauh said illicit fentanyl needs to be considered a Weapon of Mass Destruction.”
This media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
Glad to announce CEO Nikolaj Sørensen was elected as board member at Gesynta Pharma´s AGM, this week. Gesynta is an important partner as they own the rights to OX-MPI. A drug candidate with orphan drug designation status for the development of a treatment for systemic sclerosis.
-
Orexo
@OrexoABpubl
Orexos R&D chef, Robert Rönn, i en intervju med @LifeSciSwe om bolagets nya formuleringsplattform amorphOX. #ox124 #ox125 #ox640
-
Orexo
@OrexoABpubl
For the 4th consecutive year we attend Handelsbanken Mid/Small Cap Seminar. A closed event fully targeting institutional investors. #orexo
-
Orexo
@OrexoABpubl
If passed by the US congress this bill is set to become a game changer for the DTx market as it will create viable reimbursement routes & bring evidence-based therapies in the hands of patients suffering from mental illness and SUD. #modia #digitalhealth
www.pharmexec.com/view/billing-codes-for-dtx-would-open-t… -
Orexo
@OrexoABpubl
Congrats @Ethypharm for bringing deprexis® to France! This highly individualized digital therapeutic is backed up by strong clinical evidence in 12 RCTs & has the potential to help patients suffering from symptoms of mild to severe #depression @GAIA_COM www.prnewswire.com/fr/communiques-de-presse/ethypharm-dig…
-
Orexo
@OrexoABpubl
Thanks to @Redeye_ which is hosting the Growth Day today. At 10.05 am you can view our CEO attending a Q&A session. Also a brand new company video are recorded and are among others visible on Redeyes event platform www.redeye.se
-
Orexo reposted
Dagens industri
@dagensindustri
Stockholmsbörsen stiger kraftigt på fredagen efter styrka i USA på torsdagen efter två dagar i rad med uppgångar.
www.di.se/nyheter/aktieexperten-om-kraftiga-borslyftet-da… -
Orexo
@OrexoABpubl
A week ago at ABG Sundal Collier. Gonzalo A. Castanon, Life Science analyst, is asking about the synergies with combining our lead product for opioid use disorder with the CBT grounded digital therapy MODIA. The full presentation can now be viewed on our website. #opioidcrisis
-
Orexo
@OrexoABpubl
Sustainable companies do not only contribute to a better society, they also reduce operational risks & create long term value for shareholders. Thank´s to The Swedish Association of the Pharma Industry, @LIFse, for leading the way in this important topic.
www.lif.se/press/ -
Orexo
@OrexoABpubl
Deprexis - one of the most clinical proven #digital therapies - can help people suffering from #depression.
🔊 Find out more by listening to Dennis Urbaniak, SVP Digital Therapeutics @Orexo, in a chat with Health Professional Radio healthprofessionalradio.com.au/digital-therapeutics-for-p… -
Orexo
@OrexoABpubl
Today #orexo presents at an open event hosted by Erik Penser Bank. The presentation that will be held by the CEO starts at 12.30 and can be viewed here: youtu.be/DwXnnM-KKeI via @YouTube #opioidcrisis #innovation #digitalhealth @EP_Access
-
Orexo
@OrexoABpubl
Today we look forward to have our CEO Nikolaj Sørensen presenting at @ABGSC Life Science Summit -an event open for institutional investors. Time slot is 3.30-3.55 pm, which also incl. a Q&A session. During the day the presentation deck will be available on #orexo s website.
-
Orexo
@OrexoABpubl
According to @CenterOfDisease fatal overdoses increased 15% in 2021. In total >107 000 Americans lost their lives in an #overdose, of these 2/3 where caused by synthetic opioids, such as #fentanyl #ox124 www.wsj.com/articles/drug-overdose-deaths-reached-a-recor… via @WSJ
-
Orexo
@OrexoABpubl
Today is the first ever National #fentanylawarenessday, set up to draw attention to the growing problem of illicit #fentanyl in fake pills and street drugs across the US. To get a full picture, we had a talk with Geri-Lynn Utter, Medical Liaison at #orexo www.orexo.com/posts/2022-05-10-one-pill-can-kill-fentanyl…
-
Orexo
@OrexoABpubl
Färsk intervju med Erik Pensers Life Science analytiker Klas Palin. Dryga 20 minuter som mycket väl sammanfattar den operationella utvecklingen per affärsområde i Q1 samt vad som drev de förbättrade finansiella resultaten youtu.be/-CjDGOkGRWU via @YouTube #orexo
-
Orexo
@OrexoABpubl
Since US launch in 2013 accumulated net revenues for our lead product surpassed SEK 4.2 billion in Q1 2022. For future growth drivers - view below. #orexo
-
Orexo
@OrexoABpubl
Promising start to 2022. In Q1 we saw revenues grew across the line of all drugs, i.a. thanks to FX tailwinds & favorable price development. Along with good cost control & improved synergies-US Pharma ↔ DTx-we are glad to report a positive EBITDA. #orexo
www.orexo.com/posts/2022-04-28-orexo-interim-report-q1-2022 -
Orexo
@OrexoABpubl
As earlier communicated we will publish our Q1 Report tomorrow at 8 am CET. In the afternoon at 2 pm investors, analysts & media are invited to join a call where the latest development & priorities going forward are presented. Also a Q&A will be held. ▶ www.orexo.com/posts/2022-04-19-invitation-to-presentation…
-
Orexo
@OrexoABpubl
NEWS: Proud to announce our partner Gesynta Pharma which owns the rights to OX-MPI has been granted Orphan Drug status in the US by the FDA. An important milestone that can open up for effective & safe treatment for patients with systemic sclerosis. #orexo
www.orexo.com/posts/2022-04-27-orexo-s-partner-gesynta-ph… -
Orexo
@OrexoABpubl
Along with @Accord Healthcare we attend Sigtunadagarna hosted by U-Fold @uppsalauni. 2 days filled with top of the line seminars where experts give an updated view about #opioid dependence focusing on treatment excellence from a holistic perspective.🔽Kajsa Lagerlund &Robert Rönn
-
Orexo reposted
Behavioral Health Tech
@GoingDigitalBHT
.@OrexoABpubl's Dennis Urbaniak will be joining us at #gdbht2022 sharing their innovative approach to improving access and patient outcomes.
Reserve your spot today! And consider donating to @afspnational
next.brella.io/join/GDBHT2022/ -
Orexo reposted
Families Against Fentanyl
@FafFentanyl
Over 30k people have signed our petition so far! Let's declare illicit fentanyl a WMD, promote harm reduction policies & increase access to mental health programs/life saving treatments!!
-
Orexo
@OrexoABpubl
Learn more about Orexo’s Digital Therapeutics portfolio (exhibit 328) at #natcon22, the largest event of its kind, in the Washington, D.C., metro area. Hope to see you there today! eventscribe.net/2022/NatCon22/aaStatic.asp?SFP=REpETUZHWk… @NationalCouncil #accesstocare #digitalhealth
-
Orexo reposted
Orexo
@OrexoABpubl
@direktstudios sheds light on digital therapeutics in an interesting talk with our CEO Nikolaj Sørensen focusing on reimbursement, evidence-based DTx and overall opportunities. youtu.be/biLKnY6w6xg via @YouTube #modia #digitaltransformation #accesstocare
-
Orexo
@OrexoABpubl
@direktstudios sheds light on digital therapeutics in an interesting talk with our CEO Nikolaj Sørensen focusing on reimbursement, evidence-based DTx and overall opportunities. youtu.be/biLKnY6w6xg via @YouTube #modia #digitaltransformation #accesstocare
-
Orexo
@OrexoABpubl
Orexo´s novel and innovative drug delivery platform amorphOX will serve as the backbone in the development of our future pharmaceuticals. The applicability is wide as it can be used with different:
1️⃣APIs
2️⃣Dosage forms
3️⃣Administration routes
#orexo #innovation -
Orexo
@OrexoABpubl
🔊In case you did not followed @Redeye_ #digitalhealth event LIVE last week. Here is a recorded version where our CEO Nikolaj Sørensen presents Orexo´s take on this new groundbreaking treatment option ▶ scientifically proven digital therapeutics. www.redeye.se/video/event-presentation/837740/orexo-nikol…
-
Orexo
@OrexoABpubl
On March 22 our lead product was added to NY State Medicaid formulary.
Brief facts #opioidcrisis NY State:
▶2nd largest Medicaid bup/nal treatment State
▶Gross value close to USD 180m-Medicaid
▶Overdose death tolls approx +40% in 2021
▶Additional public funding allocated -
Orexo
@OrexoABpubl
Great, action packed day last week at @Redeye_. A day full with presentations by companies in the Digital Health industry. We also had the pleasure to join a panel session with @AbVicore, @GoContigo & @ElsaScience discussing macro trends, policy changes & the future of DTx.#orexo
-
Orexo
@OrexoABpubl
GET TO KNOW #orexo – the 2021 Annual Report is out. It gives a deeper knowledge about the company, our business landscape & financial development. It also includes the Sustainability Report, which outlines major steps taken to contribute to a more sustainable society #esef
-
Orexo
@OrexoABpubl
Excited to exhibit at #natcon22, the largest conference in #mentalhealth and substance use treatment, from April 11-13! Stop by #orexo s exhibit 328 to learn about our Digital Therapeutics portfolio. Hope to see you there! eventscribe.net/2022/NatCon22/aaStatic.asp?SFP=REpETUZHWk… @NationalCouncil #digitalhealth
-
Orexo
@OrexoABpubl
Time for another internal Wednesday breakfast at the head quarter in 🇸🇪. An excellent opportunity to share information with the colleagues. Today all were gathered to listen to CEO Nikolaj Sørensen presenting the internal objectives, with a focus on status&priorities. #leadership
-
Orexo
@OrexoABpubl
Today #orexo welcomes its shareholders´ to attend the AGM on April 21. It will take place in Uppsala, Sweden and will start at 4 pm. For more details about the AGM and corporate governance in general at Orexo view here ▶ orexo.com/about-us/corporate-governance/
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen intervjuas av @direktstudios Kajsa Söderberg efter en presentation i förra veckan. #transformation #digitaltherapeutics #pharmaceuticals youtu.be/m_EM3TqckA4 via @YouTube
-
Orexo
@OrexoABpubl
NEWS: #orexo are glad to announce Fredrik Järrsten as new CFO. With extensive experience from working with business development and M&A & of having strong relation with the capital market he will play a key role in our ongoing #transformation journey to build a stronger company.
-
Orexo
@OrexoABpubl
At our internal breakfast today our colleague Petter Werén, VP Procurement and Business Development, talked about the collaboration with our partner @Accord_HC which is about to initiate the launch of our lead product in the EU according to plan in Q1. #opioidcrisis #orexo
-
Orexo
@OrexoABpubl
Today CEO Nikolaj Sørensen presented at the Stockholm Corporate Life Science Days. The Q&A session was held by @cstjerngren who among others asked about the potential with our novel Drug Delivery platform amorphOX™. #transformation #lifesciences
-
Orexo
@OrexoABpubl
At Orexo we stand in solidarity beside the people of the Ukraine during this tragic time. As we see people suffering and leaving their homes, we are compelled to help. Today #orexo is donating to the UNHCR to help those in need. @Refugees #westandwithukraine
-
Orexo reposted
Lin Grensing-Pophal
@LinWriter
Thanks to @DUrbaniak of @OrexoABpubl for input to my @SHRM piece on the opportunities and potential risks of virtual mental health care. www.shrm.org/topics-tools/news/benefits-compensation/virt… #benefits #mentalhealth
-
Orexo
@OrexoABpubl
While all our thoughts go to the Ukrainian people this morning we are glad to announce that we will be able to help more patients who are suffering from opioid dependence in NY state in the US. Read the PR www.orexo.com/posts/2022-02-24-orexo-s-lead-product-zubso…
#accesstocare #opioidcrisis #westandwithukraine -
Orexo
@OrexoABpubl
Post 2 (2)...new opportunities but also other challenges comparing to the development of drugs. We are glad that our CEO Nikolaj Sorensen inspired to this chronicle and we look forward to share more details regarding these 4 P:s in the next edition of @NLifeScience #tranformation
-
Orexo
@OrexoABpubl
Post 1(2). Nice chronicle in @NLifeScience where @HelenaStrigard, Director General @SwedenBIO highlights that a greater number of Swedish Life Science Companies are now preparing for market entrance. Commercializing pharma means completely….. nordiclifescience.org/the-four-ps-of-market-entry/ #orexo
-
Orexo
@OrexoABpubl
Intressant artikel skildrad från en läkares perspektiv på plats i USA. Tunga droger som #fentanyl & #metamfetamin sveper över landet & påverkar både individer & samhällen skoningslöst. Demokratisering av vården är en av flera lösningar som måste till för att nå en förändring.
Kvartal
@kvartalet
Hur påverkas USA av drogepiedemin? Läs läkaren Erik W. Larssons reportage.
kvartal.se/henrikhojer/artiklar/festen-ar-over-i-usa/cG9z… -
Orexo
@OrexoABpubl
#orexo upcoming IR presentations that will take place in near-time
▶ Erik Penser Life Science Day, Feb. 24
▶ Sthlm Corporate Finance Life Science Day, March 8
▶ Økonomisk Ugebrev, March 16
▶ Redeye Digital Health Day, March 31
For details please view:
orexo.com/investors/financial-calendar-events/ -
Orexo
@OrexoABpubl
TILLBAKABLICK - VD Nikolaj Sørensen i en intervju med DI Börsmorgon strax efter Q4 rapporten gick ut den 27 januari. Orexo: Zubsolv-lansering vissa marknader i EU 2022 - Di TV @dagensindustri www.di.se/ditv/vd-intervjuer/orexo-zubsolv-lansering-viss…
-
Orexo reposted
Healthcare Hashtag Project
@healthhashtags
Top Influencers of #aharuralhealth: @ahahospitals @HuntzingerGroup @Iodine_Software @InstaMed @OrexoABpubl More 📊 hcsm.io/3nsFSao
-
Orexo
@OrexoABpubl
Mental Illness - Covid-19 impact in numbers ▶ Among US adults who received mental health services in 2020, 17.7 million experienced delays or cancellations in appointments. Source: National Alliance on Mental IlIness @NAMICommunicate #mentalhealthmatters
-
Orexo reposted
AHA Center For Health Innovation
@AHACtrHlthInnv
Our #aharuralhealth Care Leadership Conference sponsors help make this event possible -- we'd like to thank @LaerdalMedical @LegatoTweet @LocumTenens_com @MEDHOSTinc @MEDITECH @Motient_io @NuanceInc @OCHINinc
@OrexoABpubl for their support! We're glad you're here! -
Orexo
@OrexoABpubl
Healthcare Direkt är tillbaka igen. Nu bl a med en intervju med VD Nikolaj Sørensen i 5️⃣ snabba frågor om vår mest avancerade läkemedelskanditat OX124 som närmar sig USA marknaden. Intervjun som ägde rum i slutet av november börjar ca 13.40 in i sändning
www.youtube.com/watch?v=t1O1vOH2WgM -
Orexo
@OrexoABpubl
#innovation is fundamental to the transformation taking place in #ruralhealth care. We’re excited to be part of the 2022 #aharuralhealth Leadership Conference as a sponsor – please come visit us during the conference that will be initiated this weekend. ruralconference.aha.org
-
Orexo
@OrexoABpubl
In our Q4 Reports we do a follow up on our guiding by comparing actual numbers with the last updated outlook. Note: Net revenues development for our lead product, was foremost impacted by generic competition at UHG & Humana where our drug earlier held an exclusive position #orexo
-
Orexo
@OrexoABpubl
Life Science analytikern Klas Palin, Erik Penser, i en längre intervju med VD Nikolaj Sørensen som spelades in i anslutning till publicering av Q4 rapporten i torsdags.
#transformation #pipeline #digitalhealth
youtu.be/Ihx4HFfh-xc via @YouTube -
Orexo
@OrexoABpubl
The Q4 report is published - in the quarter we reached multiple R&D milestones, we launched MODIA and in January we entered a collaboration with Walgreens. Financially, our lead product showed strong profit contribution, while sales QoQ declined slightly ▶orexo.com/posts/2022-01-27-orexo-q4-2021-incl-full-year-r…
-
Orexo
@OrexoABpubl
We’re sponsoring the 2022 AHA Rural Health Care Leadership Conference – where #aharuralhealth leaders can connect with their peers to lead #transformation. We’re proud to be part of such a prestigious event! ruralconference.aha.org #orexo #digitalhealth
-
Orexo
@OrexoABpubl
Next week on January 27 we will announce the Q4 Report. The same day we invite to a call where members of Orexo´s mgmt team will present the latest development and the way going forward. For more info view link below. STAY TUNED. #orexo
www.orexo.com/posts/2022-01-20-invitation-to-presentation… -
Orexo
@OrexoABpubl
Today we look forward to have Mikaela Odlander, Director & head of Digital Therapeutics EMEAA, joining a panel session at a Global DTx event discussing around the topic "Accelerating the Journey Towards Compliance, Reimbursement & Commercialization" www.amg-world.co.uk/wp-content/uploads/2021/10/DTx-Global…
-
Orexo
@OrexoABpubl
We’re hiring! By joining our US SALES FORCE you’ll experience unique opportunities to make a difference to people’s lives. Are you passionate about EMPOWERING PEOPLE who are suffering with mental illness & substance use disorders? Join us! Find out how ▶ orexo.com/about-orexo/become-one-of-us/
-
Orexo
@OrexoABpubl
🎇As we approach the end of 2021, we would like to thank everyone who has supported us through an eventful year. While we continue EMPOWERING PEOPLE suffering from #mentalillness & #addiction we look forward to another year where we are showing progress across all our businesses
-
Orexo
@OrexoABpubl
NEWS: Read this interview where Robert Rönn, SVP and Head of RnD at #orexo, reflects on creating pioneering pharmaceuticals, filing successful patents and his vision for the new drug delivery platform, amorphOX™. #lifesciences #transformation #ox640 ▶ www.orexo.com/posts/2021-12-22-robert-rönn-svp-and-head-o…
-
Orexo
@OrexoABpubl
As #fentanyl is widely spread in the US, more and more Americans are at risk to die of an overdose. Today it is the most common cause of death among people, in the age of 18-45. Actions need to be taken to stop this crisis hitting so many. www.foxnews.com/us/fentanyl-overdoses-leading-cause-death… #foxnews
-
Orexo
@OrexoABpubl
Yesterday the team leading the OX124 project updated us on the product and its progress as we met both IRL & virtually over breakfast. Their dedication to delivering this transformative product to the US market in 2023 is an inspiration to us all at #orexo. #overdosemedication
-
Orexo
@OrexoABpubl
Opioid misuse is growing faster among young adults. In previous studies #childhood trauma has been linked to e.g. chronic #pain & #mentalillness but it has been unclear if it´s related to #opioid abuse. However, new findings indicates there is a connection www.newswise.com/articles/childhood-trauma-increases-risk…
-
Orexo
@OrexoABpubl
Great piece of article in @FiercePharma about our new drug delivery platform amorphOX and OX640 where we aim to develop a nasal adrenaline medication.
www.fiercepharma.com/drug-delivery/orexo-unveils-nasal-ep… -
Orexo
@OrexoABpubl
Tack @LmMarknaden @Digitalhalsa för frukosteventet idag på temat DTx. Intressant föredrag från #orexo och Mikaela Odlander, Director Digital Therapeutics, med fokus på USA marknaden medan John Drakenberg, grundare Alex Therapeutics, berättade om senaste utvecklingen inom EU.
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen intervjuas av @BioStock_SWE. På agendan står senast utvecklingen inom FoU, allmänna råd till bolag som ska ta produkter ut på marknader samt värdet & utmaningarna med en hållbar affär. #orexo @SwedenBIO #swedenbiosummit
BioStock
@BioStock_SWE
BioStock Studio: Orexos vd om nyckeln till marknadsgenomslag
@OrexoABpubl #lifesciences www.biostock.se/2021/12/biostock-studio-orexos-vd-om-nyck… -
Orexo
@OrexoABpubl
Discovery of misuse of substances in DC, that are 10 X more powerful then #fentanyl, is concerning as the drugs could be less vulnerable to some of the primary tools used today to prevent #overdoses. #ox124 a.msn.com/01/en-us/AARgxFB
-
Orexo reposted
Nordic Life Science
@NLifeScience
"OX640 has the potential to transform the adrenaline market offering nasal delivery and less restricted handling and storage requirements," says Nikolaj Sørensen, CEO, @OrexoABpubl nordiclifescience.org/orexo-initiates-new-development-pro…
-
Orexo
@OrexoABpubl
According to Reports and Data the epinephrine (more commonly known as adrenaline) market size today exceed USD 2 billion and is expected to show continuous strong growth in the coming years. Read more here: www.biospace.com/epinephrine-market-size-to-reach-usd-4-7… #orexo
-
Orexo
@OrexoABpubl
NEWS: Orexo to develop a nasal adrenaline medication based on the amorphOX platform. Adrenaline is commonly used for the acute treatment of allergic reactions -a global and growing health problem. Development and commercial partnerships will be considered. www.orexo.com/posts/2021-12-02-orexo-develops-a-nasal-adr…
-
Orexo
@OrexoABpubl
Our CEO Nikolaj Sørensen in @Redeye_ "Hot Seat". A fireside chat focusing on the company´s digital therapeutic venture. The recording took place PRE Q3 Report & the recently communicated R&D news. #orexo #digitalhealth #digitaltransformation #mentalhealth www.redeye.se/video/event-presentation/828140/redeye-hots…
-
Orexo
@OrexoABpubl
Drivers expected to fuel the digital therapeutic market:
👉Healthcare systems challenged
👉Consumers (patients) in the center
👉Widespread technology acceptance
👉Value-based care
Explore more below -
Orexo
@OrexoABpubl
Today #orexo looks forward to present at @aktiespararna Stora Aktiedagen. At 2 pm Nikolaj Sørensen CEO will give a company presentation focusing on the latest business development and the priorities going forward. #aktiespararnaevent
www.aktiespararna.se/tv/live -
Orexo
@OrexoABpubl
amorphOX™, is an inventive powder-based technology, that is very rapidly dissolving, stable & works with different APIs, dosage forms & administration routes. This makes it a versatile platform with significant potential. #innovation #orexo
youtu.be/C-Nm_2QfOGY via @YouTube -
Orexo
@OrexoABpubl
Today we are proud to inform about the amorphOX™ platform, our new proprietary drug delivery technology, which will be instrumental in our work to continue developing differentiated drugs for the treatment of significant unmet medical needs. Read the PR
www.orexo.com/posts/2021-11-26-orexo-provides-information… -
Orexo
@OrexoABpubl
The number of overdose deaths has surpassed 100,000 annually for the first time in history. #fentanyl #opioidcrisis #orexo
edition.cnn.com/2021/11/17/health/drug-overdose-deaths-re… -
Orexo
@OrexoABpubl
Today we are proud to announce positive results from the pivotal trial for OX124 - our life-saving overdose medication. Read PR here: orexo.com/posts/2021-11-16-orexo-announces-positive-resul…
#opioidaddiction #mentalhealth #pipeline -
Orexo
@OrexoABpubl
Our colleague Petter Wereén, VP Procurement and Business Development, attended @CPhIWW in Milano earlier this week, which opened up for good opportunities to meet existing suppliers and establish new potential partnerships. #businessdevelopment #pipeline #supply
-
Orexo
@OrexoABpubl
Meet us in November
▶Nov 11, Redeye Life Science Day
▶Nov 18, Aktiespararna Vellinge
▶Nov 25, Erik Pensers Bolagsdag
▶Nov 29, Stora Aktiedagen
View details here orexo.com/investors/financial-calendar-events/ #orexo -
Orexo
@OrexoABpubl
Färsk längre intervju där Erik Pensers Life Science analytiker Klas Palin intervjuar VD Nikolaj Sørensen om den senaste utvecklingen i Q3 samt prioriteringarna framåt #orexo @EP_Access
Orexo - Intervju Erik Penser Bank - 8 november 2021 youtu.be/hfZEhCk3wdA via @YouTube -
Orexo
@OrexoABpubl
Q3 Report–Steady progression on our journey to build a broader and stronger Orexo
✅Increased US Pharma net revenues QoQ
✅Improved US Pharma EBIT QoQ/YoY
✅Increased R&D activities, e.g OX124 pivotal study ✅New commercial DTx contracts signed
Go to PR www.orexo.com/posts/2021-11-03-orexo-q3-2021-interim-report -
Orexo
@OrexoABpubl
Tomorrow at 8am CET we publish our Q3 Report. At 1pm investors, analysts & media are welcome to join a presentation where Nikolaj Sørensen CEO, Dennis Urbaniak EVP DTx & Joe DeFeo CFO will take you through the latest development & the way going forward. More info on our website▶
-
Orexo
@OrexoABpubl
Record-high numbers in fatal overdoses in the US force the Biden administration to tackle the crisis from multiple angles. #accesstocare #opioidcrisis #orexo www.npr.org/2021/10/27/1049245787/biden-hhs-tackle-drug-o…
-
Orexo
@OrexoABpubl
Last week we attended the Behavioral Healthcare’s Annual Meeting in Washington DC. Great to connect with so many behavioral health leaders committed to improving access and care to those in need. @NABHbehavioral #nabh21 #behavioralhealth Photo: Chris Ferenzi Photography
-
Orexo
@OrexoABpubl
Look forward to commence a partnership with @just_miine_ which will allow access to our clinically proven digital therapies #vorvida and #deprexis on their online healthcare platform. #mentalhealth Read their PR 🔽: www.prnewswire.com/news-releases/a-virtual-care-company-j…
-
Orexo
@OrexoABpubl
We are so proud to have Dennis Urbaniak,EVP Digital Therapeutics, in a nice piece of article @Forbes where he gives his advice about how companies can support their employees suffering from mental illness in a new post #covid19 working landscape #mentalhealth #employeeengagement
Forbes
@Forbes
Remote Workers Report Negative Mental Health Impacts, New Study Finds www.forbes.com/sites/bryanrobinson/2021/10/15/remote-work…
-
Orexo
@OrexoABpubl
Today we are delighted to announce that MODIA™, our novel digital therapy for #opioid dependence, has been published in well-renowned Journal of Medical Internet Research (JMIR) Mental Health. Learn more www.orexo.com/posts/2021-10-18-modia-paper-published-in-t… #mentalhealth #opioidcrisis
-
Orexo
@OrexoABpubl
About #deprexis in the @themightysite ⏩ "We want them to take in the content, practice it, and get it cemented into their behavior, because that’s what’s going to give them a longer-term clinical benefit,” said Michael Sumner, CMO @OrexoABpubl #mentalhealth
-
Orexo
@OrexoABpubl
Today our thoughts go to people around the world who are suffering from MENTAL ILLNESS. As we EMPOWER these peoples life it is key to understand their needs and challenges. In our blog we shed LIGHT on them & giving hope there is a road to recovery ⏩ blog.orexo.com
-
Orexo
@OrexoABpubl
In this insightful article @bustle, you can read about how #vorvida not only helped a psychologist overcome her unhealthy #alcohol intake but also reduced the workload at the clinic. www.bustle.com/life/heres-what-happened-when-i-tried-drin… via @bustle
-
Orexo
@OrexoABpubl
Drug addiction is highly correlated with mental illness. According to Orexo´s REZOLV study in 2016, 32% of patients with #opioid dependence were also diagnosed with #depression. #mentalhealth #deprexis
-
Orexo
@OrexoABpubl
#orexo Investment Case - 5 themes for long-term growth. #innovation #transformation #leadership
-
Orexo
@OrexoABpubl
Increased alcohol intake during #covid19 causes challenges for employers when people get back to their workplace. @HRdotcom Dr Pollack gives employers a tool kit to prevent & manage alcohol misuse among its workers #vorvida #hr
www.hr.com/en/magazines/all_articles/how-employers-can-pr… -
Orexo
@OrexoABpubl
deprexis effectiveness in managing #depression has been evaluated in 11 clinical trials. E.g. the Beevers study among US adults. Listen ⬇ when Dr Beevers elaborates on how DTx can contribute to get more people suffering from depression under treatment. podcasts.apple.com/us/podcast/obsessed-with-kicking-depre…
-
Orexo
@OrexoABpubl
WE ARE HIRING. #orexo is a pioneer in bringing together traditional LIFE SCIENCE with TECH-knowledge. Join our exciting journey! orexo.com/about-us/career/?jobid=172971
#stockholmhub #transformation #digitalhealth -
Orexo
@OrexoABpubl
“One day I woke up and the leaves on the tree were a lot greener than they’d ever been” IN OUR LATEST BLOG, Marguerite shares how she struggled with #addiction until she found the inner strength and right treatment to turn her life around. Read here: blog.orexo.com
-
Orexo
@OrexoABpubl
Joseph R Volpicelli Ph.D of Psychiatry visiting @thatsoberguypodcast and among others he talks about how DTx and vorvida® can help more people who are suffering from #alcohol #addiction and are in need for psychological support. Starting at the 13min mark
aca.st/5c148c -
Orexo
@OrexoABpubl
Fint exempel i dagens @Svd om hur Internetbaserad KBT framgångsrikt kan hjälpa människor som lider av mental ohälsa.
✅Evidensbaserad DTx
✅24/7
✅Enskilt eller som del i vårdprogram
✅Demokratisering av vården www.svd.se/det-varsta-sag-ut-som-att-jag-struntade-i-skolan -
Orexo
@OrexoABpubl
För dem som inte redan sett intervjun där @KarlsonMatilda @Pareto_Sverige intervjuar VD Nikolaj Sørensen så passa på och se den här #orexo / Pareto Securities’ 12th Annual Healthcare Conference youtu.be/hPIWHF830dE via @YouTube
-
Orexo
@OrexoABpubl
#alcohol consumption during the #pandemic has reached record-high levels. #vorvida can help people cut back on drinking based on their own behaviours and habits. Learn more by reading this nice piece of article @inversedotcom www.inverse.com/mind-body/what-heavy-drinking-does-to-you…
-
Orexo
@OrexoABpubl
Bra artikel i @LifeSciSwe om vikten att sammanföra traditionell Life Science med Tech-kompetens för att stärka konkurrenskraften i uppbyggnaden av det nya vårdlandskapet www.lifesciencesweden.se/article/view/805713/bjorn_arvids…
-
Orexo
@OrexoABpubl
Recorded version of the presentation at Pareto Healthcare Conference last week can be viewed below.#orexo
Orexo presenting at Pareto Healthcare Conference Sep 1 2021 youtu.be/etRd9kIxxos via @YouTube -
Orexo
@OrexoABpubl
Thanks @Pareto_Sverige for hosting Pareto Healthcare Conference where our CEO Nikolaj Sørensen will present at 12.30 CET today. He also looks forward to the interview with @KarlsonMatilda. Presentation deck can be find on our website, Investors/Presentations... STAY TUNED #orexo
-
Orexo
@OrexoABpubl
Robert De Luca, President Orexo US Inc, on how #orexo is working to improve OUD patients lives in near-time. The article is part of a media campaign reaching millions of readers through today´s issue of @USATODAY #modia #endoverdose #opioidcrisis
www.futureofpersonalhealth.com/opioid-awareness/enhancing… -
Orexo
@OrexoABpubl
#vorvida™, our evidence based DTx for #alcohol misuse, and which is rooted in CBT techniques is presented in below article by @romper - focusing on how vorvida™ can empower stressful multi-tasking moms who have started seeking relief in alcohol #orexo www.romper.com/life/avoiding-the-wine-mom-trap-5-drinking…
-
Orexo
@OrexoABpubl
Synthetic opioids containing illicitly manufactured fentanyl continues to drive the surge in opioid overdoses in the US, according to @CDCgov. Learn more about its causes and that greater access to treatment is underway. Link to News Article www.orexo.com/posts/2021-08-30-synthetic-opioids-drive-re… #endoverdose
-
Orexo
@OrexoABpubl
At #orexo we strive to give people the best possible chance to overcome their challenges with opioid dependence and to contribute to curb the surge of fatal overdoses. Learn more about how we are approaching this growing concern➡️#endoverdose #opioidcrisis orexo.com/digital-therapies/modia/international-overdose-…
-
Orexo
@OrexoABpubl
With a record-high number of opioid overdose deaths in 2020, where a vast majority was caused by synthetic opioids, there has never been more important to put light on this growing epidemic. Orexo is tackling the crisis from multiple angles and we support the #overdose Day Aug 31
CDC Injury Center
@CDCInjury
August 31st is International Overdose Awareness Day. @OverdoseDay is an opportunity to remember loved ones lost to overdose.
Join @CDCInjury in our efforts to help #endoverdose.
Learn more: go.usa.gov/xFvFa?cid=twitter -
Orexo
@OrexoABpubl
Good to have Mike Sumner, Chief Medical Officer #orexo, attending the Pharma Forum panel discussing DTx and putting light on its important role in the future pharma landscape. #transformation #digitalhealth #himss21
-
Orexo
@OrexoABpubl
Our Blog sheds light on lives affected by #addiction and the road to #recovery - “Today, I focus on the present and living every day with intention and purpose.” Read Mike´s moving story here: blog.orexo.com/2021/07/05/mikemyroadtorecovery/
#opioidcrisis -
Orexo
@OrexoABpubl
NEWS: The pivotal study for our rescue medication OX124 has been initiated. A New Drug Application is expected to be filed with the FDA in H2 2022. #opioidcrisis #addiction. Read the PR here www.orexo.com/posts/2021-07-16-orexo-s-flagship-pharmaceu…
-
Orexo
@OrexoABpubl
Q2 Interim Report – In O2 we saw increased activities in R&D and the DTx business. The greatest highlight was that a commercial DTx contract was signed with a large US healthcare provider. Lead product sales remained stable vs Q1. Read the report here orexo.com/investors/regulatory-press-releases/2021-07-15-…
-
Orexo
@OrexoABpubl
Today we announce a commercial partnership has been signed with @SoberGridApp the largest social media community for people in #recovery from #addiciton. The deal gives a large group of users access to our digital therapies vorvida & deprexis. Read PR-> orexo.com/posts/2021-07-12-orexo-signs-commercial-partner…
-
Orexo
@OrexoABpubl
WELCOME to join us on July 15 at 3 pm CET when Nikolaj Sørensen, CEO and Joe DeFeo, CFO present the Q2 Interim Report. This event follows the announcement of the report that will be publish at 8 am CET the same day. View details here >orexo.com/posts/2021-07-06-invitation-to-presentation-of-…
-
Orexo reposted
FirstWord HealthTech
@fwhealthtech
Orexo enrols first patient in pivotal study of modia with buprenorphine, naloxone for OUD
www.firstwordhealthtech.com/story/5340155
@OrexoABpubl #digitalhealth #healthtech #addiction -
Orexo
@OrexoABpubl
Thanks to @BusinessFocus_ for the interview with our CEO Nikolaj Sørensen resulting in this article which gives a nice introduction to our company and the important health issues we are addressing. #mentalhealth #addiction #digitalhealth #opioidcrisis
Business Focus MAG
@BusinessFocus_
Sweden-based @OrexoABpubl is targeting an area that is rapidly becoming a focus for #medical professionals around the world – #mentalhealth. www.businessfocusmagazine.com/2021/07/01/orexo-ab-a-healt…
-
Orexo
@OrexoABpubl
Glad to announce we have initiated a pivotal study testing our DTx modia™ with OUD patients treated with bup/nal medications. To the study Orexo brings deep category expertise, having served the US OUD market over the last 8 years #digitalhealth Read PR: cisn.co/2TghLkv
-
Orexo
@OrexoABpubl
According to new data presented by @CDCgov, which applies to the period Dec. 1, 2019 – Nov. 30, 2020, the number of fatal opioid overdoses in the US amounted to more than 67,500, an increase of 36 percent. #covid19 #opioidcrisis #ox124
-
Orexo
@OrexoABpubl
According to new data from @CDCgov overdose deaths continues to surge. In parallel multiple businesses confront a workforce more addicted than ever and unemployed don´t manage do get a job as they don´t pass drug tests. www.pressherald.com/2021/06/17/opioids-rip-through-u-s-wo…
-
Orexo
@OrexoABpubl
WOMEN IN WELLNESS series: Thanks to @ChayaWeiner @AuthorityMag for a great interview with our colleague Mikaela Odlander where you shed light on how digital therapeutics can help support peoples journey towards better wellbeing #digitalhealth #depression link.medium.com/parXoPSsbhb
-
Orexo
@OrexoABpubl
Congrats to our partner Gesynta Pharma which has today announced progresses across the #development program for its first-in-class #drug candidate OX-MPI (GS-248) and submitted an IND with FDA. Read the NEWS here: cisn.co/35gbmIe #research
-
Orexo
@OrexoABpubl
We’re delighted to be welcoming Mattias Springfelter back to Orexo in his new role as Head of Pharmaceutical Development. Mattias is already working with his highly skilled team to realise the exciting potential in our pharma pipeline. #ox124 #rnd
-
Orexo
@OrexoABpubl
In May a fund managed by @HealthCapVC, 1 of the largest specialized providers of venture capital within life sciences in Europe, and which was fully invested in Orexo, distributed all it holdings to the owners of the fund. View the updated shareholder list orexo.com/investors/the-share/
-
Orexo
@OrexoABpubl
Thanks to @handelsbanken who once again has giving us the opportunity to present at the Nordic Mid Small Cap Seminar targeting institutional investors worldwide. #orexo s presentation incl. a Q&A that can be seen among the attendees will start 12 noon time CET today #mentalhealth
-
Orexo
@OrexoABpubl
#orexo looks forward to present @Redeye_ Growth Day today. Our CEO will give a brief company presentation starting at 1.30 pm CET. You can view us here www.redeye.se/events/808637/redeye-growth-day-2021 #addiction #mentalhealthmatters #transformation
Redeye
@Redeye_
EVENT: Redeye Growth Day. Tomorrow 08:00-17:00.
Over 70 growth companies within Tech and Life Science are participating. Tune in to the live stream.
Schedule and more information:
www.redeye.se/events/808637/redeye-growth-day-2021 -
Orexo
@OrexoABpubl
NEWS: The patent protection for our lead product in the US continues to strengthen with 2 new patents expiring in 2032. In total there will now be 9 patents listed in the Orange Book relating to this drug. Read the PR incl. CEO comments here orexo.com/posts/2021-06-02-orexo-continues-to-strengthen-… #opioidcrisis
-
Orexo
@OrexoABpubl
It is an honor for us that you are offering deprexis to your hard working #nurses who have done a tremendous work on the frontline saving lives during #covid19. Using deprexis, one of the most clinically proven DTx, can help you move forward in your own way overcoming #depression
-
Orexo
@OrexoABpubl
Today we look forward to attend @ABGSC Life Science Summit. At 12.30 pm our CEO will give a company update focusing on the latest development in our pharma business & the DTx venture as well as the prioritizes going forward. For more info please view orexo.com/investors/financial-calendar-events/abg-sundal-…
-
Orexo
@OrexoABpubl
Thrilled having our colleague Mikaela Odlander on @Pharma_Intell list of 30 Rising #leaders across the biopharma, medtech & #healthtech sectors. Her creativity, drive & business mind will push boundaries and fuel the digitalization in the healthcare arena. insights.citeline.com/IV124773/In-Vivos-2021-Rising-Leade…
-
Orexo
@OrexoABpubl
At Orexo, we are passionate about improving the quality of life for our patients and society and ensuring sustainable practice throughout our business.
Read our sustainability report to learn more: orexo.com/media/05sn0vwv/orexo_sustainabilityreport2020_2…
#innovation #sustainability #responsiblebusiness -
Orexo
@OrexoABpubl
Impressed by our our partner @GAIA_COM - a world-leader in DTx - that today received fully reimbursement also for #vorvida in Germany. Congrats to this powerful team! #digitaltherapeutics #addiction #mentalhealth
Matthias Zenker, MD
@matthiaszenker
What a blast - 4 of 5 of the RCT-proven DiGA-DTx are GAIA products #diga #vorvida #deprexis #elevida #velibra #dtx #rct #digitaltherapeutics @GAIA_COM
www.linkedin.com/posts/marioweiss_vorvida-gaia-gaiadtx-ac… -
Orexo
@OrexoABpubl
Erik Penser Banks Life Science analytiker Klas Palin i en längre intervju med VD Nikolaj Sørensen. Samtalet ger en fördjupad bild av var #orexo befinner sig i nuläget och prioriteringarna framåt. Från 30 apr 2021 ir@orexo.com youtu.be/kfniARwuq_k via @YouTube
-
Orexo
@OrexoABpubl
I morgon kl 10 kan du lyssna på vår VD presentera hos Erik Penser. Temat för eventet är kommersialisering och vårt fokus kommer bl a vara att berätta om hur vi nu kapitaliserar på vår befintliga säljplattform i USA till att oxå inkludera DTx. youtu.be/nUMFXo8ev5w via @YouTube
-
Orexo
@OrexoABpubl
Imorgon kl 9 presenterar VD Nikolaj Sørensen på Aktiedagen. Du kan följa presentationen live på @aktiespararna s länk nedan. @AktiesparEvent
www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-4-m… -
Orexo
@OrexoABpubl
Our Q1 2021 report was released this morning. During the quarter, #orexo has made good progress on multiple fronts as we continue to invest in future growth drivers. Read the full report here www.orexo.com/posts/2021-04-29-orexo-q1-2021-interim-report #addiction #mentalhealth #transformation
-
Orexo
@OrexoABpubl
#natcon21 is the largest conference in #mentalhealth and addiction treatment–a destination for next-level learning, peer-to-peer engagement and connections with experts. At Orexo we are really excited to be an exhibitor at this important event. Looking forward to seeing everyone
-
Orexo
@OrexoABpubl
EMPOWERING PEOPLE: Our colleague PsyD Geri Lynn Utter met with Authority Magazine to give her advice to people suffering from #mentalillness : 5 Ways That Anyone Can Optimize Their Mental Wellness by Candice Georgiadis link.medium.com/GmIAKK7oLfb
-
Orexo
@OrexoABpubl
INVITATION: Next week on April 29 the Q1 Report will be published. At 2 pm investors & analysts are welcome to listen to our CEO Nikolaj Sørensen that along with CFO Joe DeFeo will present the latest development and prioritizes going forward. For details www.orexo.com/posts/2021-04-22-invitation-to-presentation…
-
Orexo
@OrexoABpubl
THIS IS BEYOND. Such an inspiring and hopeful story our colleague PSyD Gery-Lynn Utter brings to her important work at #orexo. You are a role model for so many 🧡 #addiction #mentalhealth
www.nbcphiladelphia.com/news/health/young-woman-who-came-… -
Orexo
@OrexoABpubl
To avoid being captured in the vicious circle of #addiction there is a need of counselling support to cope with AUD in the aftermath of Covid-19. In particular woman are suffering. According to @weillcornell alcohol consumption among women grew 41% in 2020 weillcornell.org/news/alcohol-use-during-the-covid-19-pan…
-
Orexo
@OrexoABpubl
Ethypharm acquires the rights to deprexis & vorvida in 4 European countries from our partner @GAIA_COM. Yet another good sign that EU starts to realize the strong potential clinically proven DTx products have to offer patients suffering from mental illness www.firstwordmedtech.com/node/1044932
-
Orexo
@OrexoABpubl
At #orexo we have a strong dedication and understanding of #opioid #addiction. We know that the most efficient way to treat these patients is to combine pharma treatment with psychotherapy. Therefore our digital therapy modia™ will be an important tool on their way to recovery.
-
Orexo
@OrexoABpubl
#orexo - also traded on the #otcqx Best Market under ticker symbol $ORXOY - will be presenting today at 2:30 PM ET at the @LifeSciForum #virtualinvestorevent. Click the link below for complimentary registration to the live event! www.virtualinvestorconferences.com/wcc/eh/4814904/virtual… @OTCMarkets
-
Orexo reposted
Espander
@Espander
Today March 24, Nikolaj Sørensen CEO of Orexo will perform an investors presentation with a prolonged Q/A at 3-4 pm (CET). To join via TEAMS - click the link:
teams.microsoft.com/l/meetup-join/19%3ameeting_MjRmNjdhN2… -
Orexo
@OrexoABpubl
GET TO KNOW #orexo - For a deep dive into our business, our landscape and our financial development read the Annual Report published today, also including the Sustainability Report. You can download the full version here cisn.co/3f6AWWr
-
Orexo
@OrexoABpubl
Tomorrow, starting at 9 am CET, Nikolaj Sørensen, CEO, will give a company presentation at Stockholm Corporate Finance Life Science Seminar. You are welcome to view the presentation here (press the link in the table). orexo.com/investors/financial-calendar-events/stockholm-c… @borsveckan #orexo
-
Orexo
@OrexoABpubl
NEWS - Today we announce that the patent portfolio for the lead product in the US continues to strengthen. The new patent protects the product until September 2032. Read the PR here orexo.com/news-room/press-releases-and-news/2021-03-17-or… #addiction #opioids
-
Orexo
@OrexoABpubl
In 2020 the number of shareholders in #orexo increased by 39 percent. On April 13 we welcome the shareholders to virtually attend the AGM for 2021. For more info read the Notice published today orexo.com/investors/regulatory-press-releases/2021-03-10-… #usmarket #digitalhealth #pipeline
-
Orexo
@OrexoABpubl
#mentalillness & substance use disorders - #orexo is focusing on areas of great human suffering with wider societal implications. Learn more about our therapeutic areas and how a holistic treatment approach can have a huge impact on those peoples lives➡️
orexo.com/key-therapeutic-areas/ -
Orexo
@OrexoABpubl
We’re delighted to have been awarded an #employeeengagement Best Practice #award by @DecisionWise. Our employees are the backbone of #orexo, and we are proud to be recognised for our commitment towards them. For more information visit: techtodaynewspaper.com/cgi-sys/suspendedpage.cgi #leadership
-
Orexo
@OrexoABpubl
Friendly Reminder - Tomorrow on March 4th, Nikolaj Sørensen, CEO, will give a company update @Redeye Investor Forum Online. The presentation starts at 2.40 pm and will be followed by a brief Q&A. For more info view: orexo.com/investors/financial-calendar-events/redeye-inve… Welcome to join. #orexo
-
Orexo
@OrexoABpubl
Bob DeLuca, president of #orexo US, met @PsychTimes virtually and talked about modia™ our new and upcoming digtial therapy. Evidence-based and rooted in CBT techniques it will help close the gap in care for patients suffering from #opioid #addiction. www.psychiatrictimes.com/view/effectively-treating-opioid…
-
Orexo
@OrexoABpubl
CHANGED DATE - Orexo will attend Redeye Investor Forum on March 4. Our CEO Nikolaj Sørensen will give a company update starting at 2.40 pm CET which will be followed by a brief Q&A session. For more information please see below.
orexo.se/investerare/finansiell-kalender-events/redeye-in… -
Orexo
@OrexoABpubl
Big congrats to our partner @GAIA_COM - a world leader in DTx. With also #deprexis fully reimbursed GAIA is progressing very well under the new German law to reimburse digital therapeutics. #research #transformation #digitalhealth
-
Orexo
@OrexoABpubl
Check out #orexo’s CEO and president, Nikolaj Sørensen, in the @Scrip article ‘What Does 2021 hold for Biopharma? Part 4, Technology and Disease’ scrip.pharmaintelligence.informa.com/SC143776/Scrip-AsksW… #orexo #dtx #mentalhealth
-
Orexo
@OrexoABpubl
NEWS: Glad to announce that we now will start testing modia™, for #opioid #addiction, in patients in collaboration with Magellan RX Mgmt and apexb.io. Proven the clinical value is critical to ensure patients get the treatment they deserve. www.orexo.com/posts/2021-02-10-orexo-starts-to-test-modia…
-
Orexo
@OrexoABpubl
Financial Times about how the pandemic has overturned peoples working condition. Many employers are struggling with employees who are suffering from abnormal stress, loneliness and despair. A development that has caused a surge in mental illness globally. on.ft.com/3aRaGM1
-
Orexo
@OrexoABpubl
NEWS 2 (2) – The strengthened financial position will enable us to continue to invest in our pipeline and digital therapeutics and to capture market opportunities when they emerge to further grow the company. Thanks @ABGSC which acted as financial advisor and sole bookrunner.
-
Orexo
@OrexoABpubl
NEWS 1 (2) - We are overwhelmed by the great interest and confidence institutional investors have shown in our financial ability and future success - which made it possible for us to successfully issue a new corporate bond today. Read the PR here: orexo.com/investors/regulatory-press-releases/2021-02-04-…
-
Orexo reposted
Matthias Zenker, MD
@matthiaszenker
Thank you, Mikaela, for your support and commitment! @dtx_alliance @OrexoABpubl
Orexo
@OrexoABpubl
We are delighted to announce that Mikaela Odlander, Director of DTx at #orexo, will be joining forces with @dtx_alliance as a work group co-leader, to help progress policy and regulatory issues for digital therapeutics in Europe. ➡️ www.firstwordmedtech.com/node/1042579 #mentalhealthawareness
-
Orexo
@OrexoABpubl
We are delighted to announce that Mikaela Odlander, Director of DTx at #orexo, will be joining forces with @dtx_alliance as a work group co-leader, to help progress policy and regulatory issues for digital therapeutics in Europe. ➡️ www.firstwordmedtech.com/node/1042579 #mentalhealthawareness
-
Orexo
@OrexoABpubl
✅According to a recently published research report @BMJ_Open deprexis significantly improved depression outcomes in one of the largest RCTs incl. 1013 participants - no matter of sociodemographic group. Learn more➡️bmjopen.bmj.com/content/11/1/e041389 #mentalhealthmatters #depression
-
Orexo
@OrexoABpubl
OX124 is approaching the final development phase. New expected timing for filing the New Drug Application is mid-2022. Despite not being granted Fast Track Designation we will continue to work closely with FDA to expedite the route to make this important drug available in the US.
-
Orexo
@OrexoABpubl
Q4 Presentation - As earlier communicated we are providing more information on this quarter during our conference call today at 2pm CET. For call in details see orexo.com/news-room/press-releases-and-news/2021-01-15-in… Welcome to join. #mentalhealth #opioidcrisis #digitalhealth
-
Orexo
@OrexoABpubl
REPORT RELEASE: In Q4 sales from our lead product was stable and continued to show strong profitability. Multiple DTx reimbursement concepts were tested and sales started to take off late in the period. OX124 developed according to plan. Read PR here www.orexo.com/posts/2021-01-28-orexo-q4-2020-incl-full-ye…
-
Orexo
@OrexoABpubl
NEWS: We are pleased to share that we have strengthened the IP rights for our flagship pharmaceutical project OX124, a rescue medication to treat opioid overdose. #opioidcrisis #overdose #pipeline www.orexo.com/posts/2021-01-27-orexo-strengthens-ip-right…
-
Orexo
@OrexoABpubl
Our partner, Gesynta Pharma, has announced the first patients have been dosed in its Phase II study of OX-MPI (GS-248) in systemic sclerosis. Read the news here: orexo.com/posts/2021-01-26-orexo-s-partner-gesynta-pharma… #orexo #partner #pipeline
-
Orexo
@OrexoABpubl
Orexo is very pleased to see the decision by the US government to open up for nearly all doctors to prescribe addiction medicine including our lead pharma product #opioidcrisis #addiction #modia
HHS Expands Access to Treatment for Opioid Use Disorder google.com -
Orexo
@OrexoABpubl
Amerikanska regeringen, HHS, tar till åtgärder för att fler amerikaner ska få behandling för sitt opioidberoende.
trader.di.se/index.php/news/detail/bc9d5603-2f7a-4b0f-99b… -
Orexo
@OrexoABpubl
Intressant artikel i dagens @SvD om hur bristen på psykologer och terapeuter resulterat i en kraftig överförskrivning av antidepressiva läkemedel med stor risk för långsiktiga biverkningar #mentalhealth #digitalhealth #deprexis esvd.svd.se/shared/article/massmedicineringen-ett-okontro…
-
Orexo
@OrexoABpubl
Drug addiction is a disease that affects the brain & behavior having a strong impact on QUALITY OF LIFE. People suffering from #addiction will most likely experience #mentalillness and vice versa. A holistic treatment approach can have an instrumental impact on those peoples life
-
Orexo
@OrexoABpubl
A #pandemic causing isolation and instability has resulted in a surge in fatal #overdoses in the US. Adding fuel to an already serious crisis. A range of actions are desperately needed, i.e. eliminating barriers to preventive and life-saving medications lat.ms/2LrONK2
-
Orexo
@OrexoABpubl
Today we announce that we have further strengthened the company´s intellectual property until September 2032 for our lead product on the US market. Read the PR and comments from our CEO here www.orexo.com/posts/2020-12-30-orexo-announces-new-us-pat… #opioidcrisis #orexo
-
Orexo
@OrexoABpubl
Dennis Urbaniak, EVP Digital Therapeutics, interviewed by @BioWorldMedTech about our digital therapies for treatment of mental illness, such as #depression, #alcoholism and opioid #addiction. Issues that are growing rapidly in the wake of the #covid19 pandemic.
-
Orexo
@OrexoABpubl
Already in the early phase of the #covid pandemic virtual care increased by 6000% vs last year. This sudden change will most likely increase the #digitization pace within the healthcare sector and making virtual care an integral part of the provider model blog.thehcigroup.com/healthnxt-the-next-great-advance-in-…
-
Orexo
@OrexoABpubl
As we approach the end of 2020 we would like to thank everyone who has supported us through an unprecedented year. We look forward to another year of progress as we grow our DTx business and push beyond traditional treatments to EMPOWER PEOPLE suffering from mental illness #orexo
-
Orexo
@OrexoABpubl
#orexo s flagship pharma pipeline asset OX124 designed to reverse opioid overdoses, including those from more stronger synthetic opioids, such as fentanyl, that today are the leading cause of death. ➡️Listen to our CEO talking about this project @AktiesparEvent in early December.
This media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
Affärsvärlden sätter KÖP-rekommendation på #orexo. Satsningen på digitala terapier känns spännande och potentialen lockande @AFV_magasin www.affarsvarlden.se/analys/digitala-terapier-minskar-ber…
-
Orexo
@OrexoABpubl
According to a new retrospective analysis fatal overdoses surged in the US during the first wave of #covid19 jamanetwork.com/journals/jamapsychiatry/fullarticle/10.10…. Will also remind our followers that you are always welcome to reach out to ir@orexo.com if you have any Qs related to our business.
-
Orexo
@OrexoABpubl
Our President and CEO, Nikolaj Sørensen, recently had a sit down with @DDWJournal to discuss our launch of our digital therapeutics in the US. To read the discussion in full, please follow the link: www.ddw-online.com/sitting-down-with-orexo-digital-therap… #addiction #digitaltransformation
Drug Discovery World
@DDWJournal
Sitting down with…Orexo, digital therapeutic expert
www.ddw-online.com/sitting-down-with-orexo-digital-therap…
#drugdiscovery -
Orexo
@OrexoABpubl
NEWS: We are excited to announce we have entered an exclusive license and supply agreement with @Accord_HC in Europe for our lead product for opioid #addiction. Read here: orexo.com/en/media/non-regulatory-press-release-and-news?… #mentalhealth #recovery
-
Orexo
@OrexoABpubl
PROVIDING EVIDENCE-BASED DTx - deprexis® effectiveness in managing the symptoms of #depression has been evaluated in multiple published clinical trials with more than 2,800 patients. Listen to CEO Nikolaj Sorensen talking about this at @AktiesparEvent earlier this week.
-
Orexo
@OrexoABpubl
BUILDING FOR THE FUTURE - Entering closely related therapeutic areas with large unmet needs. Listen to CEO Nikolaj Sorensen giving his remarks within this field, @AktiesparEvent in Stockholm, today.
#digitaltransformation #mentalhealth #addictionThis media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
Aktiespararnaevent
@AktiesparEvent
Vi fortsätter Stora Aktiedagen Stockholm med @OrexoABpubl $ORX
Följ oss live på www.aktiespararna.se/tv/live
#aktiespararnaevent -
Orexo
@OrexoABpubl
Tomorrow we look forward to present at the Life Science Day hosted by @redeye. Follow our CEO giving a brief company update live at 9.50 am CET here ➡️
www.redeye.se/events/792760/save-the-date-redeye-life-sci… #digitaltransformation #addiction #mentalhealth -
Orexo
@OrexoABpubl
Thanks to @Accenture for being our partner in the build-up of a digital infrastructure incl. current and future DTx therapies and for connecting us to an ecosystem of healthcare services ->facilitating for among others patients, payers & distributors orexo.com/media/non-regulatory-press-release-and-news?rel…
-
Orexo
@OrexoABpubl
Recently we reached an important milestone, when our main product for the treatment of opioid addiction (OUD) reached gross sales of 1 billion USD, since its launch. With the income from the sales, we are continuing our journey developing the company #transformation #addiction
-
Orexo
@OrexoABpubl
Patients are always closest to our hearts - read our latest blog post here blog.orexo.com/2020/11/12/tara-overcoming-my-addiction/ #addiction #mentalhealth
Mikaela Odlander
@OdlanderM
Our latest blog post is up! Today we share Tara’s story; starting from childhood PTSD that later turned into adult drug and alcohol addiction, finding the right treatment, dealing with shame and stigma and learning to live again in recovery! blog.orexo.com/2020/11/12/tar… @OrexoABpubl
-
Orexo
@OrexoABpubl
Today you can also join us virtually @Redeye_ seminar - FUTURE OF HEALTHCARE - where CEO Nikolaj Sørensen will give a presentation starting 9.40 am CET. To get access to the deck please view here orexo.com/investors/reports-presentations-and-audiocasts/ #digitalhealth #addiction #mentalhealth
-
Orexo
@OrexoABpubl
Proud to have CEO Nikolaj Sorensen on the panel tomorrow discussing the challenges in the healthcare landscape and how to leverage opportunities arising. #digitalhealth #transformation #mentalhealth #orexo
LSX Leaders
@LSXLeaders
[Webinar] Convergence - A Cross-Sector Approach To Healthcare’s Biggest Challenges
Join us Thurs 12 Nov 14:00 GMT
Hear from @JNJInnovation @HumaForHealth @OrexoABpubl @ajackiehunter @benevolent_ai & Melanie Senior
Book web-eur.cvent.com/event/924dd67e-2215-4b52-a37b-241d301b9…
Choose 'Content Only Ticket' -
Orexo
@OrexoABpubl
RETHINK HOW YOU DRINK - vorvida® is an online platform that uses cognitive behavioral therapy techniques to help change the behavioral around alcohol. Read more about our recently launched product in the US here orexo.com/productstherapies/vorvida/ #alcohol #addiction #mentalhealth
-
Orexo
@OrexoABpubl
Tydliggörande: Orexos uppdaterade guidning för 2020 avseende bolagets huvudprodukt är att nettoförsäljningen för kv 4 förbättras mot kv 3 och för helåret förväntas nettoförsäljningen minska mot 2019. Vi beklagar felaktigt årtal i svensk rättelse. orexo.se/sv/media/regulatoriska-pressmeddelanden?releaseI…
-
Orexo
@OrexoABpubl
NEWS: Q3 Interim Report is announced. Read more here ➡️orexo.com/en/investors/reports-presentations-and-audiocas… #orexo #digitaltransformation #mentalhealthmatters
-
Orexo
@OrexoABpubl
Tomorrow at 8 am CET we will go out with the Q3 Interim Report. In the afternoon CEO Nikolaj Sørensen and CFO Joe DeFeo will present the report and investors, analysts and media are welcome to join financialhearings.com/event/12771 #orexo STAY TUNED
-
Orexo
@OrexoABpubl
Bridging the distance between rural settings and quality health support – we’re looking forward to @dtx_alliance’s webinar tomorrow at 2pm EDT/ 8pm CEST on how DTx address the disparities in health experienced in rural areas.
#digitaltherapeutics #healthaccess -
Orexo
@OrexoABpubl
Nice piece by @FiercePharma➡️Dennis Urbaniak, EVP Digital Therapeutics, is interviewed about the DTx venture focusing on the vorvida marketing campaign to drive awareness of this novel CBT digital therapy. #digitaltransformation #addiction
www.fiercepharma.com/marketing/orexo-fast-tracked-digital… -
Orexo
@OrexoABpubl
#orexo and @Lyfebulb are delighted to announce the winner of the 2020 Innovation Challenge as Rohan Dixit, of @getlief, for their wearable patch that monitors heart rate variability. More info here: orexo.com/media/non-regulatory-press-release-and-news?rel…
#digitaltherapeutics #mentalhealth -
Orexo reposted
Lyfebulb
@Lyfebulb
FINALIST PITCHING: youturn is an affordable health care add-on and online solution that helps employers address substance abuse in the workplace by providing resources and support for employees who may be struggling #lyfebulborexo20 @OrexoABpubl @recovery_lyfe #recoveryinnovation
-
Orexo reposted
Lyfebulb
@Lyfebulb
FINALIST PITCHING: PeerrxMed is a free, peer-supported program designed to help physicians and others on the care team move toward thriving both personally and professionally. . #lyfebulborexo20
@OrexoABpubl
@recovery_lyfe
#recoveryinnovation -
Orexo reposted
Lyfebulb
@Lyfebulb
FINALIST PITCHING:
@Litespritegames is the first video game to win a U.S. Surgeon General Award and we are the only one being recommended by clinics today #lyfebulborexo20
@OrexoABpubl @recovery_lyfe #recoveryinnovation -
Orexo reposted
Lyfebulb
@Lyfebulb
FINALIST PITCHING: @rhanbury Richard of @Sana_Health, a wearable device that uses audio/visual stimulation to guide the user into a state of deep relaxation. @OrexoABpubl @recovery_lyfe #lyfebulborexo20 #recoveryinnovation
-
Orexo reposted
Lyfebulb
@Lyfebulb
UP NEXT: Beau of @SoberGridApp, a free iOS/Android app that connects you with a network of other sober people. @OrexoABpubl @recovery_lyfe #lyfebulborexo20 #recoveryinnovation
-
Orexo reposted
Lyfebulb
@Lyfebulb
NOW PITCHING: @rd108 Rohan of @getlief, an HRV wearable device that helps to reduce stress and anxiety in real time using heart rate variability biofeedback training. @OrexoABpubl @recovery_lyfe #lyfebulborexo20 #recoveryinnovation
-
Orexo reposted
Lyfebulb
@Lyfebulb
NEXT PRESENTER: @GotitDoneGal Lucinda of @iallyinc, an app created for family caregivers, offering community support and expert resources. @OrexoABpubl @recovery_lyfe #lyfebulborexo20 #recoveryinnovation
-
Orexo reposted
Lyfebulb
@Lyfebulb
FIRST UP TO PITCH: Mehran of @NeuroQore that offers a rapid 4-day treatment for treatment resistant depression. @OrexoABpubl @recovery_lyfe #lyfebulborexo20 #recoveryinnovation
-
Orexo
@OrexoABpubl
Intressant arikel i @dagensnyheter ➡️Efter att ha genomfört 4 studier med 5600 deltagare konstaterar forskare på @karolinskainst är digitala KBT terapier är lika effektiva som fysiska möten. #orexo #vorvida #digitalhealth
- dn.se www.dn.se/insidan/alkoholhjalp-via-internet-kan-fungera-l… -
Orexo
@OrexoABpubl
Yesterday finalists for the #orexo and @Lyfebulb 2020 Innovation Challenge started to pitch their digital solutions to address the unmet needs of SUD recovery. The winner will be announced later today! For more info please see: orexo.com/pipeline/orexo-and-lyfebulbs-innovation-challange/ #mentalhealth #addiction
-
Orexo
@OrexoABpubl
“To shed light on lives affected by addiction and the road to recovery” – our mission and reason for setting up a blog platform on which to share the stories and insights from individuals coping with #addiction, #recovery and #mentalhealth. Read the blog➡️blog.orexo.com
-
Orexo
@OrexoABpubl
Nice piece by @pharmaphorum covering nearly most said on our telco last week where parts of our mgmt team gave an update on our exciting and promising DTx venture. #digitalhealth #mentalhealth pharmaphorum.com?p=72649 via @pharmaphorum
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen i en intervju med @direktse om satsningen inom digitala behandlingar. #orexo #digitaltransformation #mentalhealth
www.aktiespararna.se/analysguiden/article/799040 -
Orexo
@OrexoABpubl
THANKS - We are pleased to see that we had more than 330 people listening live to our conference call yesterday when we gave an update on our new and promising DTx venture. For those who couldn´t attend the presentation and want to view it -you find it➡️tv.streamfabriken.com/orexo-pressconference-2020/register
-
Orexo
@OrexoABpubl
The key advantage of digital therapeutics is real-time, immediate access to treatment for patients.
Join us at 3pm CET/ 2pm BST today to find out more about our digital therapeutics offering: tv.streamfabriken.com/orexo-pressconference-2020/register
#digitaltherapeutics #mentalhealth #digitalhealth -
Orexo
@OrexoABpubl
#covid19 #depression #alcoholism #orexo
Trinity Health
@TrinityHealthND
President and CEO John M. Kutch announced a partnership with Orexo to provide digital therapies that will help staff members address issues of depression & alcohol abuse, problems that have begun to surface nationwide as healthcare workers address the needs of #covid19 patients.
Orexo
@OrexoABpubl
NEWS: Pleased to announce the partnership with @trinityhealthND who will offer their frontline workers our clinically proven digital therapies deprexis and vorvida to help them cope with depression and alcohol abuse #digitalhealth
www.trinityhealth.org/digital-therapies-help-frontline-wo… -
Orexo
@OrexoABpubl
NEWS: Pleased to announce the partnership with @trinityhealthND who will offer their frontline workers our clinically proven digital therapies deprexis and vorvida to help them cope with depression and alcohol abuse #digitalhealth
www.trinityhealth.org/digital-therapies-help-frontline-wo… -
Orexo
@OrexoABpubl
Nu på måndag den 21 sep kl 11 deltar #orexo i @aktiespararna s Aktiedag i Göteborg. Via nedan länk kan du höra vår VD presentera bolaget med fokus på vad som i nuläget driver tillväxt inom våra terapiområden, DTx satsningen, RnD & strategin framåt. www.aktiespararna.se/tv/live
-
Orexo
@OrexoABpubl
CEO Nikolaj Sørensen will present at @RIConferences today, local US time at 3:00 PM EST. Get details on the webcast here: www.virtualinvestorconferences.com/wcc/eh/4814904/virtual… @OTCMarkets (OTCQX: ORXOY) #orexo #mentalhealth. For more info➡️ir@orexo.com
-
Orexo
@OrexoABpubl
Digital Ten: Digital health news you need to know and thanks for highlighting our recently published collaboration with @GoGoMeds beta.firstwordmedtech.com/story/5105409 via @fwmedtech
-
Orexo
@OrexoABpubl
NEWS Orexo DTx: #orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options. #mentalhealth #addiction Read the DTx PR here: orexo.com/en/media/regulatory-press-releases?releaseId=75…
-
Orexo
@OrexoABpubl
#orexo #digitalhealth #digitaltransformation 5(5)
DTx are reviewed and cleared or approved by regulatory bodies as required to support product claims regarding risk, efficacy and intended use -
Orexo
@OrexoABpubl
Thanks @Pareto_Sverige for hosting the 11th Healthcare Conference which turned out to be a successful virtual event. Also thanks to @KarlsonMatilda who recorded an interview with our CEO available at their digital platform. For access to the presentation, www.orexo.com
-
Orexo
@OrexoABpubl
Our CEO Nikolaj Sørensen, joins @WsgJohn on the latest episode of @BioBossPodcast, discussing Nikolaj’s journey to becoming CEO, digital therapeutics and the impact of #covid19 on #mentalhealth. Listen here: bioboss.buzzsprout.com/236855/episodes/5159299-25-nikolaj… #digitaltherapeutics #addiction
BioBoss
@BioBossPodcast
New podcast, Nikolaj Sørensen, CEO Orexo Therapeutics—Apple Podcasts rebrand.ly/vh8ht5u & biobosspodcast.com #orexo,#opioidaddiction,#opioidcrisis,#opioidepidemic,#substanceabuse,#therapeutics,#digitaltherapies;#digitalhealth,#digitaltransformation,#leadership,,#orexo
-
Orexo
@OrexoABpubl
NEWS 2(2): “We are incredibly pleased by the response to the innovation summit initiative and appreciate the engagement manifested the entrepreneurs, who have invested significant time and effort into the program.” said Mikaela Odlander, Director of Digital Therapeutics at #orexo
-
Orexo
@OrexoABpubl
NEWS 1(2): #orexo and @lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders. Read the PR here: orexo.com/media/regulatory-press-releases?releaseId=50D02…
-
Orexo reposted
OTC Markets Group
@OTCMarkets
Join Joe Coveney, OTC Markets VP; Lena Wange from @OrexoABpubl (OTCQX: $ORXOY #orxoy) & Adam Kostyal from #nasdaqnordic to discuss the benefits of gaining access and exposure to American investors through the secondary US OTC Market. Register: informaconnect.com/lsx-nordic-congress/ @LSXLeaders
-
Orexo
@OrexoABpubl
We are pleased to highlight the International Overdose Awareness Day today, and the continued need for greater awareness of overdose and #addiction.
#ioad2020. To learn more about our key therapeutic area view orexo.com/key-therapeutic-area/ -
Orexo reposted
Redeye
@Redeye_
Nikolaj Sorensen, VD på Orexo, blir intervjuad av Redeyes analytiker om bolagets patentsituation och framstegen inom digital terapi.
Länk: www.redeye.se/research/792150/orexo-interview-with-ceo-ni…
$OREXO #orexo -
Orexo
@OrexoABpubl
CEO remarks Q220➡️"With a foundation in our profitable pharma business, we have been able to invest & act on opportunities where we are uniquely positioned to help millions of people suffering from mental illness, whether caused by depression, alcohol misuse or opioid dependence"
-
Orexo
@OrexoABpubl
-
Orexo
@OrexoABpubl
Thanks @Pareto_Sverige for hosting this conference targeting institutional clients. Our CEO will present on Sep. 3 at 1pm and will among others talk about our new exciting venture within digital therapeutics and why DTx is about to become an integral part of the healthcare sector
Pareto Securities AB
@ParetoSecSE
Pareto Securities’ 11th Annual Healthcare Conference 🧬
On 2-3 September 2020, Pareto Securities are pleased to invite you to attend our virtual Healthcare Conference.
If you wish to attend, contact your Pareto representative.
Become a client: kund.paretosec.com -
Orexo
@OrexoABpubl
In a published opinion piece written by our colleague PsyD. Geri Lynn Utter, she sheds light on how patients in recovery are suffering in the wake of #covid19 and how access to #mentalhealth treatment and psychosocial support has drastically changed www.chestnuthilllocal.com/2020/08/06/dealing-with-relapse…
-
Orexo
@OrexoABpubl
What is DTx 3(5)? DTx can be used independently or in concert with medications, devices or other therapies and incorporate advanced technology best practices #orexo #digitalhealth #digitaltransformation
-
Orexo
@OrexoABpubl
Q&A session at Nordea Small Cap Days. Analyst Klas Pyk is asking our CEO Nikolaj Sorensen to give an update about the development in the new exciting DTx venture targeting SUD and #mentalhealth issues. @NordeaMarkets ➡️
This media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
Today we look forward to attend Nordea Small Cap Days targeting Nordic institutional clients. Our CEO will start presenting at 9 am and it will be followed by a Q&A session moderated by analyst Klas Pyk @NordeaMarkets. To view the presentation deck -> orexo.com/media/2084/orexo-presentation-nordea-small-cap-…
-
Orexo
@OrexoABpubl
-
Orexo
@OrexoABpubl
Intervju 2(2): Orexo kommenterar nyheten om att Sun Therapeutics vill lansera generika på bolagets huvudprodukt i en intervju med Läkemedelsmarknaden-Insikt Medicin www.insiktmedicin.se/articles/697656/2020-08-10-11-34-50-…
-
Orexo
@OrexoABpubl
Intervju 1 (2): Orexo kommenterar nyheten om att Sun Therapeutics vill lansera generika på bolagets huvudprodukt i en intervju med Nyhetsbyrån Direkt.
www.aktiespararna.se/analysguiden/article/777042 -
Orexo
@OrexoABpubl
Overdose deaths in the US rose to record numbers in 2019 according to preliminary data from @CDCgov. 72,000 Americans died, a 7% increase vs 2018 when the mortality fell for the first time in 25 years. #addiction #opioidcrisis
-
Orexo
@OrexoABpubl
Q2–BUILDING FOR FUTURE GROWTH-Preparation for accelerated DTx launch and pipeline progress-As expected, lead product volume declined YoY, due to changed UHG position. In parallel, it showed strong profit contribution, partially compensated for the increased DTx & RnD investments
-
Orexo
@OrexoABpubl
As earlier communicated the Q2 Interim Report will be out tomorrow at 8 am CET. At 3 pm CET investors, analysts & media are invited to attend a Q2 presentation incl. a Q&A. You can also post Qs to ir@orexo.com at latest 11 am CET. WELCOME TO JOIN US!➡️
orexo.com/en/investors/financial-calendar-events?eventId=… -
Orexo
@OrexoABpubl
NEWS: Proud to announce our partner Gesynta has successfully finalized a new funding round, enabling to accelerate the development of their lead project OX-MPI for treatment of inflammatory conditions, such as the life threatening disease systemic sclerosis. #innovation
-
Orexo
@OrexoABpubl
An urgent call to increase funding and solutions for treatment of mental health illness in the wake of the #covid19 #pandemic www.edsurge.com/news/2020-05-30-the-next-pandemic-mental-…
-
Orexo
@OrexoABpubl
NEWS Post 2(2) In addition to the US launch of two digital therapeutics we are also accelerating the launch of our third digital therapy for the treatment of opioid use disorders. Launch is expected to take place one year ahead of the original plan in Q2 2021. #opioidcrisis
-
Orexo
@OrexoABpubl
NEWS post 1(2) We are delighted to announce the US launch of two scientifically proven digital therapeutics for the treatment of depression symptoms and alcohol misuse respectively. Read the full PR here: orexo.com/media/regulatory-press-releases?releaseId=CF58A…
#mentalhealthmatters #digitaltherapeutics -
Orexo
@OrexoABpubl
Key DRIVERS to secure DTx reimbursement: 1️⃣Demonstrate strong clinical data 2️⃣Able to reduce costs among payers 3️⃣Increase treatment results
-
Orexo
@OrexoABpubl
This morning we released positive results from the human PK study of our nalmefene opioid overdose rescue medication, OX125, which may provide an effective response to long acting opioids such as fentanyl.
Read the release here: orexo.com/media/regulatory-press-releases?releaseId=59A51… #addiction #opioidcrisis -
Orexo
@OrexoABpubl
Strong evidence that opioid-related deaths and emergency departments visits increase during times of economic weakness – according to researchers at Vancouver School of Economics at the University of British Columbia in a study from 2017 www.nber.org/aginghealth/2017no3/w23192.shtml
-
Orexo
@OrexoABpubl
UPCOMING DTx LAUNCHES. To get everybody on board we recently gathered all our valued colleagues at our digital therapeutics “All Orexo” virtual town hall meeting where interesting presentations and engaging discussions were held. #mentalhealthmatters #team
-
Orexo
@OrexoABpubl
#addiction recovery advocate Tim Ryan about the escalating struggle addicts currently are facing and what communities, employers and families can do to support. #covid19 www.ehstoday.com/health/article/21134240/a-pandemic-withi…
-
Orexo
@OrexoABpubl
"New synthetic opioid show the need for new and more powerful opioid rescue medications” #opioidcrisis #addiction
EIN Presswire: Press Releases
@EINPresswirePR
ISO: The New Deadly Synthetic Opioid Hitting American Streets s.einnews.com/1sJKNv50tk
-
Orexo
@OrexoABpubl
Treatment of depression -> adding psychotherapy to drug treatment is more helpful than medication alone in treating major depression as they have different effects on the brain - Harvard Health #mentalhealthmatters #depression www.health.harvard.edu/staying-healthy/medication-or-ther…
-
Orexo reposted
Virtual Investor Conferences
@RIConferences
Don't miss today's #virtual Investor Conference featuring presentations from senior executives at @PointsBetUSA @OrexoABpubl @GrayscaleInvest @GFBanorte_mx @CSIsolutions @Starpharma_ASX starting at 10:30am ET.
Register to join: www.virtualinvestorconferences.com/events/event-details/i… -
Orexo
@OrexoABpubl
“FDA also thinks software can help people with the mental burdens of the #pandemic”. Thanks to @TSimonite for this nice piece in the legendary @WIRED Magazine where among others #orexo s EVP Digital Therapeutics, Dennis Urbaniak is interviewed. www.wired.com/story/therapist-in-chatbot-app/
-
Orexo
@OrexoABpubl
Orexo DTx -> We now accept applications to our #innovation challenge in partnership with @Lyfebulb ! Applicants should be Patient Entrepreneurs - those who have been affected by a substance use disorder themselves, or as a support partner lyfebulb.com/innovation-award/orexo-2020/
-
Orexo
@OrexoABpubl
Alcohol and drug misuse on the rise during the #covid19 pandemic and the US will likely need to turn its attention to the millions of Americans who have developed substance use disorders during the pandemic. www.therecoveryvillage.com/drug-addiction/news/drug-alcoh… via @recoveryvillage
-
Orexo
@OrexoABpubl
Canada reports an escalating number of fatal and non-fatal overdoses. The number is similar to the historic peak in the summer of 2017. The development could most likely be explained by the #covid19 pandemic. #opioidepidemic #addiction nationalpost.com/wcm/19c64bce-32cc-4db1-9fb3-f150913f461e via @nationalpost
-
Orexo
@OrexoABpubl
"Overdose Deaths on the Rise Again Amid #covid19". According to a report from the ODMAP organization in the US, raw numbers show a double-digit increase in fatal and non-fatal drug overdoses due to the corona pandemic. #addiction #opioidepidemic www.psychcongress.com/article/overdose-deaths-rise-again-…
-
Orexo
@OrexoABpubl
Allt fler svenska life science bolag vågar ta steget och satsa på kommersialisering i egen regi. #orexo s vd om pipelinerapporten: "Har skett en förskjutning" - Insikt Medicin @vinnovase @SwedenBIO www.di.se/va-insights//articles/691592/2020-06-08-11-48-1…
-
Orexo
@OrexoABpubl
Proud to have CEO Nikolaj Sørensen in the @SwedenBIO Hack jury analyzing and commenting innovative ideas to drive the expansion power in the Swedish Life Science industry #innovation youtu.be/Ia59Rga04G8 via @YouTube
-
Orexo
@OrexoABpubl
TODAY at 11.20 am - view our CEO Nikolaj Sørensen who will give a brief company update at #redeyegrowthday2020. For direct access➡️ www.redeye.se/newevents/585379/growth-day-1
-
Orexo
@OrexoABpubl
We are hiring❗️See jobs➡️www.linkedin.com/company/orexo-us-inc/jobs/ #mentalhealth #wemakeadifference
-
Orexo
@OrexoABpubl
WITH MARKS OF WISDOM SHE CONTINUES TO INSPIRE US ALL 2(2)
......Today, in her role as Medical Science Liaison at #orexo, she play a key role in raising awareness around addiction and mental health issues. Read the full company interview here: cisn.co/3enksW7 #mentalhealth -
Orexo
@OrexoABpubl
WITH MARKS OF WISDOM SHE CONTINUES TO INSPIRE US ALL 1(2) Our colleague Geri Lynn Utter is the right person at the right place. As a child of parents who suffered from drug addiction she against all odds, became a PsyD. A moving story depicted in her first book“Mainlining Philly”
-
Orexo
@OrexoABpubl
INVESTOR PRESENTATION - Tomorrow at 12 noontime Nikolaj Sørensen, CEO, will give a company update and among others he will talk about the upcoming US launches of 3 digital therapies in 2020, at @ABGSC Healthcare Seminar -> view more orexo.com/investors/financial-calendar-events?eventId=3154 #mentalhealthawareness
-
Orexo reposted
Lyfebulb
@Lyfebulb
www.prnewswire.com/news-releases/orexo-and-lyfebulb-partn… We are thrilled to announce our newest partnership with @OrexoABpubl to help those struggling with alcohol and opioid use disorders, particularly during these unprecedented times of #covid19 with an increased unmet need for digital treatment solutions.
-
Orexo
@OrexoABpubl
NEWS DTx- Orexo is pleased to announce our partnership with @lyfebulb, which will boost patient-driven innovation in the space of opioid use disorder and alcohol misuse. orexo.com/en/media/regulatory-press-releases?releaseId=C3… #opioidepidemic #alcholism #innovation
-
Orexo
@OrexoABpubl
Congrats to our partner Gesynta Pharma, which today published positive phase 1 study results for OX-MPI. At #orexo we look forward to follow the continued development of these exciting and important project.
orexo.com/media/regulatory-press-releases?releaseId=ED1E6… -
Orexo
@OrexoABpubl
För dem som missade gårdagens sändning av Healthcare Direkt. "Orexos vd om köpet av USA-rättigheterna för deprexis" #orexo #mentalhealth #depression youtu.be/pF4tpjnMdxQ via
@YouTubehttps://youtu.be/pF4tpjnMdxQ via @YouTube -
Orexo
@OrexoABpubl
According to @WHO #depression is a leading cause of disability around the world and contributes greatly to the global burden of #mentalhealth illness. The effects can be long-lasting or recurrent and can dramatically affect a person’s ability to function and live a rewarding life
-
Orexo
@OrexoABpubl
CEO´s remarks on the latest deal with @GAIA_COM #mentalhealth #depression #covid19
-
Orexo
@OrexoABpubl
#orexo acquires the US rights to commercialize deprexis®, a world-leading digital therapy to manage #depression. With COVID-19 the need for digital therapies is huge and the US launch of our 3 therapies, also incl vorvida® & OXD01, will accelerate in 2020. orexo.com/media/regulatory-press-releases?releaseId=9CC5F…
-
Orexo
@OrexoABpubl
Erik Bertilsson, förvaltare Lancelot Asset Management, i en intervju med @dagensindustri om utsikterna för vårt bolag #orexo #addiction #pipeline #digitalhealth
”Otroligt lågt värderad” – tre läkemedelsbolag som vinner i krisen www.di.se/nyheter/forvaltaren-tre-lakemedelsbolag-som-vin… -
Orexo
@OrexoABpubl
When implementing portfolio mgr Mr Greenblatts investment philosophy➡️”by simply and systematically applying a formula that seeks out good businesses when they are available at bargain prices”➡️on companies listed at NasdaqOMX #orexo comes out as no. 1️⃣
www.placera.se/kommentar/metoden-for-att-hitta-vinnarakti… -
Orexo
@OrexoABpubl
KEEP UPDATED by watching today´s virtual company presentation by our CEO Nikolaj Sørensen starting at 3.45 pm CET. To view just follow this link www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-4-m… and thanks @aktiespararna for hosting the event. #aktiedagen #pipeline #digitalhealth
-
Orexo
@OrexoABpubl
#orexo welcomes Gergana Almqvist as our new analyst @Redeye_. Yesterday she made her first interview with our CEO, elaborating on the latest development in Q1 and what can drive values going forward. #addiction #pipeline #digitalhealth
Redeye
@Redeye_
🎥 Långintervju med Orexos vd Nikolaj Sørensen. Bland annat diskuteras Q1:an, pipelinen och digital therapy. (20 min):
$ORX
www.redeye.se/research/781009/orexo-interview-with-ceo-ni… -
Orexo
@OrexoABpubl
Our CEO about timing for US product launching:"In light of #covid19 and changes to market access for digital therapies, we will consider investing in an earlier and broader launch, if the opportunity exists for vorvida®and OXD01." For full Q1 CEO comments orexo.com/about-us/ceo-comments/
-
Orexo
@OrexoABpubl
NEWS: Q1 Report 2(2) The impact of COVID-19 has been limited and the timelines for OX125 and OX124 is unchanged at this stage. In parallel the company is assessing to accelerate the launch of vorvida® in the US. Welcome to join our telco today, more info on our website.
-
Orexo
@OrexoABpubl
NEWS: #orexo Q1 Report - Resilient business driving continued growth in challenging times 1(2). In Q1 a solid financial performance was reported, with both profitability and cash improving. The main driver was Zubsolv US with an EBIT margin of 46 percent.
-
Orexo
@OrexoABpubl
The COVID-19 pandemic will fuel the demand for digital therapies and within mental health care there is a clear need. #addiction #digitalhealth www.statnews.com/2020/04/13/remote-mental-health-livongo-… via @statnews
-
Orexo
@OrexoABpubl
#covid19. Thanks to Digital Therapeutics Alliance who is calling for broader access to DTx tools. “A lot of private payers are starting to reimburse and provide access to these tools, but patients on the public side don’t have the same options,” said Megan Coder, @dtx_alliance.
-
Orexo
@OrexoABpubl
This World Health Day #orexo joins the global community in celebrating the efforts of nurses, midwives and healthcare workers worldwide, especially now as they stand in the frontline of the COVID19 pandemic
#worldhealthday #thankshealthheroes”
World Health Organization (WHO)
@WHO
It's #worldhealthday! Take a minute to say #thankshealthheroes! www.pscp.tv/w/cVsbFjI2MTAyMHwxeXBLZFFscWFZcUdXC9ZC_9m1yi7…
-
Orexo
@OrexoABpubl
"Därför kan några av våra kliniska forskningsprojekt bli försenade, men det är för tidigt att säga om det påverkar tidslinan till lansering, säger #orexo s VD Nikolaj Sørensen, i en färsk intervju med @LifeSciSwe om #covid19 s påverkan på verksamheten. www.lifesciencesweden.se/article/view/712379/orexo_forskn…
-
Orexo
@OrexoABpubl
2 (2) STRATEGIC AGENDA -> Our road-map for long-term growth #orexo #addiction #digitalhealth
-
Orexo
@OrexoABpubl
1(2) PROUD OF WHAT WE HAVE ACHIEVED -> Today we stand on a strong operational and financial ground
#orexo -
Orexo
@OrexoABpubl
IN THE WAKE OF COVID-19. According to the Center of Disease Control the hospitalization rate for substance use disorders in Louisiana increased by more than 35%, 3 years after the hurricane Katarina. Experts fear that could happen again-on a national scale www.businessinsider.com/experts-say-coronavirus-may-cause…
-
Orexo
@OrexoABpubl
A HELPING HAND - As the healthcare system and elderly care centers are facing extremely challenging times, Orexo has donated ✅respiratory equipment ✅protective coveralls ✅gloves to 2 elderly centers in the Uppsala region #togetherapart #covidー19
-
Orexo
@OrexoABpubl
TRANSPARENCY IS KEY in the wake of the corona crisis. Thanks @OTCMarkets for hosting today´s Virtual Life Sciences Investor Forum. We look forward to attend! Hope you will join us at www.virtualinvestorconferences.com/wcc/eh/4814904/virtual…
#virtualinvestorconference #digitalhealth -
Orexo
@OrexoABpubl
#covidー19 IMPACT. The need for #social_distancing, #remotework ing and lack of routines may lead to increased stress and anxiety. Thus people suffering from #addiction are facing challenging times in the wake of the corona pandemic. #digitalhealth -> eur02.safelinks.protection.outlook.com?url=https://www.ps…
-
Orexo
@OrexoABpubl
Lena Wange, IR & Communication Manager, i tidningen @LmMarknaden (Pharma Market Newsletter incl. #digitalhealth) om #orexo s nya satsning inom digitala behandlingar, DTx. Digitala terapier ett huvudspår när Orexo breddar verksamheten - Insikt Medicin www.insiktmedicin.se/articles/676611/2020-03-19-12-02-39-…
-
Orexo
@OrexoABpubl
JOIN VIRTUELLY. Shortly our CEO, Nikolaj Sørensen, will present at @Redeye_ Digital Investor Forum. His presentation will start today 3.20 pm and will be followed by a minor Q&A. STAY TUNED! #digitalhealth #addiction
www.redeye.se/live/digital-19-mars -
Orexo
@OrexoABpubl
#orexo Rättelse via @direktse #orexocmd20
www.aktiespararna.se/analysguiden/article/729458 -
Orexo
@OrexoABpubl
#orexo sees significant potential with vorvida® but has not given any guidance on sales for vorvida®, the estimates mentioned by an analyst was for 2021, not 2020
www.di.se/bors/telegram/26500ff0-9274-4823-9489-93b4cd895… #orexocmd20. If you have any Qs ->ir@orexo.com -
Orexo reposted
Matthias Zenker, MD
@matthiaszenker
He is right - we are.
Orexo
@OrexoABpubl
“We're able to develop digital therapies that are well liked by patients and that have the same effectiveness as personal consultations. Our treatments are available 24/7 on mobile devices, addressing a high unmet demand for help.” Dr Mario Weiss, CEO and founder of GAIA AG
-
Orexo
@OrexoABpubl
Thank you to everyone who attended our Capital Markets Day this afternoon, and to the speakers and everyone at Orexo who made this a great event. If you have any questions, please do get in touch!
-
Orexo
@OrexoABpubl
“We're able to develop digital therapies that are well liked by patients and that have the same effectiveness as personal consultations. Our treatments are available 24/7 on mobile devices, addressing a high unmet demand for help.” Dr Mario Weiss, CEO and founder of GAIA AG
-
Orexo
@OrexoABpubl
"We have seen a dramatic demand for our services recently because we can treat patients without seeing them and scale our resources. We don’t require human interactions, which demonstrate the power of digital solutions." Dr Mario Weiss, CEO and founder of GAIA AG
-
Orexo
@OrexoABpubl
We are looking forward to shortly hearing from Dr Mario Weiss, the CEO and founder of Orexo’s partner GAIA AG, discuss how GAIA are leading the way globally in #digitaltherapeutics. #orexocmd20 #growthstrategy #dtx
-
Orexo
@OrexoABpubl
“For our OXD01, our aim to develop the first #dtx that will show significant sustainable outcomes for patients suffering from opioid use disorder and make it available globally. In this market, we anticipate USD 150-225m in net sales.” EVP Digital Therapeutics, Dennis Urbaniak
-
Orexo
@OrexoABpubl
“We have two #dtx with the potential to disrupt the current treatment of substance use disorder in the US. We will focus on a insight-driven strategy, precision targeting, value creation, customer engagement and resource optimization.” EVP Digital Therapeutics, Dennis Urbaniak
-
Orexo
@OrexoABpubl
“The pricing of digital therapy is scattered, with significant differences driven by sophistication and clinical evidence of the technology. For our pipeline, we expect the pricing of Orexo therapies to be in the range of USD 600-1,000 per treatment.” EVP DTx, Dennis Urbaniak
-
Orexo
@OrexoABpubl
"Within a few months, we will have the opportunity to support patients suffering from alcohol misuse by providing access to a new #dtx, replacing the need for frequent visits to a counsellor during treatment. " EVP Digital Therapeutics, Dennis Urbaniak
-
Orexo
@OrexoABpubl
Our new EVP Digital Therapeutics, Dennis Urbaniak, will shortly be discussing #digitaltherapeutics and its transformation of patient care at the Orexo Capital Markets Day, #dtx #orexocmd20 Stay tuned!
-
Orexo
@OrexoABpubl
"With a differentiated rescue medication profile that is faster, stronger and longer lasting, we hope to be able to save more patients with the first dose of rescue medication, avoiding a second overdose." Johannes Doll, EVP and Chief Commercial Officer
-
Orexo
@OrexoABpubl
"Our current development projects are addressing critical unmet needs within addiction and are fully in line with Orexo's aim of becoming a leading company within #addiction" Johannes Doll, EVP and Chief Commercial Officer
-
Orexo
@OrexoABpubl
Johannes Doll, EVP and Chief Commercial Officer, is now presenting on Orexo’s exciting pipeline and future potential. Watch it live here: tv.streamfabriken.com/orexo-cmd-2020 #orexocmd20
-
Orexo
@OrexoABpubl
"Our lead product is growing in the open market and we have been able to grow our business despite generic competition. We remain in a solid position, which demonstrates our focus & being able to deliver the right messages to physicians." Robert DeLuca, President of Orexo US Inc
-
Orexo
@OrexoABpubl
"Our lead product is the foundation of what we are continuing to build as we move forward. Importantly, this product has another 12 years of life, is profit generating and will continue to be a revenue generator ." Robert DeLuca, President of Orexo US Inc.
-
Orexo
@OrexoABpubl
Kicking off our Capital Markets Day is our CEO and President, Nikolaj Sørensen, presenting Orexo’s strategy for short and long term growth at 1.30pm CET. You can watch all the #orexocmd20 activities live streamed here: tv.streamfabriken.com/orexo-cmd-2020
-
Orexo
@OrexoABpubl
We’re excited to host our #cmd today! Join us at Helio GT30 or check out www.orexo.com to find details on how to attend online. See you there.
-
Orexo
@OrexoABpubl
We’re getting ready for our #cmd today, and look forward to welcoming attendees here in Stockholm or via conference call and webcast. The full agenda is available here orexo.com/media/regulatory-press-releases?releaseId=BDE59… as well as details on how to register and how to attend online #orexocmd20
-
Orexo
@OrexoABpubl
NEWS – On the CMD today the company will present the sales potential for both the pharma projects and the digital therapies. Among others OX124 is expected to reach a sales potential of USD 70 m – USD 110 m in the US. Read more orexo.com/media/regulatory-press-releases?releaseId=8D25F… #orexocmd20
-
Orexo
@OrexoABpubl
Stockholm Corporate Finance Healthcare Seminar igår. Moderator Charlotte Stjerngren frågar vår VD vad vi framför allt vill uppnå med vår kapitalmarknadsdag nästa vecka den 17 mars #orexocmd20 #pipeline #digitalhealth
-
Orexo
@OrexoABpubl
Today our CEO Nikolaj Sorensen gives a company update at Stockholm Corporate Finance Healthcare Seminar in Stockholm, Sweden. The presentation incl. Q&A takes place between 9.30-10.00 am CET and can be viewed live here financialhearings.com
-
Orexo
@OrexoABpubl
NEWS - vorvida® submitted with FDA to enable commercialization in the US already later this year.
Dennis Urbaniak, EVP DTx, will provide additional details and comments about the market for DTx in the US at the Capital Markets Day March 17. #orexocmd20 #impact #digitalhealth -
Orexo
@OrexoABpubl
STRATEGY FOR FUTURE GROWTH. From a strong financial and operational platform #orexo are focusing to take the company to the next level with the aim of becoming a leader in treatment of #addiction. On the Capital Markets Day we will share more details about our growth strategy.
-
Orexo
@OrexoABpubl
The White House Counsil of Economic Advisors, an advisory committee to the American President, estimates the #opioidepidemic costs for the US Society amounted to USD 696 billion in 2018 and more than USD 2.5 trillion, 2015-2018. #opioidcrisis
-
Orexo
@OrexoABpubl
OUR EMPLOYEES ARE KEY TO OUR SUCCESS. Proud to have our first global intranet launched with the ultimate aim to continue to drive engagement and to build bridges operationally and geographically. #leadership #bestcompany
-
Orexo
@OrexoABpubl
Tullen: "Sverige har en opioidepidemi". 2019 beslagstogs dubbelt så mycket av den syntetiska opioiden tramadol i Sverige och vården har slagit larm om att allt fler, särskilt unga, söker hjälp för beroende av smärtstillande opioider. www.svd.se/tullen-sverige-har-en-opioidepidemi via @SvD
-
Orexo
@OrexoABpubl
▶️Good to see you all together and thanks @OTCMarkets for a great collaboration. Look forward to arrange more joint activities in 2020⏫
OTC Markets Group
@OTCMarkets
Dennis Urbaniak @DUrbaniak and Mike Myers from @OrexoABpubl (OTCQX: $ORXOY) stopped by our offices last week to catch up with @robertpower1 & Joe Coveney from our Corporate Services team.
Watch our #otcqxvideo with Orexo's CEO: youtu.be/pQ4rdtTtBeg -
Orexo
@OrexoABpubl
Interesting article in the @TheTimes last week about the overprescription of opioids in the UK despite little evidence of clinical benefit for the treatment of chronic pain. #opioidcrisis #addiction #digitalhealth”
www.thetimes.co.uk/article/most-opioids-prescribed-needle… -
Orexo
@OrexoABpubl
We believe digital therapeutics will become an integral part of the healthcare landscape and #addiction is one of the areas where it is most needed. We asked Dennis Urbaniak EVP Digital Therapeutics 4 Qs about our new DTx venture youtu.be/BB34PRTG4pc via @YouTube
-
Orexo reposted
Dennis Urbaniak
@DUrbaniak
Thanks so much to our friends at @OTCMarkets for hosting us today. @OrexoABpubl
-
Orexo
@OrexoABpubl
#orexo s partner @GAIA_COM has once again proved the effectiveness and value of digital therapy. Orexo look forward to our future collaboration to show similar effectiveness in the treatment of alcohol- and opioid use disorder. #addiction #digitalhealth
gaia-group.com/en/news/effectiveness-of-gaia-digital-ther… -
Orexo
@OrexoABpubl
The strong financial position enables #orexo to pursue its growth strategy with the overall aim to add more products to our fully owned US commercial infrastructure. #addiction #digitalhealth #orexocmd20
-
Orexo
@OrexoABpubl
Dagens Q rapport -> @direktse och Magnus Bernet sammanfattar presentationen från dagens tele-konferens. Pulicerat av bl a DI nedan. #orexo #addiction #digitalhealth
www.di.se/bors/telegram/29702615-229c-4f67-a6d7-54bfe6b95c2d -
Orexo
@OrexoABpubl
NEWS: We published our Q4 & FY19 report today and are pleased to announce record-high financial results and with strong fundamentals in place we will continue to deliver our strategy for future growth. Look forward to an exciting 2020! #addiction #pipeline #digitalhealth
-
Orexo
@OrexoABpubl
NEWS-The PK study forOX338, evaluating novel formulations of ketorolac for treatment of pain showed promising results with improved bioavailability&tolerability vs the reference product. Now we will continue to optimise the formulation to ensure obtaining a unique product profile
-
Orexo
@OrexoABpubl
As earlier communicated we will announce our Q4 results, also incl. the FY 2019, at 8 am CET on January 30. A presentation will be held by Nikolaj Sørensen, CEO, and Joseph DeFeo, CFO, at 2 pm CET. Link to the webcast here: tv.streamfabriken.com/orexo-q4-2019 Welcome to join us!
-
Orexo
@OrexoABpubl
The @lyfebulb-Helsinn #innovation Award will be presented to an innovator with outstanding entrepreneurial potential to commercialize an idea to better manage cancer using drugs,medical devices or healthcareIT. Proud that Dennis Urbaniak, EVP DTx, is a member of the renowned jury
Lyfebulb
@Lyfebulb
lyfebulb.com/innovation-award/helsinn-2020/ Congrats to our Finalists for the third annual Lyfebulb-Helsinn Cancer Innovation Summit & Award. #patiententrepreneurs will pitch their Innovations @ #lyfebulbhelsinn20 for a chance to win one of TWO $25k prizes to further their business!#cancerinnovation
-
Orexo
@OrexoABpubl
➡️The highlights from 2019 and what to expect in 2020➡️Recently our US President, Robert DeLuca presented at DNB´s NALS Conference in NYC, and was also interviewed by Edison who acted as a co-hoster of the event. Watch the video below. www.edisongroup.com/edison-tv/executive-interview-orexo-a…
-
Orexo
@OrexoABpubl
As we prepare to put another year behind us, we look forward to an exciting and promising 2020, filled with opportunities for our lead product on the US market, exciting pipeline advancements and growing our digital health business. STAY TUNED! #addiction #digitalhealth
-
Orexo
@OrexoABpubl
From last week - another great article covering Orexo’s #vorvida deal with @GAIA_COM by @MedtechCate at @Medtech_Insight. You can read the full article here: insights.citeline.com/MT125961/Orexo-Expands-Digital-Ther…
-
Orexo reposted
Dennis Urbaniak
@DUrbaniak
Our US President Robert DeLuca sharing the @OrexoABpubl story at the Nordic American Life Science conference
-
Orexo
@OrexoABpubl
Save the Date -> #orexo invites investors, analysts and media to a Capital Markets Day on March 17, 2020. #orexocmd20 #digitalhealth @GAIA_COM Read more ->
orexo.com/media/press-releases?releaseId=F6490C4D8AD0E77F -
Orexo
@OrexoABpubl
#orexo strengthen its competencies and resources within digital health by appointing Dennis Urbaniak, one of the leading experts in #digitalhealth in the US, as EVP Digital Health. #addiction read more orexo.com/media/press-releases?releaseId=0038155572D9B761
-
Orexo
@OrexoABpubl
Our vorvida deal with @GAIA_COM is covered by @MedtechTinaTan in @fwmedtech. Thank you Tina for this great piece reflecting Orexo’s evolving development in the digital therapeutics field.
Tina Tan
@MedtechTinaTan
This second deal for #vorvida comes 3 months after $ORX and .@GAIA_COM first teamed up for an #opioidaddiction DTx. vorvida is market-ready and has RCT data in the bag, so should bring in revenue sooner.
-
Orexo
@OrexoABpubl
By acquiring vorvida® for treatment of Alcohol Use Disorder #orexo has extended its partnership with @GAIA_COM who is a global leader in #digitaltherapeutics. To learn more about GAIA please view below
Watch “GAIA: About the company” on #vimeo vimeo.com/195960235 -
Orexo
@OrexoABpubl
NEWS: In line with the ambition to become a leader within treatment of addiction #orexo has extended its partnership with @GAIA_COM by acquiring the US commercial rights to vorvida, ®a digital therapy for the treatment of #alcoholaddiction orexo.com/en/media/press-releases?releaseId=FCC0DB38889B7476
-
Orexo
@OrexoABpubl
Thanks @nordeamarkets for hosting Nordea Innovation Seminar today, where our CEO gave a company update. In the Q&A session analyst Klas Pyk among others asked about the strategy to entering #digital therapeutics ➡️
This media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
MEET US - view our updated investor calendar for the coming months. #digitalhealth #addiction
orexo.com/investors/financial-calendar-events/ -
Orexo
@OrexoABpubl
Today and tomorrow #orexo meets investors and B2B companies at #jefferies Healthcare Conference in London. To view the presentation, held by our CEO, Nikolaj Sørensen, please go to the investor section/presentations on our website. #digitalhealth
www.jefferies.com/IdeasAndPerspectives/Conferences/325/11… -
Orexo
@OrexoABpubl
#digitalhealth “Our strategy is to focus on solutions with SCIENTIFICALLY PROVEN therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.” Nikolaj Sørensen, President and CEO, (Q3 report) #orexo @GAIA_COM
-
Orexo
@OrexoABpubl
Trevlig läsning i @dagensindustri #orexo
-
Orexo
@OrexoABpubl
The use of digital therapeutics is increasing with #digital poised to play a key role in most, if not all, future interactions with health care providers. The latest issue of
@NLifeScience Magazine highlights #orexo s DTx partnership with @GAIA_COM. #opioidusedisorder -
Orexo
@OrexoABpubl
To broaden and diversify our shareholder base the #orexo share is also available as an ADR at OTC Market in the US. Below is an interview where our CEO, Nikolaj Sørensen is interviewed by Bob Power Vice President at OTC Market.
OTC Markets Group
@OTCMarkets
Nikolaj Sorensen, CEO of @OrexoABpubl (OTCQX: $ORXOY) joins the #otcqxvideo series to share how Orexo is developing treatments focused on opioid addiction.
>> Watch now: youtu.be/pQ4rdtTtBeg
#tuesdaythoughts -
Orexo
@OrexoABpubl
Orexo på plats på Stora Aktiedagen i Göteborg. Kl 18.20 presenterar EVP & Chief Commercial Officer Johannes Doll. Lyssna på presentationen live nedan. @aktiespararna www.aktiespararna.se/nyheter/folj-livesandningen-fran-sto…
-
Orexo
@OrexoABpubl
HUGE SOCIETY COSTS FOR OPIOID ABUSE - According to Society of Actuaries and their report “Economic Impact of Non-Medical Opioid Use in the US” the total economic burden of the #opioidcrisis in the US from 2015-2018 was at least USD 631 billion. Read more:
www.soa.org/globalassets/assets/files/resources/research-… -
Orexo
@OrexoABpubl
Watch the video interview with Nikolaj Sørensen CEO and Johannes Doll CCO about the Q3 highlights and how to take the company to the next level #addiction #digitaltherapeutics @GAIA_COM www.redeye.se/research/584519/orexo-video-interview-ceo-n… via @Redeye_
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen i en intervju med @dagensindustri och Cathrine Hofbauer efter rapportsläppet i veckan #orexo Orexos vd efter succérapporten: ”Hiskelig marknadsutveckling” www.di.se/nyheter/orexos-vd-efter-succerapporten-hiskelig…
-
Orexo
@OrexoABpubl
Part 2(2) In Q319 we signed new and exciting partnership agreement with @GAIA_COM to develop a #digitaltherapy for Opioid Use Disorder, which we expect to file with FDA in 2021. Join our conference call at 2pm to hear more about how we will progress this tv.streamfabriken.com/orexo-q3-2019
-
Orexo
@OrexoABpubl
Part 1(2) We published our Q319 report today and are pleased to announce that strong financials continue to drive our focus on broadening the pipeline and product portfolio and to build a presence in #digitaltherapies. Read the report here orexo.com/en/investors/reports-presentations-and-audiocas…
-
Orexo
@OrexoABpubl
We will announce our Q3 results at 8 am CET on October 24. A presentation will be held by Nikolaj Sørensen, CEO, and Joseph DeFeo, CFO, at 2 pm CET. Link to the webcast here: tv.streamfabriken.com/orexo-q3-2019 Welcome to join us!
-
Orexo
@OrexoABpubl
Orexos hemsida ligger nu uppe igen. Tack för visat tålamod och vi beklagar återigen problemet med hostingen av sidan.
-
Orexo
@OrexoABpubl
Orexos hemsida ligger tyvärr nere pga tekniska problem relaterat till hosting. Leverantören arbetar intensivt med att åtgärda problemet som drabbat flera företag. Vi beklagar det inträffade och räknar med att det är åtgärdat inom kort. Vid frågor vänligen kontakta ir@orexo.com
-
Orexo
@OrexoABpubl
Our colleague Lovisa Case, the SSE MBA's scholarship winner for 2020, together with the well known jury. #orexo #opioidcrisis
Stockholm School of Economics
@handels_sse
Lovisa Case from Orexo AB receives this year’s MBA scholarship www.hhs.se/en/about-us/news/2019/lovisa-case-from-orexo-a…
-
Orexo
@OrexoABpubl
SHE STANDS OUT. At #orexo we are so proud to have this super talent, Lovisa Case, PhD, on-board. Together with her colleagues she will make a big difference for all these people suffering from opioid use disorder. @dagensindustri @handels_sse #leadership
weekend.di.se/nyheter/arets-mba-stipendiat-viktigt-att-ly… -
Orexo
@OrexoABpubl
DIGITAL THERAPEUTICS-Great piece about #digitaltherapeutics in the @EveningStandard. Exciting to see that #dtx are evolving and being implemented by the @NHSuk (Department of Health & Social Care). Read more www.standard.co.uk/futurelondon/health/how-apps-and-vr-ar… #orexo @GAIA_COM
-
Orexo
@OrexoABpubl
Senaste numret av Privata Affärer, Tema Hälsovårdsfonder - spännande investeringstillfällen i sektorn. Kul att HealthInvests ansvariga förvaltare, proffsiga Anders Hallberg, lyfter fram #orexo som ett guldkorn i sin portfölj.
-
Orexo
@OrexoABpubl
Orexo´s new partner @GAIA_COM, a global leader within developing world class digital therapeutics, is highlighting that September is the #painawarenessmonth
-
Orexo
@OrexoABpubl
We’re on our way to the Sachs Annual Biotech Europe Forum where CEO, Nikolaj Sørensen, will provide an introduction to #orexo and discuss recent company developments. Come find us tomorrow at 3:30 pm CET orexo.com/en/investors/financial-calendar-events?eventId=… #sachs_bef19 #orexo #opioidcrisis
-
Orexo
@OrexoABpubl
As 1/3 of the patients with opioid dependence also are suffering from depression this not comes as a surprise @NIDAnews www.drugabuse.gov/about-nida/noras-blog/2019/09/suicide-d…
-
Orexo
@OrexoABpubl
#orexo i senaste numret av @LifeSciSwe Perspektiv #opioidcrisis - "Orexo har lösningen på problemet", VD Nikolaj Sørensen. Läs artikeln nedan. www.lifesciencesweden.se/article/view/676883/orexos_vd_om…
-
Orexo
@OrexoABpubl
#orexo - titta gärna på nedan
Direkt Studios
@direktstudios
Healthcare Direkt är igång! Vi gästas av vd för @OrexoABpubl Nikolaj Sørensen.
youtu.be/xTv0YFzSi88 -
Orexo
@OrexoABpubl
Imorgon kl 9.30 presenterar VD Nikolaj Sørensen på @aktiespararna @aktiedagen i Stockholm. På agendan -> tillväxtstrategi, pipeline, marknad&försäljning och finansiell info. #orexo Presentationen sänds live nedan:
www.aktiespararna.se/tv/live -
Orexo
@OrexoABpubl
Det finns hjältar och så finns det HJÄLTAR - läs om hur hårt barnen drabbas av opioidkrisen i USA @SvD esvd.svd.se/svenskadagbladet/50100/article/965612/28/1/re…
-
Orexo
@OrexoABpubl
Nordic Life Science News highlights #orexo s new collaboration with the global leader in digital therapeutics, @GAIA_COM, nordiclifescience.org/orexo-signs-partnership-agreement-w…
-
Orexo
@OrexoABpubl
The marijuana legalization in the US will increase the risk for opioid misuse, rather than reducing it, this according to a new report by Hazelden Betty Ford in collaboration with the University of Maryland School of Public Health
spoke.com/press_releases/5d71ec263433271306008b75 #opioidcrisis -
Orexo
@OrexoABpubl
Yesterday at @ABGSC - Our CEO about parts of our growth strategy #orexo
This media couldn't be displayed. See it on the original post. -
Orexo
@OrexoABpubl
SVD - 2(2) - Enligt politikerna i Oklahoma ska pengarna gå till att finansiera den kostsamma opioidkrisen som slagit brett i samhället. Låt oss då hoppas att fler människor som är beroende nu får den hjälp som de behöver och att Oklahoma blir vägledande för andra delstater.
-
Orexo
@OrexoABpubl
SVD - 1(2) - Under 3 år har 18 milj recept med opioider skrivits ut i Oklahoma med 3.9 milj invånare, vilket fått tusentals människor att bli beroende alternativt att de dött av överdoser. Nu får de ansvariga betala tillbaka. esvd.svd.se/svenskadagbladet/50093/article/961570/20/1/re…
-
Orexo
@OrexoABpubl
#orexo looks forward to present at ABGSC Introduce Investor Days on Monday Sep. 2. The presentation will start at 9 am and will be held by our CEO Nikolaj Sørensen. For more information see the event calendar on our website.
www.introduce.se/artiklar/2019/8/invitation---introduce-i… -
Orexo
@OrexoABpubl
Finwire News
@Finwire
Morgan Stanleys warrantförsäljning bakom onsdagens kurspress i Orexo - vd articles.finwire.com/FWM003B148-morgan-stanleys-warrantfo… #biotech #exclusive #healthcare #lifescience #pharmaceuticals
-
Orexo
@OrexoABpubl
"Ser ingen orsak till aktiekursens nedgång idag 28 aug." @Finwire s journalist @AnnaMSundstrom fick några kommentarer från VD Nikolaj Sorensen angående dagens kursutveckling #orexo
articles.finwire.com/FWM003AFBC-orexo-ser-ingen-orsak-til… -
Orexo
@OrexoABpubl
Life Science Sweden intervjuar VD Nikolaj Sørensen om den senaste utvecklingen i vem som bär ansvaret för opioidkrisen i USA #orexo www.lifesciencesweden.se/article/view/673577/orexos_vd_de…
-
Orexo
@OrexoABpubl
Our CEO in an interview with PharmaBoardroom about the journey form a pure R&D Co. to a fully fledged Specialty Pharma Co., the take on the US #opioidcrisis and the way going forward.
pharmaboardroom.com/interviews/nikolaj-sorensen-ceo-orexo/ -
Orexo reposted
Tina Tan
@MedtechTinaTan
Interest in #digitaltherapeutics is obviously high as one of my most read articles this week is the .@OrexoABpubl .@GAIA_COM #opioidaddiction tie-up. Here's the piece in full www.firstwordmedtech.com/node/1021871?tsid=33 Happy Friday!
-
Orexo
@OrexoABpubl
Nikolaj Sørensen, CEO #orexo and Dr. Mario Weiss, CEO @GAIA_COM in a nice interview with @MedtechTinaTan about the new partnership #opioidcrisis #digitalhealth
Tina Tan
@MedtechTinaTan
The resulting Orexo/Gaia product unlikely to be in US before 2022, but would this mean Sandoz will have a major headstart with reset-O? A headstart, yes but may not be a significant lead.
-
Orexo
@OrexoABpubl
Orexo will together with its partner GAIA develop a new Dtx to increase access and improve treatments of OUD. Why digital therapies, why now and why together with GAIA? Our CEO, answers this Qs in the latest version of Orexo Our View. youtu.be/zqLeOkWY3jc via @YouTube
-
Orexo
@OrexoABpubl
NEWS: Orexo signs agreement with GAIA. Our CEO, Nikolaj Sørensen, commenting on the partnership to develop and commercialize a new digital therapy for the treatment of Opioid Use Disorder. @GAIA_COM #orexo #opioidepidemic #digitaltherapeutics Read more orexo.com/en/media/press-releases?releaseId=B4A65108A4D7F345
-
Orexo
@OrexoABpubl
Boktips -> Läs journalisten Jonas Kullbergs reportagebok om den största hälsokrisen i USA i modern tid - opioidkrisen #orexo
arbetet.se/2019/08/13/i-usa-dovas-smartan-till-dods/ -
Orexo
@OrexoABpubl
Q219 financial snapshot (LTM=Last Twelve Months)
-
Orexo
@OrexoABpubl
VD Nikolaj Sørensen i en intervju med Healthcare analytikern Klas Palin på Redeye (video) www.redeye.se/research/583683/orexo-intervju-med-vd-nikol… via @Redeye_
-
Orexo
@OrexoABpubl
Proud to have you within our partner network – congrats to your accomplishment taking this important project, OX-MPI, in phase 1. An essential milestone in your efforts to offer patients suffering from microvascular disease a novel and efficient treatment. www.gesynta.se/2019-07-09-PR-First-subject-dosed-FINAL_EN…
-
Orexo
@OrexoABpubl
#orexo Q2 2019 Interim Report announced. IMPROVING ALL FUNDAMENTALS orexo.com/en/investors/reports-presentations-and-audiocas…
-
Orexo
@OrexoABpubl
#orexo looks forward to attend tomorrow and Nikolaj Sørensen, CEO, will give his company presentation at 10 am EST or 4 pm CET. The presentation will include the latest update as Orexo also tomorrow announce its Q2 2019 Interim Report. Stay tuned! #opioidaddiction #opioidepidemic
Virtual Investor Conferences
@RIConferences
Join our #virtualinvestor Event tomorrow featuring presentations from CEOs and senior executives of Life Science companies starting at 9:30am ET. Register here: www.virtualinvestorconferences.com/events/event-details/l…
@TrendlinesGroup @OrexoABpubl @NervgenC @crescolabs @NextGreenWave @lexariacorp #otcqx -
Orexo
@OrexoABpubl
Pleased to announce that #orexo has signed an agreement for the lead product in Australia and New Zealand with Mundipharma Aus. who has worked closely with us in the approval process. The launch in Aus. will be initiated early next year. Read the full PR orexo.com/en/media/press-releases?releaseId=5B0245CC1F3C72BA
-
Orexo
@OrexoABpubl
Part 2 (2) If you can´t attend the telco you are welcome to send your questions ahead of the telco to ir@orexo.com, no later than 11.00 am CET on July 11.
-
Orexo
@OrexoABpubl
Part 1 (2) Welcome to join us! On Thursday #orexo invites investors, analysts and media to attend a telco where Nikolaj Sørensen, CEO and Joseph DeFeo, CFO will present the latest development and the way going forward. Stay tuned! #interimreport #q2 orexo.com/en/media/press-releases?releaseId=040031455FA30919
-
Orexo
@OrexoABpubl
Här är #orexo gärna med och delar med sig av resan från ett renodlat F&U bolag till ett fullfjädrat och lönsamt specialistläkemedelsbolag, med USA som största hemmamarknad. #lifescience #healthcare @SwedenBIO
SwedenBIO
@SwedenBIO
Unga, innovativa bolag behöver tidigt få med sig vad som efterfrågas på en global marknad. Vi behöver B2B-samarbeten och ”intelligent kapital” dvs kompetenta och kunniga ägare. #lifescience #healthcare
-
Orexo
@OrexoABpubl
US business leaders ready to fight the #opioidcrisis. There is a desperate need to find a solution to the opioid-related workforce shortage to secure long term growth for their businesses. #orexo #opioidepidemic www.wave3.com/2019/06/26/first-ever-kentucky-opioid-summi…
-
Orexo
@OrexoABpubl
-Interesting piece in @FThealth discussing how patient data can improve long-term treatment of opioid dependent patients alongside established treatment options #opioidcrisis #orexo
-
Orexo
@OrexoABpubl
Taking #orexo to the next level. Nikolaj Sorensen, CEO, @Redeye_ Growth Day yesterday. #leadership #innovation
-
Orexo
@OrexoABpubl
One of #orexo s key objectives is to add more products to the US commercial platform. This week our colleagues Michael Sumner, CMO and Lovisa Case, Director Project Mgmt addended #bio2019 @BIOConvention #opioidaddiction
-
Orexo reposted
EFN Ekonomikanalen
@EFNTV
”Allt eller inget för Orexo.”
Intervju med Nikolaj Sörensen, vd @OrexoABpubl
efn.tv/2KrS2P6 -
Orexo
@OrexoABpubl
Today attending Handelsbanken Mid/Small Cap Conference in Sthlm, Sweden, meeting institutional investors and Handelsbankens own price awarding TV channel EFN who interviewed our CEO Nikolaj Sorensen. #orexo @EFNTV
-
Orexo
@OrexoABpubl
Idag presenterar #orexo VD Nikolaj Sørensen på @aktiespararna #småbolagsdagen. Vi börjar kl 14 i sal 2 och finns också tillgängliga för frågor. Presentationen kan även ses live på www.aktiespararna.se/tv/live - ir@orexo.com.
-
Orexo
@OrexoABpubl
Investor seminar in CPH, where our CEO finalize the presentation talking about #orexo future value drivers 1️⃣Growing key market 2️⃣Strong financial position & profitability 3️⃣M&A & business development 4️⃣Expanding pipeline5️⃣Strong track record of developing products
-
Orexo
@OrexoABpubl
COME AND LISTEN TO US. We look forward to presenting the company on a number of investor conferences in near term in cities such as Stockholm, Copenhagen and New York City. For details see our Event Calendar orexo.com/en/investors/financial-calendar-events/ #orexo
-
Orexo
@OrexoABpubl
According to a new research published in the American Journal of Drug and Alcohol Abuse -> "Anxiety sensitivity is associated with increased opioid misuse among adults with chronic pain." #opioidaddiction "opioidepidemic #orexo www.psypost.org/2019/05/study-finds-anxiety-sensitivity-i… via @PsyPost
-
Orexo
@OrexoABpubl
Listen to an interview (shortened version) with CEO, Nikolaj Sorensen, where he shares his experiences that have shaped his approach to transforming Orexo from being a pure R&D Co. to a fully-fledged profitable specialty pharma Co. #leadership youtu.be/23WcH2O7vwY via @YouTube
-
Orexo
@OrexoABpubl
Lyssna på en längre intervju med #orexo s VD Nikolaj Sørensen där han delar med sig av sina tidigare erfarenheter som också format Orexos framgångsrika resa från ett renodlat R&D bolag till ett fullfjädrat, lönsamt, specialistläkemedelsbolag. youtu.be/JLIah_JdJNI via @YouTube
-
Orexo
@OrexoABpubl
INNOVATION IS THE HEART OF WHAT WE DO - #orexo is built on the principle of innovation which remains at the core of the work of continuing to develop new formulation technologies. Read more orexo.com/en/pipeline/innovation/ #opioidaddiction #innovation
-
Orexo
@OrexoABpubl
OREXO IS EMBRACING ALL ASPECTS OF OPIOID ADDICTION - #opioidaddiction is a chronic medical condition with a number of associated co-morbidities which often requires life-long treatment. Read more about #orexo s key therapeutic area on our web site -> orexo.com/en/key-therapeutic-area/
-
Orexo
@OrexoABpubl
#orexo - updated top 15 shareholder list now available at our group web site or below here -> orexo.com/en/investors/the-share/
-
Orexo
@OrexoABpubl
Intervju med VD Nikolaj Sørensen om den senaste utvecklingen i Q1 2019 med fokus på stark lönsamhet, stabilitet och tillväxt på en dynamisk marknad och 3 av 4 R&D projekt redo för nästa utvecklingsfas. Intervju via länk nedan. #orexo
redeye.solidtango.com/widgets/embed/2sel8m6t?auto_play=true -
Orexo
@OrexoABpubl
Q119- #orexo Demonstrating resilience and growth in a dynamic market. Profit contribution from the US business continues to increase, fuelled by strong key product growth and significant lower COGS, supporting further enhancement of pipeline development orexo.com/investerare/rapporter-presentationer-och-audioc…
-
Orexo
@OrexoABpubl
On Thursday, May 2, at 8 am #orexo will go out with the Q1 Interim Report. In the afternoon at 2 pm you are invited to attend a telco where Nikolaj Sørensen, CEO, and Joseph DeFeo, CFO, will present the report. Stay tuned! orexo.com/media/pressreleaser?releaseId=8856A6B65AE5AEA9
-
Orexo
@OrexoABpubl
In our interview with @PharmaScrip , you can read more about our strategy moving forward and our current pipeline advancements. Read more here: scrip.citeline.com/SC125040/Defusing-US-Opioid-Crisis-Off… #opioidcrisis #opioidepidemic
-
Orexo
@OrexoABpubl
Today #orexo welcomes its shareholders to attend the AGM held in our head quarter in Uppsala Sweden. We are proud to be located in such an inspiring environment as Uppsala - with a tradition of being a University city since the 14th century. #opioidcrisis orexo.com/media/pressreleaser?releaseId=5DB39B6E93C0509C
-
Orexo
@OrexoABpubl
#orexo #opioidcrisis #treatmentgap
Harry Nelson
@nelsonh
Heading home from the American Society of Addiction Medicine conference. What do you make of 5 of the 6 top conference sponsors being #pharmaceutical : @Alkermes (Vivitrol); @Indivior (Suboxone/Sublocade); @GileadSciences @OrexoABpubl (Zubsolv); @TitanPharma ((Probuphine). #mat
-
Orexo
@OrexoABpubl
#orexo Färsk intervju med VD Nikolaj Sørensen som ger sin syn på den senaste utvecklingen med fokus på utfallet i patenttvisten, marknadsutveckling, aktiviteter i pipeline och strategin framåt för att ta bolaget in i nästa fas. Tryck på länk nedan.
redeye.solidtango.com/widgets/embed/fzuytb5r?auto_play=true -
Orexo
@OrexoABpubl
#orexo s partner Gesynta Pharma secures 6 MEUR for development programs in
financing round led by @Industrifonden. An important step in their efforts to develop a treatment for microvascular diseases in chronic inflammatory conditions.
www.gesynta.se/2019-04-04-PR-Investment.pdf -
Orexo
@OrexoABpubl
Yesterday - Thanks to @aktiespararna i Västra Blekinge och Bromölla (part of the Swedish Shareholders’ Association) for inviting #orexo and Lena Wange, IR &. Comm. Mgr, to give a company presentation. Next to Lena below stands Mats Widesjö who runs this local association.
-
Orexo
@OrexoABpubl
#orexo ->Value drivers for long-term growth
-
Orexo
@OrexoABpubl
#orexo has a strong patent protection, until Sep. 2032, for its key product in the US. Today´s decision by the US District Court has no impact on our profitable and growing key product business. #opioidepidemic #opioidcrisis Read the full PR orexo.com/media/pressreleaser?releaseId=0020074004643A77
-
Orexo
@OrexoABpubl
Alarming numbers from Vancouver, Canada, with 43 overdoses in one single night. First responders and volunteers seemed to have done an incredible job saving lives. Let us just hope that these people get under treatment to avoid this to happen again. #orexo
-
Orexo
@OrexoABpubl
Never underestimate networking! This week #orexo will attend #bioeuropespring in Vienna, Austria. Our colleagues Lovisa Case and Petter Wereen at Business Development will for sure get inspired and bring fresh ideas back home. #growthstrategy #opioidepidemic
-
Orexo
@OrexoABpubl
WE MAKE A DIFFERENCE. Read the CEO interview in the 2018 Annual Report that was published today. #leadership #talents #opioidepidemic #orexo
orexo.com/media/1795/orexo_annual-report-2018_published-m… -
Orexo
@OrexoABpubl
CLARIFICATION 3(3) The District Court also issued on Jan. 11 2019 a non-appealable judgement that #teva also infringes #orexo s long-term patent 330. If there are any questions related to this matter please send them to ir@orexo.com.
Dana Elfin
@Dana_A_Elfin
Drugmaker #teva Can Challenge Validity of #orexo Patent (Corrected) news.bloomberglaw.com/pharma-and-life-sciences/teva-can-c…
-
Orexo
@OrexoABpubl
CLARIFICATION 2 (3) What is not mentioned is that #orexo´s key product has patent protection by the long-term patent 330, until Sep. 2032 in the US, according to a decision declared by the US Court of Appeal in Sep. 10 2018. #teva
Dana Elfin
@Dana_A_Elfin
Drugmaker #teva Can Challenge Validity of #orexo Patent (Corrected) news.bloomberglaw.com/pharma-and-life-sciences/teva-can-c…
-
Orexo
@OrexoABpubl
CLARIFICATION 1 (3) Below article relates to #orexo s short-term patent 996 protecting our key-product in the US until Sep. 2019. #teva
Dana Elfin
@Dana_A_Elfin
Drugmaker #teva Can Challenge Validity of #orexo Patent (Corrected) news.bloomberglaw.com/pharma-and-life-sciences/teva-can-c…
-
Orexo
@OrexoABpubl
#orexo - a profitable specialty pharma co. - with the aim of becoming a leader within #addiction. Listen to the inspiring presentation given today by Nikolaj Sorensen, CEO, at Stockholm Corporate Finance Seminar tv.streamfabriken.com/2019-03-13-orexo
-
Orexo
@OrexoABpubl
Tomorrow, March 13, #orexo s CEO Nikolaj Sørensen will present at Stockholm Corporate Finance 11e Life Science Seminar. Afterwards a Q&A session will be moderated by Linda Wikström @Linda_moderator. The event will be live-streamed, see link below.
stockholmcorp.se/stockholm-corporate-finance-11e-life-sci… -
Orexo
@OrexoABpubl
UNs Sustainability Goal5, is in focus when #orexo report on its commitment for a sustainable world. In 2018 Orexo took the Women´s Empowerment Principles Gender Gap Analysis Tool and updated the Equal Opportunities Plan. An important step in the continuing work within this field.
-
Orexo
@OrexoABpubl
Next week on Mar. 12 #orexo will attend a breakfast presentation @Redeye. Then Nikolaj Sorensen, CEO, will give a company update focusing on growth strategy, market development, pipeline progress and financial performance. The event will be live-streamed. www.redeye.se/events
-
Orexo
@OrexoABpubl
Gripande reportage i SVT om hur överdoser av fentanyl slår hårt mot delstaten New Hampshire. Enligt färsk statistik låg substansen bakom 40% av de dödliga överdoserna i USA 2017. www.svt.se/special/de-tvingas-tackla-opioidkrisen-i-USA/ via @svtnyheter
-
Orexo
@OrexoABpubl
Thanks to @NordeaMarkets who hosted Nordea Life Science Seminar today in Stockholm, Sweden. Below Nikolaj Sorensen, CEO, talking among others about the 2019 company outlook.
-
Orexo
@OrexoABpubl
Listen to Johannes Doll, EVP and Head of Corporate Development, when he gave a company presentation at Börsveckans Småbolagsdag yesterday. #orexo
financialhearings.com/event/11942 -
Orexo
@OrexoABpubl
Johannes Doll, EVP and Head of Business Development presenting #orexo at Börsveckans Småbolagsdag today. The presentation will soon be shared. Stay tuned.
-
Orexo
@OrexoABpubl
#orexo Record-breaking performance in 2018. Below some Financial Key Figures.
-
Orexo
@OrexoABpubl
Listen to CEO Nikolaj Sørensen giving a company update today at #biostocklive. On the agenda - growth strategy, market opportunities and challenges and the strong financial development. #orexo @StockBiotech
BioStock
@BioStock_SWE
VD Nikolaj Sørensen presenterar Orexo på BioStock Live STHLM. Se direktsändningen här www.biostock.se/2019/02/folj-biostock-live-sthlm-i-direkt… #swelifescience #biostockswe #biostocklive @OrexoABpubl
-
Orexo
@OrexoABpubl
Nikolaj Sørensen, CEO #orexo met up with Linus Flink Elmfors @StockBiotech for an interview at the #lsxworld Congress 2019 in London where he also attended a panel session about bringing R&D assets to the market. youtu.be/V8IdBWvwZXY via @YouTube
-
Orexo
@OrexoABpubl
#orexo’s CEO, Nikolaj Sørensen discussing how to de-risk in the quest for commercialisation. #orexo #lsxworld
-
Orexo
@OrexoABpubl
We're excited for our CEO, Nikolaj Sørensen, to be part of the #panelsession discussing strategies to consider for #clinicaltrials all the way through to regulatory approval at the LSX World Congress today. Come see us at midday! #orexo #lsxworld
-
Orexo
@OrexoABpubl
#orexo och Lena Wange, IR & Communications Manager är ikväll på plats i Uddevalla för att presentera hos @aktiespararna och berätta om den senaste utvecklingen med fokus på tillväxtstrategi, marknad, pipeline och den ökade lönsamheten.
www.aktiespararna.se/aktiviteter/aktietraff-med-orexo -
Orexo
@OrexoABpubl
VD Nikolaj Sørensen i en färsk intervju med Klas Pahlin på Redeye om den senaste utvecklingen i Kv 4 med fokus på bl a stark finansiell utveckling, möjligheter & utmaningar på den amerikanska marknaden och framsteg i pipeline #orexo youtu.be/PvgQWp8sbbc via @YouTube
-
Orexo
@OrexoABpubl
Nikolaj Sorensen, CEO, giving a Q4 company update at an investor lunch presentation at @paretosec today. Focusing on the strong financial development, the opportunities and challenges in the US market, pipeline advancements and the strategy going forward. Thanks for a great day!
-
Orexo
@OrexoABpubl
Welcome to, Sweden, @PotterClarkson, #orexo s advisor together with @MilbankLaw in the extensive patent litigation against Actavis. Your knowledge, experience & drive were instrumental in the successful defense of our key product in the US. @SwedenBIO
SwedenBIO
@SwedenBIO
Thank you for a great evening with friends @PotterClarkson We wish you great success in your new office in Stockholm
-
Orexo
@OrexoABpubl
#orexo Q4 FY Report-2018 was a pivotal year, enabling to fully focus on delivering our strategies for future growth. EBITDA amounted to the record high no. of SEK 116.6m, fueled by a strong development in the US, with a tripled earning contribution in Q4 orexo.com/investerare/rapporter-presentationer-och-audioc…
-
Orexo
@OrexoABpubl
On Wednesday, January 30, at 8 am #orexo will go out with the Q4 & FY Report. In the afternoon at 2 pm you are invited to attend a telco where Nikolaj Sorensen, CEO, and Joseph DeFeo, CFO, present the report. Stay tuned! orexo.com/media/pressreleaser?releaseId=57FC3DE038FB37D9
-
Orexo
@OrexoABpubl
Orexo positiva till FDA-satsningar för nya läkemedel mot opioidöverdoser - Lena Wange IR & Communications Mgr kommenterar FDA:s beslut om att öka tillgången till akut behandling av överdoser som förra året tog 70 000 amerikaners liv. #orexo - invst.ly/9tkb8
-
Orexo
@OrexoABpubl
#orexos VD, Nikolaj Sørensen, i en intervju med @dagensindustri om bl a de spännande tillväxtmöjligheterna som öppnas när bolaget gått segrande ur den långdragna patenttvisten. #opioidcrisis #treatmentgap
-
Orexo
@OrexoABpubl
#orexo shareholders by end of 2018
orexo.com/en/investors/the-share/ -
Orexo
@OrexoABpubl
CEO Nikolaj Sorensen in an interview with Danish MEDWATCH about the recently shared positive results for OX124 where #orexo aims to develop a rescue medication for overdoses able to reverse the effect of the most powerful opioids #opioidcrisis medwatch.dk/secure/Medicinal___Biotek/article11114384.ece
-
Orexo
@OrexoABpubl
The US #opioidcrisis. Alarming numbers from Massachusetts in the US shows that nearly 5 percent of the people over 11 abuse opioids and that its growing fastest among children and young adults, 11 to 25 years. #orexo upi.com/6838679t via @upi
-
Orexo
@OrexoABpubl
NEWS: The PK study, OX124-001, which assessed #orexo ´s novel naloxone nasal spray formulations for opioid overdose reversal, showed positive study results. Assuming further successful development, it expects to be filed with FDA in 2021. Read the PR orexo.com/media/pressreleaser?releaseId=6707EE4686448F0F
-
Orexo
@OrexoABpubl
#0rexo VD krönikör i Life Science Sweden Magazine - Läsvärda reflektioner för den som funderar på att ta steget in på den amerikanska läkemedelsmarknaden
-
Orexo
@OrexoABpubl
Season´s Greetings from the #orexo team! A successful year is now behind us, with a patent dispute resolved in our favour, record sales in the US, a European launch and several exciting projects in the pipeline. We now look forward to an exciting and eventful 2019.
-
Orexo
@OrexoABpubl
1 of several highlights from the #orexocmd18 day was when DITV, interviewed Nikolaj Sorensen, CEO, and Governor Chris Christie, also keynote speaker at the CMD, on how to combat one of largest health crises ever in the US, the #opioidcrisis. www.di.se/ditv/ditv/ditv-moter-tidigare-guvernoren-chris-…
-
Orexo
@OrexoABpubl
“Addiction is a disease, and it deserves to be treated.” Chris Christie, Former Governor of New Jersey and former Chairman of the US President’s Commission on Combating Drug Addiction and the #opioidcrisis, #orexocmd18
-
Orexo
@OrexoABpubl
“This crisis started in doctor’s offices in America… it began by using opioids legally and prescribed by physicians.” Chris Christie, Former Governor of New Jersey, #orexocmd18 #opioidcrisis
-
Orexo
@OrexoABpubl
“There is a clear need for non-opioid alternatives to treat pain to avoid and prevent addiction. A Uni of Pennsylvania study found that 20% of people treated in the ER for a sprained ankle left with an opioid prescription in 2015. “Johannes Doll, EVP &Head of Corp Development
-
Orexo
@OrexoABpubl
“Our goal at Orexo is to build a product portfolio aimed at fighting the #opioidepidemic from every angle, and our projects always start with a unmet medical need.“ Johannes Doll, EVP and Head of Corporate Development, Orexo #orexocmd18
-
Orexo
@OrexoABpubl
”Like diabetes, #addiction is a long-lasting brain disease – “a disease of the free will”, which can be treated”Fred Nyberg, Professor at Uppsala University, Sweden #opioidcrisis
-
Orexo
@OrexoABpubl
”It's wildly accepted that addiction should be defined as a chronic brain disease, with behavioral, biological, social, emotional and physical aspects, that is characterized by an inability to control substance abuse.” Fred Nyberg, Professor at Uppsala University #orexocmd18
-
Orexo
@OrexoABpubl
"We are lowering our COGs by 35%, and will further enhance our profitability and competitiveness. EBIT margin is also set to improve to 36% ” Joseph DeFeo, EVP and Chief Financial Officer, Orexo #orexocmd18
-
Orexo
@OrexoABpubl
“We are applying commercial rigor, and Orexo’s US operations is now a significant profit contributor.” Joseph DeFeo, EVP and Chief Financial Officer, Orexo #orexocmd18
-
Orexo
@OrexoABpubl
“Our edge is our ability to learn & adapt, and we apply sophisticated targeting to optimize the allocation of our field force.” Robert A. DeLuca, President Orexo US Inc. #orexocmd18
-
Orexo
@OrexoABpubl
“Orexo US is currently capitalizing on the market, and is well positioned to continue to improve performance and be an enabler for our strategic plan.” Robert A. DeLuca, President Orexo US Inc. #orexocmd18
-
Orexo
@OrexoABpubl
“Looking forward, we estimate that there will be some 6 million patients eligible for treatment by 2023, and that is a conservative estimate.” Dan Hawkins, Founder & Managing Director, Clarion Healthcare #orexocmd18 #opioidcrisis
-
Orexo
@OrexoABpubl
“Most opiate misusers & OUD patients today started their opiate use through legitimate prescribing, and many of them are chronic pain patients.” Dan Hawkins, Founder & Managing Director, Clarion Healthcare #orexocmd18
-
Orexo
@OrexoABpubl
"We have three very exciting programs, and have a strong and concrete base in our R&D program." Nikolaj Sørensen, CEO of Orexo #orexocmd18
-
Orexo
@OrexoABpubl
"Every stone will be turned to increase profitability." Nikolaj Sørensen, CEO of Orexo #orexocmd18
-
Orexo
@OrexoABpubl
"Agile acquisitions will be scaled to bring more into Orexo, and our top priority is to seek new opportunities." Martin Nicklasson, Chairman of the Board of Directors, Orexo #orexocmd18
-
Orexo
@OrexoABpubl
"With a strong financial foundation and strengthened patent for Zubsolv, we are now well positioned for new and ambitious objectives." Martin Nicklasson, Chairman of the Board of Directors, Orexo #orexocmd18
-
Orexo
@OrexoABpubl
The Capital Markets Day started at Grand Hotel in Stockholm Sweden today when Nikolaj Sorensen CEO and Governor Chris Christie were interviewed by @dagensindustri #orexocmd18 #orexo
-
Orexo
@OrexoABpubl
Today is a big day for #orexo as we host the first Capital Markets Day since2012. The main with the event is to give a clearer view about the Company´s growth strategies. You can follow the event on the web and #orexocmd2018. ForDetails orexo.com/media/pressreleaser?releaseId=CCF7F11505BD7A5B WELCOME TO JOIN US
-
Orexo
@OrexoABpubl
Today #orexo presented - The journey from idea to patient crossed the Atlantic - at @SwedenBIO summit and it was really nice to meet our colleague Lovisa Case, Director of Project Mgmt, at the orexo conference desk
-
Orexo
@OrexoABpubl
The Capital Markets Day is getting closer. On the day we welcome Charlotte Stjerngren, former news anchor for Börslunch, as moderator. For more information about the CMD see the Company´s website, orexo.com/en/start/ #orexo #growthstragy #orexocmd18
-
Orexo
@OrexoABpubl
Today Robert DeLuca, President #orexo US Inc. will give a company presentation on the Nordic-American Life Science Conference hosted among others by Den Norske Bank, DNB. The event will take place in NYC.
www.meetmax.com/sched/event_51431/~public/conference_acti… -
Orexo
@OrexoABpubl
#orexo is proud to present Chris Christie as keynote speaker on the CMD that will take place in Stockholm, Sweden, Dec 6. Investors, analysts and media can get registered at financialhearings.com/event/11536/register/live_event #orexocmd2018 #opioidaddiction #opioidcrisis
-
Orexo
@OrexoABpubl
#orexo We continue to prepare for the Capital Markets Day on Dec 6 in Stockholm, Sweden, and look forward to welcoming all attendees. The full AGENDA for the day is now available on the company´s website or ->orexo.com/media/1722/agenda-orexo-capital-markets-day-dec… #orexocmd18 #growthstrategy
-
Orexo
@OrexoABpubl
Johannes Doll, EVP and Head of Corporate Development om överklagande domstolens beslut att upphäva blockeringen för Dr Reddy att på risk lansera en generika på konkurrentens film produkt - "Begränsad påverkan av Dr Reddys generikalansering -... - invst.ly/9aal4
-
Orexo
@OrexoABpubl
Today #orexo will attend @Redeye_ Life Science Day, in Stockholm, Sweden and Johannes Doll, EVP and Head of Corporate Development will give a company update at 11.40 am. Following the presentation a Q&A session will be held. To view the presentation live www.redeye.se/live/ls-day-2018
-
Orexo
@OrexoABpubl
#orexo invites investors, analysts and media to attend a Capital Markets Day on Dec 6. For more information see orexo.com/media/pressreleaser?releaseId=FE14C75383C5ABAA #orexocmd18 #growthstrategy
-
Orexo
@OrexoABpubl
We are excited to host a Capital Markets Day on Dec 6 and look forward to welcoming all attendees. During the #orexocmd18, we will provide an update on the Company’s strategy for growth, key market & position and pipeline advancements. Read more orexo.com/media/pressreleaser?releaseId=FE14C75383C5ABAA. #orexo
-
Orexo
@OrexoABpubl
The win in the patent litigation strengthen #orexo s long term business opportunities. Tonight Lena Wange IR & Communications Manager had the honor to give a company presentation at the Swedish Shareholders´ Association in Skåne county. @aktiespararna
-
Orexo
@OrexoABpubl
Part 2(2) Tonight Stephen McNeeney @PotterClarkson, Errol Taylor @MilbankLaw, Robert Rönn Head of Pharmaceutical Development #orexo and Nikolaj Sorensen, CEO, #orexo shared their view on this successful defence. Thanks also to our friends & partners @SwedenBIO and Vinge Law firm.
-
Orexo reposted
Björn Olander
@MurgataER
It was an interesting event with fruitful discussions and new insight into this important case and into the field of patents in general!
Thank you speakers from @PotterClarkson, @MilbankLaw and @OrexoABpubl.
Also thanks to @SwedenBIO and Vinge for organizing and hosting!
Orexo
@OrexoABpubl
“The successful defence of Orexo´s lead product – Experiences from pharmaceutical patent litigation in the US” - Welcome to an After Work Seminar hosted by #orexo and @swedenBIO on Nov. 8, where you will meet executives from Orexo and their legal advisors orexo.com/media/pressreleaser?releaseId=54264682855F4768
-
Orexo
@OrexoABpubl
Part 1(2)-When we wanted to fight the #opioidepidemic causing 1000s of deaths our efforts and focus had to be diverted to defend our #innovations. Thanks to this brilliant team who won the fight against 1 of the worlds largest generic companies.@PotterClarkson @MilbankLaw #orexo
-
Orexo
@OrexoABpubl
There is an interview with Nikolaj Sørensen, our CEO, in the most recent edition of the NLS Magazine, where he talks about a no of things, incl #orexo journey from an R&D Co. to a fully-fledged specialty drug company,the battle against #opioidaddiction and his view on #leadership
Nordic Life Science
@NLifeScience
Our latest issue is out! Pick up your copy at #bioeurope and read about Nikolaj Sørensen @OrexoABpubl experiences from taking a company to the U.S. market and tackling a big problem.
-
Orexo reposted
Milbank LLP
@MilbankLaw
Partner Errol Taylor, head of our #biopharma #patent #litigation practice, will speak at a seminar in Stockholm this week about his successful representation of #orexo in a patent dispute.
Orexo
@OrexoABpubl
“The successful defence of Orexo´s lead product – Experiences from pharmaceutical patent litigation in the US” - Welcome to an After Work Seminar hosted by #orexo and @swedenBIO on Nov. 8, where you will meet executives from Orexo and their legal advisors orexo.com/media/pressreleaser?releaseId=54264682855F4768
-
Orexo reposted
Potter Clarkson
@PotterClarkson
Join us next week in #stockholm with @SwedenBIO, @OrexoABpubl and @MilbankLaw for a seminar on patent litigation. Partner and patent attorney, Steve McNeeney will be presenting. #patentlitigation #opioids
-
Orexo
@OrexoABpubl
"I have known Joe since 2013 and he has been instrumental to our success in the US. I am convinced Joe is the right candidate and I am looking forward to work closely with him on the exciting journey that lays ahead of Orexo.” says Nikolaj Sørensen, President and CEO, #orexo
-
Orexo
@OrexoABpubl
“The successful defence of Orexo´s lead product – Experiences from pharmaceutical patent litigation in the US” - Welcome to an After Work Seminar hosted by #orexo and @swedenBIO on Nov. 8, where you will meet executives from Orexo and their legal advisors orexo.com/media/pressreleaser?releaseId=54264682855F4768
-
Orexo reposted
Redeye
@Redeye_
Videointervju med @OrexoABpubl's vd Nikolaj Sörensen www.redeye.se/company/orexo/581495/orexo-videointervju-me…
-
Orexo
@OrexoABpubl
Following Pareto, Q3 investor lunch presentation & CEO interview at Redeye
-
Orexo
@OrexoABpubl
#orexo - today we look forward to present at Pareto at 10 am CET
-
Orexo
@OrexoABpubl
In Q3 #orexo delivered yet another strong quarter in terms of net revenue and profitability, when excluding IP costs.The development was mainly driven by a robust contribution from the US operations, where the lead product continued its strong performance orexo.com/investerare/rapporter-presentationer-och-audioc…
-
Orexo
@OrexoABpubl
"President Trump on Combating the Opioid Crisis: President Trump delivers remarks on the administration’s efforts over the past year to combat the opioid crisis."
Watching President Trump on Combating the Opioid Crisis. Watching at @CSPAN www.c-span.org/video/?453554-1/president-trump-violence-p… #orexo -
Orexo reposted
ASAM
@ASAMorg
ASAM praises President Trump (@POTUS, @realDonaldTrump) for signing H.R. 6, the SUPPORT for Patients and Communities Act, into law. #hr6 #treataddictionsavelives. READ: www.asam.org/advocacy/news/asam-advocacy-blog/2018/10/24/…
-
Orexo
@OrexoABpubl
#orexo will host a CapitalMarketsDay on Dec. 6, in Stockholm, Sweden. Orexo´s mgmt team will then provide a strategy update and give a deeper pipeline insight. KeyNote speaker will be the US president´s former advisor on how to combat the #opioidcrisis. orexo.com/media/pressreleaser?releaseId=E1BBDDF93D12F271




























































































































































































































































































































































































































